Split (3)

train · 92 rows

input stringlengths 317 13.1k	output dict
This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment. ;NA; Inclusion Criteria: 1. Participation in the Tracon sponsored 4309ST101 study and thought to have potential to derive clinical benefit from continued treatment in the opinion of the parent study investigator from uninterrupted dosing of TJ004309 in combination with atezolizumab. 2. Willing or able to comply with study treatment and standard of care testing and procedures. Exclusion Criteria: 1. Any unresolved ongoing toxicity or clinical event that would make continued treatment with TJ004309 inappropriate. 2. Current treatment in another clinical study or treatment with other standard of care therapy. 3. Currently pregnant. 4. Current evidence of any condition (including medical, psychiatric or substance abuse disorder), therapy, or laboratory abnormality that might interfere with the patient's participation or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of ABBV-383. In Part 2, the step-up dose identified in Part 1 will be used followed by the target dose of ABBV-383. Around 80 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 30 sites across the world. Participants will receive ABBV-383 as an infusion into the vein in 28 day cycles for approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires. ;NA; Inclusion Criteria: - Must have measurable disease as outlined in the protocol. - Eastern Cooperative Oncology Group (ECOG) performance of <= 2. - Relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) 2016 criteria. - Must be naïve to treatment with ABBV-383. - Must have received at least 3 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal antibody. Exclusion Criteria: - Received B-cell maturation antigen (BCMA)-targeted therapy.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary endpoint is the disease-free survival rate at 3 years. ;NA; Inclusion Criteria: - Received radical resection of non-small cell lung cancer without prior anti-tumor therapies including radiotherapy, chemotherapy, target therapy and immunotherapy. - Histologically diagnosed Non-small cell lung cancer based on the judgement of at least 2 pathologists. - Stage IA with high risk factors including micropapillae or solid components, vascular invasion, spread through air spaces, low differentiation, tumor budding and insufficient lymph node dissection; Stage IB with or without high-risk factors. The pathological stage is based on the 8th edition of AJCC lung cancer staging. - EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al. - ECOG performance status 0-1. - Sufficient organ function in liver, renal, kidney and hematology. - With written signed informed consent form, ability to report adverse events, and good adherence to clinical study. Exclusion Criteria: - Lung cancer with small cell or neuroendocrine cancer cell. - EGFR exon 20 insertion positive. - Concurrent with other diver mutations including alterations in ALK, ROS1, MET et al. - Women who are pregnant or breastfeeding. - Use of CYP3A4 strong depressant within 7 days or CYP3A4 strong inducer within 21 days prior to initial administration, use of other anti-tumor treatment including traditional Chinese medicine within 14 days before enrollment. - Concurrent with other malignancies excluding carcinoma in situ. - With uncontrolled systematic diseases such as active bleeding, unstable angina, heart infarction within 1 year, chronic heart failure and uncontrolled hypertension and diabetes mellitus; with active infection of HBV, HCV or HIV, or other infections requiring injection of antibiotics. - Gastrointestinal disorders which may affect drug taking or absorption. - With history of QT prolongation or relative risk factors including heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome et al. - With history of interstitial lung disease or relative risk. - Allergic to any component of furmonertinib tablet. - Mental illness or drug abuse. - Live vaccination within 30 days before enrollment. - Other situation judged by investigator such as failure to follow the rules of study. - Attending another study of investigational drug, or received other study drugs or medical devices with 4 weeks before enrollment.	{ "inclusion_biomarker": [ [ "EGFR mutation" ], [ "EGFR exon 19 deletion" ], [ "EGFR L858R" ], [ "EGFR S768I" ], [ "EGFR G719X" ], [ "EGFR L861Q" ], [ "EGFR T790M" ] ], "exclusion_biomarker": [ [ "EGFR exon 20 insertion", "ALK alteration" ], [ "EGFR exon 20 insertion", "ROS1 alteration" ], [ "EGFR exon 20 insertion", "MET alteration" ] ] }
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome. ; ; Inclusion Criteria: 1. Men and women ≥ 18 years of age, at the time of signing the ICD (Informed Consent Document). 2. Subject must understand and voluntarily sign an ICD prior to any study-related assessments/procedures being conducted. 3. Relapsed or refractory AML (Acute Myeloid Leukemia) (Parts A and B) or relapsed or refractory (R/R) higher-risk MDS (Myelodysplastic Syndrome) (HR-MDS) (Part B only) as defined by World Health Organization criteria who are not suitable for other established therapies. 1. In Part A, R/R AML 2. In Part B, R/R AML including - Relapsed after allogeneic HSCT or - In second or later relapse or - Refractory to initial induction or re-induction treatment or - Refractory or relapse after HMA treatment (HMA failure defined as primary progression or lack of clinical benefit after a minimum of 6 cycles or unable to tolerate HMA due to toxicity) or - Refractory within 1 year of initial treatment (excluding those with favorable risk based on cytogenetics) 3. In Part B, R/R HR-MDS (Revised International Prognostic Scoring System score (IPSS-R) > 3.5 points, IPSS-R calculated during screening period): - IPSS-R intermediate risk (in combination with more than 10% bone marrow blasts or poor or very poor IPSS-R cytogenetic risk) or - IPSS-R high or - IPSS-R very high risk 4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2. 5. At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI) without conditioning. 6. Subjects must have the following screening laboratory values: - Corrected serum Ca or free (ionized) serum Ca within normal limits (WNL). o Corrected Ca (mg/dL) = Total Ca (mg/dL) - 0.8 (albumin [g/dL] - 4) - Total White Blood Cell count (WBC) < 25 x 10^9/L prior to first infusion. Prior or concurrent treatment with hydroxyurea to achieve this level is allowed. - Potassium and magnesium within normal limits or correctable with supplements. - Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) or alanine aminotransferase/serum glutamate pyruvic transaminase (ALT/SGPT) ≤ 2.5 x Upper Limit of Normal (ULN). - Uric acid ≤ 7.5 mg/dL (446 μmol/L). Prior and/or concurrent treatment with hypouricemic agents (eg, allopurinol, rasburicase) are allowed. - Selected electrolytes within normal limits or correctable with supplements. - Serum bilirubin ≤ 1.5 x ULN (upper limit of normal). - Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated. - International normalized ratio (INR) < 1.5 x ULN and Partial thromboplastin time (PTT) < 1.5 x ULN. Exclusion Criteria: 1. Subjects with acute promyelocytic leukemia (APL) 2. Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is clinical suspicion of CNS involvement by leukemia during screening. 3. Patients with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (e.g., transplant related side effects). 4. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-90009. 5. Subjects on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). 6. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90009, whichever is shorter. Hydroxyurea is allowed to control peripheral leukemia blasts. 7. Leukapheresis ≤ 2 weeks prior to starting CC-90009.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a phase 2 study to evaluate the safety and efficacy of the combination of INCMGA00012 and pelareorep and to see how well they work in treating patients with triple negative breast cancer that has spread to other parts of the body (metastatic). INCMGA00012 is a monoclonal antibody that works by attaching to the programmed cell death protein 1 (PD-1) and blocking this pathway, allowing the immune system to recognize and attack the cancer cells. Pelareorep is a type of virus called reovirus which occurs naturally and may break down cancer cells. Giving INCMGA00012 and pelareorep may slow the growth and spread of the cancer to another part of the body. ; ; Inclusion Criteria: - Metastatic or inoperable locally advanced, histologically documented triple negative breast cancer (TNBC) (negative expression of estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2] immunohistochemistry [IHC] 0 or 1+, HER2 fluorescence in situ hybridization [FISH] negative if IHC 2+, per American Society of Clinical Oncology [ASCO] College of American Pathologists [CAP] guidelines) - Pre-menopausal and post-menopausal women who have received 1-2 prior lines of systemic therapy for metastatic triple negative breast cancer. Patients must have received at least one prior line of chemotherapy - Patients who have received adjuvant therapy for locally advanced triple negative breast cancer may be eligible for the study if they relapse with metastatic disease within 6 months since completion of neo-adjuvant/adjuvant systemic therapy. The adjuvant/neoadjuvant therapy will be considered as 1 line of therapy - Availability of tumor specimen for determination of PD-L1 and additional biomarker studies. Patient should be willing to undergo a pre-treatment biopsy as well as a biopsy after cycle 2 to evaluate the tumor microenvironment - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 - Patients who have received prior treatment with anti-PD-1 or anti-PD-L1 inhibitors are eligible for the study - Absolute neutrophil count >= 1,000/uL - Platelet count >= 100,000/uL - Hemoglobin >= 9.0 g/dL - Total bilirubin =< 2 x upper limit of normal (ULN) or =< 3 x ULN for subjects with Gilbert's disease or liver metastases - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (=< 5 x ULN if evidence of hepatic involvement by malignant disease) - Estimated glomerular filtration rate (eGFR) >= 40 mL/min/1.73m^2 - Lactate dehydrogenase (LDH) < 2 x ULN - Provision of signed and dated informed consent form - Life expectancy >= 3 months, as determined by the investigator - Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be uni-dimensionally measurable as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 - For patients receiving therapeutic anticoagulation: stable anticoagulant regimen during the 14 days prior to initiation of study treatment - Subjects with central nervous system (CNS) metastases treated with radiation therapy (whole-brain radiation therapy [WBXRT] or stereotactic radiosurgery [SRS]) are eligible if, > 28 days following completion of radiation therapy (XRT), they show stable disease on post-treatment magnetic resonance imaging (MRI)/computed tomography (CT), are off corticosteroids, and are neurologically stable - Female patients of childbearing potential have a negative pregnancy test at baseline. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti estrogens, or ovarian suppression - Patients who are not postmenopausal (>= 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within 14 days of treatment initiation - Sexually active women of childbearing potential enrolled in the study must agree to use 2 forms of accepted methods of contraception during the course of the study and for 12 weeks after their last dose of study drug. Effective birth control includes (a) intrauterine device plus 1 barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method; (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) a vasectomized partner Exclusion Criteria: - Subjects who have received 4 or more lines prior treatment in the metastatic setting - Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Vitiligo, alopecia, hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, celiac disease controlled by diet alone or conditions not expected to recur in the absence of an external trigger are permitted - History of psychiatric illness or social situations that would limit compliance with study requirements. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator - Known active, untreated central nervous system (CNS) metastases and/or carcinomatous meningitis except for patients with =< 3 small (< 0.6 cm) asymptomatic brain lesions where treatment is not indicated. Patients with neurological symptoms must undergo a head computed tomography (CT) scan or brain magnetic resonance imaging (MRI) to exclude brain metastasis - Subjects previously treated with pelareorep - Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis - Prior allogeneic stem cell or solid organ transplantation - Patients may not have non-oncology vaccine therapies for prevention of infectious disease (for example, seasonal live influenza vaccine, human papilloma virus vaccine) within 4 weeks of study drug administration. Vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine - Known history of human immunodeficiency virus (HIV) or other serious immunocompromised state - Known positive hepatitis B surface antigen undergoing anti-viral treatment and/or active hepatitis C indicated by positive quantitative hepatitis C virus (HCV) ribonucleic acid (RNA) - Patient is pregnant or breastfeeding - Receipt of any investigational treatment or anti-cancer therapy within 14 days of enrollment into the study - Known hypersensitivity to the study drugs or their components - Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) class III-IV within 6 months prior to their first dose of study drugs - Prior malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 1 year prior to study entry - Active alcohol or drug abuse per treating physician - Patients may not participate in any other therapeutic clinical trials, including those with other investigational agents not included in this trial, throughout the duration of this study - Toxicity of prior therapy that has not recovered to =< grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion support) - For patients who have received prior immune-checkpoint therapy: Immune-related toxicity during prior checkpoint inhibitor therapy for which permanent discontinuation of therapy was recommended (per product label or consensus guidelines), OR any immune-related toxicity that required intensive or prolonged immunosuppression. (With the exception of endocrinopathy that is well controlled on replacement hormones)	{ "inclusion_biomarker": [ [ "ER negative", "PR negative", "HER2 negative" ] ], "exclusion_biomarker": [] }
In recent years, the goal of stopping drug therapy, also known as treatment-free remission (TFR), is emerging as one of the management goals of chronic myeloid leukemia (CML) therapy. Because there is no available data on Asian patients with CML undergoing tyrosine kinase inhibitor discontinuation (TKI), the investigators plan to recruit chronic phase CML patients with deep treatment response and good medical compliance in Taiwan to evaluate the feasibility, safety and clinical consequences of TKI discontinuation. ; ; Inclusion Criteria: 1. The participant should be an adult (age ⩾20 years) with CP-CML. 2. The BCR-ABL fusion should be in the form of either e13a2 or e14a2 (p210) 3. The participant should not have documented resistance to a 2nd-generation TKI (Nilotinib or Dasatinib) 4. The participant should have received ≥ 5 years of consecutive treatment with imatinib, or ≥ 4 years of consecutive treatment with a 2nd-generation TKI (Nilotinib or Dasatinib) 5. The participant should have achieved MR4.5 (BCR-ABL ⩽0.0032% IS) or undetectable disease in the peripheral blood or bone marrow, for ≥ 2 years, which is documented on ≥ 4 separate tests performed ≥ 3 months apart. 6. Access to a reliable qPCR-based BCR-ABL test with a sensitivity of detecting of at least MR4.5. Exclusion Criteria: 1. After evaluation, the participant is deemed to be ineligible by the investigator of this study. 2. The participant has no intention to be recruited into this study.	{ "inclusion_biomarker": [ [ "BCR-ABL e13a2" ], [ "BCR-ABL e14a2" ] ], "exclusion_biomarker": [] }
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies. ; ; Selected Inclusion Criteria: 1. Histologically confirmed relapsed/refractory hematologic malignancies, including Chronic Lymphocytic Lymphoma (CLL/SLL) and selected Non-Hodgkin's Lymphoma (NHL) 2. Prior or current documentation of CD19 expression or high likelihood of CD19 expression based on disease histology 3. No signs of symptoms of central nervous system (CNS) disease or detectable evidence of CNS or meningeal disease on magnetic resonance imaging (MRI) at the time of screening Selected Exclusion Criteria: 1. Prior CD19 directed therapy including CD19 CARTs 2. Prior allogeneic hematopoietic stem cell transplant within 6 months of enrollment 3. Prior autologous hematopoietic stem cell transplant within 6 weeks of enrollment. 4. Presence of GVHD	{ "inclusion_biomarker": [ [ "CD19 expression" ] ], "exclusion_biomarker": [] }
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers. ;NA; Inclusion Criteria: - Progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or CD20-positive non-Hodgkin's lymphoma, or diffuse large B cell lymphoma, or follicular lymphoma - Solid tumors must have at least one site of measurable disease as determined by RECIST v1.1 - Eastern cooperative oncology group performance status of 0 or 1 Exclusion Criteria: - High-grade lymphomas (Burkitt's or lymphoblastic) - Has cancer with symptomatic central nervous system (CNS) involvement - History of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months Other protocol-defined inclusion/exclusion criteria apply	{ "inclusion_biomarker": [ [ "CD20 positive" ] ], "exclusion_biomarker": [] }
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study follows a 3+3 design. ; ; Inclusion Criteria: Phase 1a (dose escalation): 1. Histologically confirmed CD20+ expressing indolent NHL (defined below), CLL or WM, failed or intolerant to standard of care therapies; 2. Relapsed/refractory following at least 2 prior lines of standard of care treatment. Prior treatments received must be documented on the enrollment request form. For FL, prior treatment must have included at least 1 rituximab containing regimen. 3. First three dose levels: in the opinion of the investigator, able to tolerate potentially subtherapeutic doses of PSB202 for the duration of a 28-day DLT observation window. Phase 1b - Dose Expansion: 4. Histologically confirmed CD20+ expression. For CD37+, if unavailable from the chart at screening, CD37+ expression may be documented from a new or archived blood specimen after enrollment. 5. Relapsed indolent NHL: histologies that may be included are CLL/SLL, MZL, MALT-lymphoma, follicular NHL, MCL or WM failed, relapsed/refractory or intolerant to at least 2 standard of care therapies. (APPENDIX B). For FL, prior treatment must have included rituximab. MCL must have received a prior alkylating agent. 6. Patients must have documented disease progression after at least two prior standard-of-care regimens. 7. Patients must have measurable disease. All Patients: 8. Signed Informed Consent; 9. Eastern Cooperative Oncology Group (ECOG) 0-2 10. Last dose of any anti-CD20 antibody therapy must have been >4 weeks before the first dose of PSB202 11. Patients with a medical history of Covid-19 positivity at within 6 months prior to enrollment, must be retested within 7 days of enrollment and confirm Covid-19 negativity by a PCR-test. 12. At least 18 years of age. There is no upper age restriction. 13. Four weeks wash-out from any other prior cancer therapy, including rituximab or BTK-inhibitors. However, some heavily pretreated patients are at risk for significant morbidity from accelerated disease progression or "flare" when treatment is discontinued prior to the initiation of subsequent effective therapy. Absent residual toxicity and with documented Medical Monitor approval, such patients may receive study drug after five drug half-lives have passed following discontinuation of the immediate pre-study therapy. 14. Adequate hematologic and coagulation status, defined as the following on C1D1 before treatment: 1. Absolute neutrophil count (ANC) ≥ 0.75 billion/L; not requiring growth factors; after the DLT period, growth factor support is allowed and considered supportive care. 2. Platelet count ≥75 billion/L not requiring transfusion support; if there is documented bone marrow involvement, platelet transfusions may be used up to 7 days prior to C1D1 to achieve this threshold. 3. Hemoglobin (Hb) ≥9 mg/dL not requiring transfusion support or growth factors. After the DLT period, growth factor support is allowed and considered supportive care. 4. Adequate coagulation, defined as aPTT and PT (INR) not greater than 1.5 × upper limit of normal (ULN) (patients appropriately anticoagulated for a preexisting medical condition [e.g., atrial fibrillation] may be eligible with documented Sponsor approval). 15. Adequate hepatic function, defined as: 1. ALT or AST ≤2.5 X the ULN or ≤5 X ULN with documented liver involvement. 2. Total bilirubin ≤1.5 X ULN or ≤3 X ULN with documented liver involvement and/or Gilbert's Disease 3. Adequate renal function, with estimated glomerular filtration rate (eGFR) ≥50 mL/minute. 16. Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation. 17. Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment; this may include barrier methods such as condom or diaphragm with spermicidal gel. Exclusion Criteria Phase 1a (dose escalation) only: 18. NHL with bulky disease defined as a mass ≥10 cm in longest diameter 19. Transformation (e.g., Richter's transformation, prolymphocytic leukemia, transformed NHL, blastoid lymphoma) prior to planned start of PSB202. In addition, no concurrent investigational therapy is permitted. All patients: Phase 1a (dose escalation) and Phase 1b (dose expansion): 20. Major surgery within 4 weeks prior to planned start of PSB202 21. Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving radiation to more than 30% of the bone marrow or receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment 22. Continuation of certain standard of care anticancer therapies, including hormonal therapy for breast and prostate cancer, and growth factor support after completion of the DLT-period, is allowed. 23. Therapeutic monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of PSB202. PSB202 may be started sooner after prior investigational agent or anticancer therapy if considered by the Investigator to be safe and within the best interest of the patient (e.g., to avoid disease flare) and with documented Sponsor approval. 24. Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia. 25. History of autologous stem cell transplant (auto-SCT) or chimeric antigen receptor-modified T cell (CAR-T) therapy within the past 180 days with any of the following: cytopenias from incomplete blood cell count recovery post-transplant, need for anti-cytokine therapy, residual symptoms of neurotoxicity > Grade 1, or ongoing immunosuppressive therapy. 26. Active graft versus host disease (GVHD, including resultant from any prior solid organ transplants, if received), or ongoing immunosuppressive therapy. 27. History of allogeneic stem cell transplant (allo-SCT) or allogeneic CAR-T at any time in the patient's medical history 28. Known central nervous system (CNS) involvement by lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS-disease may be eligible if a clinical rationale is provided by the Investigator and with documented Sponsor approval 29. Active auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) 30. Cerebrovascular accident (CVA), Transient ischemic attack (TIA), myocardial infarction, unstable angina, or New York Heart Association (NYHA) class III or IV heart failure < 6 months of study screening; mean ECG QT-interval corrected according to Fridericia's formula (QTcF) > 450 milliseconds (ms) (males) or > 470 ms (females) obtained from three ECGs; uncontrolled arrhythmia < 3 months of study screening. Patients with rate-controlled arrhythmias may be eligible for study entry at discretion of the Investigator. 31. Active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the Investigator and the Sponsor makes it undesirable for the patient to participate in the trial. Screening for chronic conditions is not required. 32. Tested positive for Human Immunodeficiency Virus (HIV) is excluded (due to potential drug-drug interactions between anti-retroviral medications and PSB202 and risk of opportunistic infections). For patients with unknown HIV status, HIV testing will be performed at Screening 33. Active viral hepatitis (B or C, HBsAg, anti-HBs/HBcAb and anti-HCV Ab tests) as demonstrated by positive serology or requiring treatment. Subjects who are anti-HBs/HBcAb (+) without detectable HBV-DNA are eligible. Subjects with a history of Hepatitis C and have received successful curative treatment are eligible. 34. Pregnancy or lactation. 35. Active autoimmune disease or history of autoimmune disease requiring systemic therapy < 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease, Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that has not been active in the 2 years prior to study screening are eligible. 36. History of drug-induced liver injury or cirrhosis 37. History of pneumonitis or interstitial lung disease 38. Patients with significant medical diseases or conditions, as assessed by the Investigator and Sponsor, that would substantially increase the risk-benefit ratio of participating in the study. -	{ "inclusion_biomarker": [ [ "CD20 expression" ], [ "CD37 expression" ] ], "exclusion_biomarker": [] }
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation. ;NA; Inclusion criteria - Subject with histologically proven, locally advanced, unresectable and/or metastatic solid tumor, for which no standard treatment is available or the subject is refractory to or intolerant of existing standard treatment. - Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA. Historical, local laboratory result (up to 5 years prior to this study) can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C mutation by a central laboratory. - Subject has tumor type requirement as follows: advanced or metastatic solid tumors including NSCLC and CRC. - Subject has measurable disease according to RECIST, v1.1. Exclusion Criteria: - Subject with unstable or progressive central nervous system (CNS) metastases. - Subject with acute myocardial infarction, severe/unstable angina; or with cardiac insufficiency of New York Heart Association Functional Classification Grade 2 or above. - Subject has corrected QT interval using Fridericia's formula (QTcF) prolongation at rest, where the mean QTc interval is > 480 msec based on triplicate measurements of electrocardiogram (ECG). - Subject with stroke or other severe cerebrovascular diseases within 12 months before enrollment; - Subject with interstitial lung disease or acute lung infection not yet recovered including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; - Subject has any history or evidence of substance abuse or medical, psychological or social conditions that may, in the opinion of the investigator, interfere with participation in the study or evaluation of the study results. - Subject has impaired gastrointestinal (GI) function or GI diseases that may significantly alter the absorption or metabolism of oral medications. - Subject has unresolved toxicities from prior anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI CTCAE, v5.0, Grade ≤ 1 (Grade ≤ 2 for peripheral neuropathy). - Subject had major surgery within 4 weeks prior to study intervention administration or last dose of palliative radiation therapy within 2 weeks prior to study intervention administration. - Subject is pregnant or lactating.	{ "inclusion_biomarker": [ [ "KRas G12C" ] ], "exclusion_biomarker": [] }
This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients. Subjects must have received no prior treatment for rectal cancer (chemotherapy, radiotherapy or surgery) and no prior treatment with checkpoint inhibitors. Eligible subjects will receive chemoradiation for a period of 5 weeks, 6 cycles of chemo-immunotherapy (mFOLFOX6 + nivolumab) for a period of 12 weeks, once every 2 weeks, and will undergo surgery after 4 weeks. ;NA; Inclusion Criteria: - Signed written IRB approved informed consent - Age ≥ 18 years - ECOG PS 0-1 - Subjects with histologically confirmed primary (non-recurrent) locally advanced rectal adenocarcinoma - Stage T3-4 N0 or TX N+ according to baseline rectal EUS and PET-CT - Patients who are planned for neoadjuvant chemoradiation and are surgical candidates - No prior chemotherapy, radiotherapy or surgery for rectal cancer - No prior radiotherapy to the pelvis, for any reason - Presence of adequate contraception in fertile patients - Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug - Women must not be breastfeeding - Ability to swallow tablets - No previous (within the last 5 years) or concurrent malignancies, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix or basal cell carcinoma of the skin Exclusion Criteria: - Active autoimmune disease. [Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll] - Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways - Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) - Pregnancy or breastfeeding	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study ; ; Inclusion Criteria: - Pathologically confirmed CD20 positive DLBCL based on 2016 WHO classification who achieved CR after 4 cycles of RCHOP therapy (examined by PET-CT, Deauville score 1-2) - Treatment naïve - IPI=0,1 - Age ≥ 14 or ≤75 years - non-mass (The length of the lesion<7.5cm) - ECOG=0,1 - Life expectancy>6 months - Informed consented Exclusion Criteria: - Have received systemic or local treatment including chemotherapy in the past - Have received autologous stem cell transplantation in the past - Past medical history of other malignant tumors, except basal cell carcinoma of the skin and cervical cancer in situ - Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases, severe infectious diseases and other diseases - Primary skin, primary central nervous system lymphoma - Left ventricular ejection fraction ≦50% - Other concurrent and uncontrolled situation which will affect the patient's medical status based on researchers decision - Laboratory test value during screening: (unless it is caused by lymphoma) Neutrophils <1.5109/L Platelet<80109/L Hemoglobin <100g/L ALT or AST is 2 times higher than the upper limit of normal, AKP and bilirubin are 1.5 times higher than the upper limit of normal E. Creatinine level is higher than 1.5 times the upper limit of normal - Psychiatric patients or other patients who are known or suspected to be unable to fully accomplish with the research protocol - Pregnant or lactating women - Patients with positive HbsAg test results need to undergo HBV-DNA test and can be admitted to the group after turning negative. In addition, if the HBsAg test result is negative, but the HBcAb test is positive (regardless of the HBsAb status), HBV-DNA is also required；if the result is positive, patients also need to be treated to become negative before entering the group - Patients living with HIV - Patients with TP53 mutations or those who have not undergone DLBCL hot spot gene screening	{ "inclusion_biomarker": [ [ "CD20 positive" ] ], "exclusion_biomarker": [ [ "TP53 mutation" ] ] }
RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose Limiting Toxicicities (which will stop the dose escalation), this will be the recommended dose for further exploration. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first). In the expansion cohort the subject will receive the recommended dose. The expansion cohort will be conducted at 4 sites. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first). ; ; Inclusion Criteria: 1. Able and willing to provide written informed consent and to comply with the clinical study protocol 2. Age ≥ 18 years 3. Histologically confirmed epithelial ovarian, fallopian tube and primary peritoneal carcinoma 4. Platinum sensitive recurrences of ovarian carcinoma who are eligible for debulking surgery to R0. 5. AEs recovered to at least grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy at time of first administration of Radspherin® 6. ECOG Performance Status Score of 0 - 1 7. Adequate renal function - Creatinine ≤ 1.8 mg/dl (159 μmol/l) and - calculated creatinine clearance using the Cockcroft-Gault formula ≥ 45 ml/min, or - measured creatinine clearance ≥ 45 ml/min 8. Adequate hepatic function - Serum bilirubin <1.5 x upper limit of normal (ULN) - Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN 9. Adequate bone marrow function: - Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/l - Platelets ≥ 100 x 10^9/l - Haemoglobin ≥ 9 g/dL 10. Adequate coagulation tests: INR ≤ 1.5 x ULN 11. For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment 12. For females of childbearing potential who have a male partner: agreement to use two adequate methods of contraception (e.g. barrier, intrauterine device, hormonal implants, combined oral contraceptives or vasectomized partner), during the treatment period and for at least 3 months after the last dose of IMP. Exclusion Criteria: 1. Neuroendocrine tumors, or non-epithelial ovarian cancers (e.g. germ cell tumors, Sex-cord tumors) 2. Tumors of borderline malignancy 3. Other synchronous visceral metastatic lesions, symptomatic CNS metastases. Metastatic lymph nodes are acceptable, except thoracic lymph nodes. 4. Pregnant or lactating (nursing) women 5. Active infections requiring antibiotics, and/or physician monitoring or recurrent fever >38.0 ⁰C associated with a clinical diagnosis of active infection 6. Active liver disease with positive serology for active hepatitis B, hepatitis C or known HIV 7. Administration of an investigational medicinal product within 28 days, or at least 5 times the half-life, prior to enrolment 8. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the last study treatment 9. Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cervical cancer in situ or in situ stage 1 synchronous endometrial cancer) 10. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease 11. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise the safety of the subjects or interfere with the evaluation of the safety of the IMP 12. In the Investigator's opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent 13. Treatment with bevacizumab (Avastin®) within 5 weeks prior to CRS 14. Known hypersensitivity to any of the excipients in the study drug 15. Persons who have been placed in an institution under an official or judicial order 16. Persons who are dependent on the sponsor financially must be excluded from participation 17. Persons with active SARS-CoV-2 infection must be excluded from participation	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
Tumours require a blood supply to provide them with oxygen and nutrients and to enable spread of cancer through blood vessels to other organs (metastasis). The formation of new blood vessels is known as angiogenesis, which is controlled by a growth factor (like a hormone) called Vascular Endothelial Growth Factor (VEGF). Many drugs have been developed that block VEGF and, in most tumour types, including ovarian cancer, the addition of VEGF inhibitors (VEGFi) to conventional anti-cancer therapy postpones recurrence of the disease. In ovarian cancer, VEGFi improve the overall outcome from the cancer in patients who have advanced stage and high-risk disease. VEGFi are now widely used in cancer medicine, yet until now there have not been any biomarkers (tests) that could be used to tell patients and their doctors whether the drugs were working or not. This is important, as VEGFi have side effects that are unpleasant for the patient. Additionally, VEGFi treatments are expensive. The VALTIVE team has discovered the first biomarker that informs doctors whether a VEGFi is blocking a tumour's blood supply. The test involves measuring a protein in the blood called Tie2, which can be measured from routine blood tests that patients have when going to the hospital. If the test shows that the amount of Tie2 decreases in the blood, it means that tumour blood vessels are blocked by VEGFi; if, on the contrary, the level increases, the blood vessels have escaped the control of VEGFi. The investigators have shown that the Tie2 test works in their initial studies in ovarian and bowel cancer. In these studies, the Tie2 blood test was based in the research laboratories. The investigators now wish to establish the test in the Christie Hospital NHS Biochemistry laboratory in Manchester so that it can be used in clinical practice rather than just as a research tool. The investigators wish to measure the relationship between loss of control of VEGF inhibitors as measured by TIE 2 and other standard ways of measuring loss of control of the tumour like increases on CT scans. There are several reasons why this test is needed for patients with ovarian cancer: - VEGFi are effective during a patient's first or subsequent treatments for advanced ovarian cancer, but it is not clear which individuals are benefitting from treatment whilst they are on treatment. - Patients who have already had one course of VEGFi can be re-treated successfully. - Patients can avoid needless side effects, if there is a way of demonstrating that the treatment is of no benefit to them. - This test will help doctors choose the best drug to control ovarian cancer and how long to continue treatment. This is very important, since other maintenance therapies are now available and the optimal duration of VEGFi therapy is well known. - Around the world many teams are developing new combination treatments including VEGFi. If these new combinations prove effective, it would be possible to use them as efficiently as possible, as they will be very expensive and may therefore be less accessible to patients. These issues highlight the critical need to establish a test in the NHS that tells patients and their doctors when VEGFi are working and when they stop working. In VALTIVE1 study, blood samples will be taken from patients who are receiving a VEGFi called bevacizumab for ovarian cancer. Patients' management will not change during their participation to the trial. The analysis of the blood sample will support the hypothesis that patients whose Tie2 level decreases in response to bevacizumab will have ovarian cancer that is controlled for much longer than those where the Tie2 level does not decrease. These results will be used to design a second trial where the investigators will prove conclusively the value of the Tie2 test. The purpose of VALTIVE1 is to optimise sample acquisition time points and analytical algorithms to support the design of VALTIVE2, a randomised discontinuation trial. In VALTIVE2, Tie2-defined, vascular non-responding patients will be randomly allocated to stop bevacizumab after 9 weeks, by when a response can be detected, or to continue bevacizumab for the conventional year of treatment. Both VALTIVE 1 and VALTIVE2 will test the theory that there is no advantage in continuing bevacizumab in a patient whose Tie2 level does not reduce in response to VEGFi. ; ; Inclusion Criteria: In order to be eligible for participation in this trial, the patient must: 1. Be willing and able to provide written informed consent for the trial 2. Age 16 years or over on day of signing informed consent 3. 3. Histologically proven ovarian, primary peritoneal or fallopian tube cancer (henceforth referred to collectively as Ovarian Cancer - OC) FIGO stage III with residual disease of more than 1cm; or stage IV; or stage III at presentation treated with neoadjuvant chemotherapy; or stage III with contraindication to debulking surgery chemotherapy 4. Planned to receive treatment with bevacizumab or biosimilar bevacizumab 5. Be scheduled to receive at least 2 successive doses of bevacizumab with 6 or more weeks of follow up blood samples after the first dose of bevacizumab if given pre-operatively; or to start bevacizumab post-operatively 6. Be eligible for receiving treatment with first line, 3-weekly carboplatin and paclitaxel chemotherapy 7. Be willing to provide blood samples and comply with trial-specific procedures Exclusion Criteria: The patient must be excluded from participating in the trial if the patient: 1. Is unsuitable for treatment with VEGF inhibitors 2. Is unable or unwilling to comply with study procedures 3. Is participating in a clinical study with an investigational product other than carboplatin, paclitaxel and bevacizumab 4. Is judged by the investigator to be unlikely to comply with study procedures 5. Is pregnant or could become pregnant and is not using adequate contraception 6. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) 7. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g. HCV RNA is detected). Testing only required if patient has a history of either of these	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 in participants with advanced solid tumors containing a TP53 Y220C mutation. ; ; Inclusion Criteria: - At least 18 years of age or 12 to 17 years of age after adequate adult safety data become available - Advanced solid malignancy with a TP53 Y220C mutation - Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 - Previously treated with one or more lines of anticancer therapy and progressive disease - Adequate organ function Exclusion Criteria: - Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug - Radiotherapy within 28 days of receiving the study drug - Primary CNS tumor (Phase 1, Phase 2 Cohort A) - History of leptomeningeal disease or spinal cord compression - Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptom - Stroke or transient ischemic attack within 6 months prior to screening - Heart conditions such as unstable angina, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities - Strong CYP3A4 inhibitors or inducers, medications with a known risk of QT/QTc prolongation, or proton pump inhibitors - History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication - History of prior organ transplant - Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer - Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection	{ "inclusion_biomarker": [ [ "TP53 Y220C" ] ], "exclusion_biomarker": [] }
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications. ; ; Inclusion Criteria: 1. Able to understand and voluntarily sign the ICF and able to comply with the study visit schedule and the other protocol requirements. 2. Patient (male or female) ≥18 years of age willing to agree to not father a child/become pregnant and comply with effective contraception criteria. 3. Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or is appropriate. 4. ECOG (Eastern cooperative oncology group) performance status ≤2 Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib): 5. Patients must be screened for Hepatitis B virus and Hepatitis C virus Exclusion Criteria: 1. Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations. (Exceptions are KRAS G12-mutant NSCLC's) 2. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. 3. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. 4. Clinically significant cardiac disease. 5. Active diarrhea or inflammatory bowel disease 6. Insufficient bone marrow function 7. Insufficient hepatic and renal function. Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib): 8. Patients with a known history of human immunodeficiency virus (HIV) seropositivity. 9. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use at the time of study entry. 10. Patients who have undergone a bone marrow or solid organ transplant 11. Patients with a history or presence of interstitial lung disease or interstitial pneumonitis 12. Bullous and exfoliative skin disorders at screening of any grade 13. Presence of clinically significant ophthalmological abnormalities that might increase the risk of corneal epithelial injury	{ "inclusion_biomarker": [], "exclusion_biomarker": [ [ "KRAS activating mutation" ], [ "NRAS activating mutation" ], [ "HRAS activating mutation" ], [ "BRAF activating mutation" ], [ "PTPN11 activating mutation" ] ] }
The incidence of breast reconstruction failure after conventional photon radiotherapy for breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for post operative breast cancer with implantation reconstruction. Proton radiotherapy for breast cancer can significantly reduce the radiation dose of the ipsilateral heart and lung, thereby reducing the incidence of cardiac events and radiation pneumonia. This study is aimed at the study of adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative breast cancer with implantation reconstruction. It can provide an ideal treatment option for such patients to effectively protect the heart and lungs without increasing the failure rate of breast reconstruction after adjuvant radiotherapy. ;NA; Inclusion Criteria: - 1: Patients with pathologically confirmed breast cancer 2: Indications: patients who need adjuvant radiotherapy after mastectomy and implant reconstruction 3: No distant metastasis 4: Had no chest and breast radiotherapy history 5: Between the ages of 18 and 80 6: ECOG general status score is 0-2,There are no serious pulmonary hypertension, cardiovascular disease, peripheral vascular disease, serious chronic heart disease and other complications that may affect the radiotherapy 7: Non pregnancy (confirmed by serum or urine β- HCG test) or lactating women 8: The patient must sign the informed consent form for receiving radiotherapy. Exclusion Criteria: - 1: No pathological confirmation； 2: Distant metastasis； 3: Had chest and breast radiotherapy history 4: Organs at risk could not achieve safe dose 5: Pregnancy (confirmed by serum or urine β- HCG test) or lactating women 6: Poor general health status, i.e. KPS<70, or ECOG>2 7: There are serious complications that may affect the radiotherapy, including: a) unstable angina, congestive heart failure and myocardial infarction requiring hospitalization in the past 6 months； b) Acute bacterial or systemic fungal infection；c) Chronic obstructive pulmonary disease exacerbation or other respiratory diseases need hospitalization； d) Patients with immunosuppression；e) With connective tissue disease, such as active scleroderma or lupus and other contraindications to radiotherapy； 8: Unable to understand the purpose of treatment or unwilling/unable to sign informed consent.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC) ; ; Inclusion Criteria: 1. Between the age of 18 to 70, male or female; 2. Diagnosed having SCLC via either histology or cytology; 3. Extensive small-cell lung cancer with recurrence or progression within ≤6 months from the end of first-line therapy; 4. At least one measurable lesion (non-intracranial, non-measurable after radiotherapy) according to RECIST version 1.1;. 5. ECOG-PS score is 0-1; 6. Expected survival time ≥12 weeks; 7. Have faverable organ and hematopoietic function, with no serious abnormality of heart, lung, liver or kidney function or immune deficiency according to laboratory tests: 8. Fertile male subjects and female subjects of reproductive age who are willing to take effective non-drug contraceptive measures from signing the informed consent form until 6 months after the last administration of the study drug. Blood pregnancy test results of women of childbearing age must be negative within 7 days before the first trial drug administration. 9. Voluntarily participate in the clinical study and sign the informed consent Exclusion Criteria: 1. Have a previous history of allergy, or are known to be severely allergic to either JK1201I or its excipients; 2. Previous treatment with topoisomerase I inhibitor (such as irinotecan, topotecan, etc.); 3. At the first use of the drug in this study, other anti-tumor chemotherapy or immunotherapy was stopped for < 4 weeks; 4. CYP3A4 strong inducer was used within 2 weeks before the first administration, or CYP3A4 suppressor or UGT1A1 suppressor was used within 1 week; 5. Patients with clinically serious gastrointestinal dysfunction (positive fecal ocidiocytic blood and severe gastrointestinal bleeding, gastrointestinal infection, obstruction or grade 1 or above diarrhea (increase of stool number ≥4 times per day)); 6. Complicated with symptomatic brain metastasis, meningeal metastasis, spinal tumor invasion, spinal cord compression; Superior vena cava syndrome, obstructive atelectasis, and bone metastasis with local symptoms that may require non-medical treatment such as radiotherapy/surgery/endoscopic therapy/interventional therapy; 7. For patients with brain metastasis (the distance from the end of whole brain radiotherapy to the first dose ≤7 days, and the distance from the end of SBRT radiotherapy to the first dose ≤3 days); 8. Patients with severe heart disease within 6 months prior to enrollment, such as unstable angina, heart failure (New York Heart Association Heart function classification > Class II), coronary angioplasty or stenting, deep vein thrombosis, myocardial infarction, etc.; Or other diseases that may affect the subject's safety, such as deep vein thrombosis, stroke, stroke (except caval infarction), poorly controlled active bleeding or known bleeding constitution, etc.); 9. Had a serious pulmonary disease, such as pulmonary fibrosis, active pulmonary tuberculosis, pulmonary hypertension, etc., within 6 months prior to inclusion; 10. Other malignant tumors occurred within 5 years before enrollment, except carcinoma in situ of the cervix, squamous cell carcinoma of the skin or basal cell carcinoma which had been treated for radical treatment before; 11. UGT1A1 suppressor (azanavir, giferozil, etc.) was used or had been used in combination drugs or within 7 days prior to the treatment of the study drugs; 12. large amounts of pleural effusion and ascites needed to be treated (continuous pleural and abdominal effusion > 1000ml within 1 week); 13. Toxicity of previous anti-tumor therapy (including chemotherapy/radiotherapy, surgical therapy, targeted therapy, immunotherapy, Chinese herbal therapy, endocrine therapy or other anti-tumor therapy) has not recovered (grade 1 or above as assessed by CTCAE version 5.0, Except for hair loss, alkaline phosphatase, glutamyltranspeptidase (GGT), or subjects eligible for inclusion after discussion with the investigator and sponsor); 14. Subjects with severe infection within 4 weeks before the first medication, including but not limited to those with infectious complications, bacteremia and severe pneumonia requiring hospitalization; 15. Pregnant or breast-feeding women; 16. Presence of human immunodeficiency virus (HIV) or active hepatitis b (HBsAg positive and HBV-DNA titer ≥1x103 copy number /mL or 200IU/ mL; 17. Subjects who have participated in other clinical trials within 4 weeks prior to obtaining informed consent; 18. Have a clear history of mental disorders; 19. Subjects considered unsuitable for the study by the investigator for other reasons.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations. ; ; Inclusion Criteria: - Patients in the dose escalation part must be ≥ 18 years of age at the time of informed consent (ICF) signature. In the phase II part, patients ≥ 12 years of age at the time of informed consent may be eligible for enrollment (not applicable in countries where enrollment is restricted by the local health authority to patients ≥ 18 years of age). Patients must have a minimum weight of 40 kg. - ECOG performance status ≤ 1 for patients ≥ 18 years of age; Karnofsky performance status ≥ 70 for patients ≥ 16 and < 18 years of age; Lansky performance status ≥ 70 for patients ≥ 12 and < 16 years of age - Patients must be suitable and willing to undergo study required biopsies according to the treating institution's own guidelines and requirements. If a biopsy is not medically feasible, exceptions may be considered after documented discussion with Novartis. For all patients in Dose Escalation - MUM: uveal melanoma with histologically or cytologically confirmed metastatic disease. Patient must be either treatment naive or have received any number of prior lines and progressed on most recent therapy - Non-MUM: advanced cutaneous or mucosal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies and has evidence of GNAQ/11 mutation based on local data For patients in Phase II - Tebentafusp naïve group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following standard therapies or that has no satisfactory alternative therapies - Tebentafusp pre-treated group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease. Patients must be previously treated with tebentafusp and have progressed - Non-MUM: patients with diagnosis of cutaneous or mucosal melanomas harboring GNAQ/11 mutations based on local data, with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies Exclusion Criteria: - Malignant disease, other than that being treated in this study. - Active brain metastases, i.e. symptomatic brain metastases or known leptomeningeal disease. - Evidence of active bleeding or bleeding diathesis or significant coagulopathy (including familial) or a medical condition requiring long term systemic anticoagulation that would interfere with biopsies. - History of anaphylactic or other severe hypersensitivity / infusion reactions to ADCs or monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction. - Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes: - 2 weeks for fluoropyrimidine therapy - 4 weeks for radiation therapy or limited field radiation for palliation within ≤ 2 weeks prior to the first dose of study treatment. - 4 weeks or ≤ 5 half-lives (whichever is shorter) for chemotherapy or biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other investigational agent. - 6 weeks for cytotoxic agents with major delayed toxicities, such as nitrosoureas and mitomycin C. - 4 weeks for immuno-oncologic therapy, such as CTLA-4, PD-1, or PD-L1 antagonists. - Clinically significant and / or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA grade ≥ 2) or clinically significant arrhythmia despite medical treatment. Other protocol-defined inclusion/exclusion criteria may apply.	{ "inclusion_biomarker": [ [ "GNAQ mutation" ], [ "GNA11 mutation" ] ], "exclusion_biomarker": [] }
An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF V600E Mutation after first-line treatment ;NA; Inclusion Criteria: - Age>=18Y - Good Organ Function - Expected survival time ≥ 3 months - Metastatic/recurrent advanced BRAF+ mCRC that have been diagnosed histologically and have failed first line treatment - ECOG score 0-1; Exclusion Criteria: - arm 1 ： Previous treatment with BRAF inhibitors or MEK inhibitors - Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable). - Active clinical severe infection; - A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.	{ "inclusion_biomarker": [ [ "BRAF V600E" ] ], "exclusion_biomarker": [] }
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also known as AKT) in cancer patients. Importantly, evidence from preclinical studies has demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase (PI3'K)-AKT activity. ;NA; Inclusion Criteria: - Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent - Life expectancy ≥12 weeks - Males and females age ≥ 18 years - Allowable type and amount of prior therapy: First line anti-Programmed death receptor and ligand (PD1/PD-L1), either single agent or in combination with chemotherapy - Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 - Measurable disease per RECIST version 1.1 - Diagnoses of advanced/metastatic NSCLC and have failed or are intolerant to 1st line anti-PD1/PD-L1, either single agent or in combination with chemotherapy, and have either exhausted or decline or not be candidates for all available standard of care therapies. - Adequate organ function - Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for 90 days following completion of therapy - Men of child-bearing potential must agree not to donate sperm while on this study and for 90 days after their last study treatment Exclusion Criteria: - Is not concurrent enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study - Is not currently on or is not anticipated to use other investigational agents within 14 days prior to and while participating in this study - Does not have mixed small cell and non-small cell lung cancer histology - Does not have any unresolved toxicity CTCAE >Grade 2 from the prior 1st immunotherapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study drug may be included - Patients who have targetable mutations that qualify for targeted therapy (e.g. mutations of epidermal growth factor receptor (EGFR), serine/ threonine- protein kinase (BRAF), anaplastic lymphoma kinase (ALK), tyrosine- protein kinase (ROS1), neurotrophic receptor tyrosine kinase (NTRAK)) will be excluded from this study - Is not on concomitant therapy intended for the treatment of cancer (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal therapy) for 14 days prior to starting study treatment, depending on the agent and during study treatment, until disease progression is documented and the patient has discontinued study treatment, with the exception of palliative radiotherapy and local therapy per PI discretion - Does not chronically use a strong cytochrome P4503A4 (CYP3A4/5) inhibitor or inducer, or sensitive CYP3A substrates with a narrow therapeutic window - Has not had recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug - Does not have uncontrolled systemic disease - Does not have uncontrolled brain metastasis - Does not have history of allergy to taxanes - Does not have history of leptomeningeal carcinomatosis - Does not have recent history of myocardial infarction (MI) or symptomatic coronary artery disease within 6 months of screening - Is not receiving active therapy for HIV, hepatitis B or hepatitis C - Does not have history of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills - Does not have history of Type I or Type II diabetes mellitus requiring insulin (Patients who are on a stable dose of oral diabetes medication greater than or equal to 2 weeks prior to initiation of study treatment - Does not have Grade greater than or equal to 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia - Does not have history of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis) - Does not have active pneumonitis - Does not have history of lung disease: interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections - Does not have uncontrolled pleural effusion/pericardial effusion/or ascites as determined by the investigator - Does not have active ventricular arrhythmia requiring medication - Does not have psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent - Is not pregnant, breast feeding or planning to become pregnant while receiving study treatment or for less than 90 days after the last dose of study treatment - For males with partners of childbearing potential, is not planning to father a child or donate sperm while receiving study treatment or for less than 90 days after the last dose of study treatment - Does not have any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results	{ "inclusion_biomarker": [], "exclusion_biomarker": [ [ "EGFR mutation" ], [ "BRAF mutation" ], [ "ALK mutation" ], [ "ROS1 mutation" ], [ "NTRAK mutation" ] ] }
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib. ; ; Inclusion Criteria: Participants that are diagnosed with MM, high- or intermediate-risk SMM in the iStopMM study will be invited to participate in this study. Each patient must meet all the following inclusion criteria to be enrolled in the study: 1. Age more than 18 years. 2. Active MM or 3. Smoldering myeloma, which is untreated, as defined by: Measurable M spike OR pathological FLC ratio AND bone marrow PC% > 10% 4. The following laboratory values obtained ≤ 30 days prior to registration - Calculated creatinine clearance ≥ 30mL/min (using CKD-EPI equation) - Absolute neutrophil count (ANC) > 1000/mm3 - Platelet count > 75000/mm3 - Hemoglobin ≥ 8.0 g/dL - Total bilirubin ≤ 1.5 x ULN - ALT and AST ≤ 3 x ULN 5. Measurable disease as defined by at least one of the following: - Serum monoclonal protein > 1.0g/L - > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis - Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio 6. Prior therapy for the treatment of solitary plasmacytoma is permitted, but >7 days should have elapsed from the last day of radiation. NOTE: Prior therapy with clarithromycin, DHEA, anakinra, pamidronate or zoledronic acid is permitted. Any additional agents not listed must be approved by the Principal Investigator. 7. ECOG performance status 0, 1 or 2 8. Negative pregnancy test done ≤7 days prior to C1D1, for women of childbearing potential only. 9. Willing to follow strict birth control measures as outlined in the protocol. 10. Female subjects: If they are of childbearing potential, agree to one of the following: Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of trial drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program (appendix 1), if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.) 11. Male subjects: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: Agree to practice effective barrier contraception during the entire trial treatment period and through 90 days after the last dose of trial drug, OR Must also adhere to the guidelines of any treatment-specific pregnancy prevention program (appendix 1), if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). Willing to return to enrolling institution for follow-up during the Active Treatment Phase of the trial. Agree not to donate sperm for at least 90 days after the last dose of carfilzomib 12. Willing to provide samples for planned research 13. Life expectancy > 6 months Exclusion Criteria: 1. MGUS or low-risk smoldering myeloma. 2. Diagnosed or treated for another malignancy ≤ 2 years before trial enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. NOTE: Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. 3. If any of the following exist at screening, subject will not be eligible for trial because this trial involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: Pregnant women Nursing women Men or women of childbearing potential who are unwilling to employ adequate contraception (per protocol) 4. Other co-morbidity which would interfere with subject's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease 5. Other concurrent chemotherapy, or any ancillary therapy considered investigational. NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment. 6. Peripheral neuropathy > Grade 3 on clinical examination or grade 2 with pain within 30 days prior to C1D1. 7. Major surgery ≤14 days prior to C1D1. 8. Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past 6 months. Note: Prior to trial entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant. 9. Known human immunodeficiency virus (HIV) positive. 10. Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection. 11. Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. 12. Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products. Known allergies, hypersensitivity, or intolerance to trial drugs. 13. Inability to comply with protocol/procedures. 14. LVEF < 40% for patients treated with carfilzomib.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a phase I, first in human, single arm, open label study that will assess safety, tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM).The study will consist of two parts: dose escalation (Part 1) and dose expansion (Part 2).The dose escalation (Part 1) of the study will evaluate the safety and tolerability of FHND6091 using a dose escalation scheme to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). And the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of FHND6091 at two selected dose levels to characterize the safety, tolerability and efficacy of FHND6091. A total of 40 evaluable participants will be enrolled in the study. The participants receiving treatment in part 1 and part 2 may continue combination treatment for a total of up to 12 cycles. After 12 cycles of therapy, the participants will continue treatment until the occurrence of PD, intolerable AEs, consent withdrawal, death or end of study based on the judgement of investigator's assessment. ;NA; Inclusion Criteria: - Patients must give written informed consent. - Male or female patients 18 years or older. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2. - Life expectancy of at least 12 weeks. - Patients with multiple myeloma who have relapsed or refractory, intolerance or refuse treatment following at least 3 regimens or lines of therapy that must include an IMID (lenalidomide or thalidomide), a proteasome inhibitor (bortezomib) , a CD38-targeted mAbs and corticosteroids. Patients must have received transplant therapy or are not suitable for transplant. - For Patients With Relapsed Refractory Multiple Myeloma must have measurable disease defined by at least 1 of the following 2 measurements: Serum M-protein ≥ 5 g/L, or Urine M-protein ≥ 200 mg/24 hours. For patients with serum free light chain as measurable disease: Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio. - Clinical laboratory values as specified below within 14 days before the first dose of study drug: 1. Hemoglobin ≥ 75 g/L, Absolute neutrophil count ≥ 1.0 x 10E9/L and Platelet count ≥ 75 x 10E9/L without blood transfusion, EPO or G-CSF and other medical support for at least 14 days prior to receiving screening. 2. Total bilirubin levels ≤ 2 x ULN, AST (SGOT) and ALT (SGPT) ≤ 2 x ULN. 3. Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/minute as calculated by Cockcroft-Gault method. 4. Corrected Serum Calcium ≤ ULN. - For man and women of childbearing potential: agreement to remain abstinent or use contraception, during the treatment period (including treatment interruptions) and for at least 180 days after the last dose of FHND6091 was administered. Women of childbearing potential should be negative by serum pregnancy test within 7 days prior dosing. Exclusion Criteria: - Documented allergy to proteasome inhibitor or ； - Patients with peripheral neuropathy ≥ Grade 2 or Grade 1 peripheral neuropathy with pain. - Patients with diarrhea > Grade 1 (Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline). - Patients received chemotherapy, radiation therapy, targeted therapy, immunotherapy or other systemic anticancer therapy within 14 days prior FHND6091 treatment. - Patients received ixazomib treatment within 5 elimination half-life prior first dose of FHND6091 treatment. - Patients received allogeneic stem cell transplantation or autologous stem cell transplant with 12 weeks before screening. - Patients with symptomatic brain metastases, leptomeningeal metastases or, spinal cord compression or central nervous system (CNS) injuries/abnormalities based on investigator judgement. - Evidence of severe or uncontrolled systemic diseases (eg, unstable or uncompensated respiratory, hepatic or renal disease), or receive major surgery. - Patients with unstable hypertension after drug treatment (SBP ≥140 mmHg, DBP ≥90 mmHg ) or heart failure, myocardial ischemia or myocardial infarction, unstable angina, arrhythmia (The corrected QT interval (Fridericia formula) interval (QTcF) > 470 msec for females and > 450 msec for men in electrocardiogram (ECG)). - Patients with active, or a history of immunodeficiency, including HIV positive or other acquired and congenital immunodeficiency diseases, or a history of solid organ transplant. - Patients with a history of other serious underlying diseases, such as: a, history of a clear neurological or psychiatric disorder, including epilepsy or dementia. b, HBV surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive HCV antibody. c, presence of infection requiring systemic treatment. - Systemic treatment with strong inhibitors of of CYP3A4 or strong CYP3A4 inducers within 5 elimination half-life prior first dose of FHND6091 treatment. - Patients have not recovered (ie, ≤ Grade 1 toxicity by CTCAE 5.0) from the reversible effects of prior antineoplastic therapy (except for alopecia ) - Patients with other malignancy； - Treatment with any investigational products within 28 days before the first dose of study treatment	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
In the current protocol, we propose a study to evaluate a novel, combined esophageal sponge-methylation biomarker strategy for the early detection of esophageal squamous cell carcinoma (ESCC) as well as its precursor, esophageal squamous dysplasia (ESD). This strategy leverages the 'EsophaCap', a swallowable, retrievable sponge, with subsequent evaluation of the sample using a novel molecular biomarker assay. This biomarker assay evaluates methylation levels in three genes, which have been shown to differ significantly between ESCC cases and controls in pilot studies. Detection of methylation markers highly associated with ESCC could help identify patients with concurrent ESCC or at high risk of imminently developing this condition. If successful, this strategy could result in a paradigm shift for esophageal cancer control strategies in Tanzania and other high-incidence ESCC regions. ; ; Inclusion Criteria: ESCC Cases (Group 1): - Male or female >= 18 years of age at screening visit. - Patients are currently seen for clinical care at Muhimbili National Hospital (MNH)-Upanga or at MNH-Mloganzila. - Patient meets one of the following two criteria- - Patients with a confirmed diagnosis of ESCC as evidenced by histological confirmation OR - Patient planned to undergo EGD with biopsy for suspected ESCC based upon any one of the following clinical criteria: (1) findings on computed tomography (CT) scan; (2) findings on barium swallow; (3) findings on endoscopy without biopsy confirmation, (4) symptoms of dysphagia and/or odynophagia without an alternative explanation for these symptoms. - Patient must be able to swallow liquid (Ogilvie's score < 3). - Patients must be well enough to participate in a 20-minute interview or have a close relative who is able to do so on their behalf. - Patients must be willing to be contacted either in person or via phone 7-10 days following administration of the 'EsophaCap' sponge device. - Native of Tanzania. - Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Non-ESCC study participants (Group 2): - Male or female ≥ 18 years of age at screening visit. - Patients are currently seen for clinical care at MNH-Upanga or at MNH-Mloganzila. - Patient is scheduled to undergo EGD for a suspected non-malignant condition with no symptoms concerning for esophageal cancer (i.e. dysphagia or odynophagia). - Patient must be able to swallow liquid (Ogilvie's score < 3). - Patients must be well enough to participate in a 20-minute interview or have a close relative who is able to do so on their behalf. - Patients must be willing to be contacted either in person or via phone 7-10 days following administration of the 'EsophaCap' sponge device. - Native of Tanzania. - Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria: ESCC Cases (Group 1): - Known pregnancy during participation in the study. - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. - Clinical instability (i.e. hypotension or a recent cardiovascular event). - Any history of upper gastrointestinal bleeding within the past 3 months (including reported history of hematemesis and/or melena). - Diagnosis of peptic ulcer disease within the last 3 months. - Known history of esophageal varices. - Patients taking anticoagulation or antiplatelet therapy/medication (warfarin, clopidogrel, aspirin, heparin or enoxaparin) for high-risk conditions. - Patients with an active extra-esophageal malignancy (not currently in remission). - Patient with a known history of a non-malignant esophageal stricture. - Patients with esophageal stents currently in place. - Patients with a history of radiation therapy to the head, neck, any part of the gastrointestinal tract (including esophagus) or thorax. - Patients who have previously received chemotherapy in the last 12 months - Patients with any history of major surgery for esophageal cancer (e.g. esophageal bypass, esophagectomy, etc.). - Patients who have a known history of or clinical symptoms concerning for tracheoesophageal fistula (aspiration history, severe cough) - Patients with a known history of small bowel obstruction - Patients with a history of bleeding complications during esophageal biopsy. - Patients with any history of a head and neck malignancy. - Patients with a known bleeding disorder - Patients with known thrombocytopenia (less than 50,000 platelets per microliter) - Individuals who are not permanent residents or natives of Tanzania. - Inability to follow instructions. - Unable to provide informed consent. Non-ESCC study participants (Group 2): - Known pregnancy during participation in the study. - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. - Clinical instability (i.e. hypotension or a recent cardiovascular event). - Any history of upper gastrointestinal bleeding within the past 3 months (including reported history of hematemesis and/or melena). - Diagnosis of peptic ulcer disease within the last 3 months. - Known history of esophageal varices. - Patients taking anticoagulation or antiplatelet therapy/medication (warfarin, clopidogrel, aspirin, heparin or enoxaparin) for high-risk conditions. - Patients with an active extra-esophageal malignancy (not currently in remission) or any history of a non-cutaneous malignancy diagnosed within the previous five years. - Patient with a known history of esophageal strictures disabling passage of the capsule. - Patient with esophageal stents currently in place. - Patients with a history of radiation therapy to the head, neck, any part of the gastrointestinal tract (including esophagus) or thorax. - Patients with a known history of small bowel obstruction - Patients with a known bleeding disorder - Patients with known thrombocytopenia (less than 50,000 platelets per microliter) - Individuals who are not permanent residents or natives of Tanzania. - Allergy to iodine - Presence of goiter. - Inability to follow instructions. - Unable to provide informed consent	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM. ;NA; Inclusion Criteria: - Adequate bone marrow function - eGFR ≥ 30 mL/min - Total bilirubin ≤ 1.5 × upper limit of normal (ULN) - Serum calcium (corrected for albumin) at or below the ULN range Exclusion Criteria: - Candidate for treatment regimens known to provide clinical benefit in MM - Active infection requiring parenteral anti-infective treatment - Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion ;NA; Inclusion Criteria: 1. Male or female subjects aged ≥18 years old; 2. Phase I dose escalation period: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, assessed by investigator that no standard therapy exists, or the tumor has relapsed, progressed or was nonresponsive to available therapies, or intolerance, or not suitable to standard therapy at current stage. Priority will be given to patients who have previously documented NTRK or ROS1 gene fusion confirmed by the central laboratory; Phase I dose expansion and Phase II: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, patients can provide a written report of pathological diagnosis of NTRK or ROS1 positive tested by qualified laboratory; 3. Phase I dose expansion cohort 1 and Phase II cohort 1: locally advanced, or metastatic solid tumor with NTRK gene fusion Phase I dose expansion cohort 2 and Phase II cohort 2： locally advanced, or metastatic NSCLC with ROS1 gene fusion that has progressed to crizotinib and other therapies or was intolerance to crizotinib Phase I dose expansion cohort 3: locally advanced, or metastatic NSCLC with ROS1 gene fusion who have not previously received crizotinib or other therapy. 4. phase I dose escalation: at least 1 measurable target lesion according to RECIST version 1.1 Phase I dose expansion and Phase II: at least 1 measurable target lesion according to RECIST version 1.1 (Tumor lesions treated with prior radiation or other local treatment are considered measurable if they show definite progression) 5. ECOG PS 0-1 6. Life expectancy ≥ 3 months. 7. Adequate organ function: Baseline laboratory values fulfilling the following requirements: Absolute neutrophils count (ANC) ≥1.5 × 109/L; Platelets (PLTs) ≥75 × 109/L; Hemoglobin ≥ 85g/L; Serum creatinine≤ 1.5 × ULN， or creatinine clearance ≥50 mL/min/1.73m2(only when serum creatinine>1.5 × ULN); Total serum bilirubin ≤1.5 × ULN; Liver transaminases (AST/ALT) ≤ 2.5 × ULN，≤3× ULN if liver metastases are present or liver cancer patients; Activated Partial Thromboplastin Time≤1.5× ULN；International Normalized Ratio (INR)≤1.5× ULN； 8. Eligible patients (male and female) who are fertile must agree to at least use a reliable contraceptive method with partner during the trial and within 90 days from the last dose; Women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose of the trial. Exclusion Criteria: 1. Received anti-tumor therapy such as chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy or other therapy within 4 weeks prior to the first dose of the investigational drug except the following: Nitroso ureas or mitomycin C within 6 weeks before the first dose of the drug; Oral fluorouracil and small molecule targeted drugs within 2 weeks prior to the first dose of drug or within 5 half life (whichever is longer); 2. Received other unmarketed investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug; 3. Major organ surgery (except biopsy) or significant trauma within 4 weeks prior to first dose of the investigational drug or required elective surgery during the trial; 4. Adverse reactions to previous antitumor therapy have not recovered to NCI CTCAE 5.0 ≤ grade 1 (except for alopecia, grade 2 peripheral neurotoxicity, stable hypothyroidism after hormone replacement therapy, etc.); 5. Inability to swallow drug, or a condition that the investigator judged to severely affect gastrointestinal absorption (eg:Chronic Diarrhea, intestinal obstruction, etc.); 6. Cerebral or meningeal metastases with clinical symptoms. The below patients were allowed to be included: those who were asymptomatic, stable, and did not require steroid treatment for more than 4 weeks prior to the start of study treatment (if the cerebral metastases had undergone radiotherapy or/and surgery, radiotherapy and surgery should be at least 1 month prior to the first dose) ; 7. Known active infections and currently need intravenous anti-infective therapy; 8. History of immune deficiencies, including positive HIV antibody tests; 9. Active Hepatitis B (HBsAg and/or HBcAb positive with HBV-DNA > 500IU/ml) or hepatitis c virus infection (positive test results of anti-HCV with positive HCV-RNA ); 10. Known interstitial lung disease (except for radioactive pulmonary fibrosis that does not require steroid therapy); 11. History of serious cardiovascular disease; 12. Pregnant or lactating women.	{ "inclusion_biomarker": [ [ "NTRK fusion" ], [ "ROS1 fusion" ] ], "exclusion_biomarker": [] }
Study STML-901-0119 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-901 in patients with Advanced Solid Tumors. ; ; Inclusion Criteria: 1. 18 years old or older. 2. Population by study stage: 1. Part 1a: Patients with advanced, metastatic, and/or progressive solid tumors for whom there is no effective standard therapy available. 2. Part 1b: Patients with histologically confirmed, advanced, metastatic, unresectable, and/or progressive solid tumors for whom there is no effective standard therapy available and their PI3K or DNA-PK pathway is deregulated or their tumor genetic profile has been shown to correlate with sensitivity to PI3K and/or DNA-PK inhibition based on clinical and preclinical experience. Specific criteria will be determined based on ongoing experiments and will be introduced in a future protocol amendment. 3. Evaluable or measurable disease. 4. Eastern Cooperative Oncology Group (ECOG) performance status ≤2. 5. Able to take oral medications. 6. If a woman of childbearing potential (WOCBP), the patient has a negative serum or urine pregnancy test within 1 week before Cycle 1, Day 1 (C1D1). Refer to Section 8.1.3 for further practical information about contraception. 7. The patient (either male or female) agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 1 month after the last dose of SL-901. Refer to Section 8.1.3 for further practical information about contraception. 8. Able to provide written informed consent. 9. Willing to provide consent for biomarker analysis of existing paraffin-embedded tumor samples. Exclusion Criteria: 1. Received an investigational anticancer drug within 4 weeks of the first planned SL-901 dose. 2. Received major surgery, radiotherapy, or immunotherapy within 4 weeks of C1D1. Localized palliative radiotherapy is permitted for symptom control. 3. Received chemotherapy regimens with delayed toxicity within 4 weeks (6 weeks for prior nitrosourea or mitomycin C) of C1D1. 4. Received chemotherapy regimens given continuously or on a weekly basis which have limited potential for delayed toxicity within 2 weeks of C1D1. 5. Clinically significant, unresolved toxicity from previous anticancer therapy ≥Grade 2 (except alopecia), as determined by the Investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. 6. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs. 7. Left ventricular ejection fraction <50%. 8. Corrected QT interval (based on Fridericia's formula) >450 msec. 9. Type 1 or 2 diabetes mellitus requiring medication. (In Part 1b, patients with type 2 diabetes mellitus controlled by medication, as indicated by a glycated hemoglobin of ≤7.5% are eligible.) 10. Known active human immunodeficiency virus, hepatitis B, or hepatitis C infection. 11. Ongoing systemic bacterial, fungal, or viral infection. 12. History of interstitial pneumonitis. 13. Absolute neutrophil count (ANC) 1.5×10⁹/L. 14. Hemoglobin <10 g/dL. 15. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5x the upper limit of normal (ULN). 16. Known hypersensitivity or allergy to the active ingredient or excipients of SL-901. 17. Breast-feeding females.	{ "inclusion_biomarker": [ [ "PI3K pathway deregulation" ], [ "DNA-PK pathway deregulation" ] ], "exclusion_biomarker": [] }
The Proseven trial is a prospective interventional study that will evaluate the toxicity and efficacy of MR-guided stereotactic body radiotherapy (SBRT) in the profound hypofractionated treatment of prostate cancer. Patients will be treated in 5 daily fractions within a short overall treatment time (OTT) of 7 days. A simultaneous integrated boost (SIB) will be delivered to the intraprostatic dominant lesion (if present) in this study. Besides a potential biological impact of this innovative prostate SBRT treatment, the reduced OTT offers also benefits in terms of patient convenience. The primary endpoint is clinician reported grade 2 or more acute gastrointestinal (GI) and genitourinary (GU) toxicity, assessed using CTCAE v 5.0 and RTOG, measured up to 3 months after the first treatment fraction. ;NA; Inclusion Criteria: - Age > 18 y - Histologically confirmed prostate adenocarcinoma - Low risk: cT1c-T2a, Gleason score 6, PSA < 10ng/mL - Favorable intermediate risk: 1 intermediate risk factor, Gleason 3+4 or less, < 50% positive biopsy cores) - Unfavorable intermediate risk: > 1 intermediate risk factor, Gleason 4+3, > 50% positive biopsy cores) - Limited high risk: cT3a with PSA < 40ng/mL or cT2a-c with a Gleason score > 7 and/or a PSA > 20ng/mL but < 40ng/mL - World Health Organization performance score 0-2 - Written informed consent Intermediate risk factors: T2b-T2c, Gleason 7, PSA 10-20 ng/mL Exclusion Criteria: - Transurethral resection (TUR) < 3months before SBRT - International Prostate Symptom Score (IPSS) > 19 - Prostate volume > 100cc on transrectal ultrasound (TRUS) - Stage cT3b-T4 - N1 disease (clinically or pathologically) - M1 disease (clinically or pathologically) - PSA > 40ng/mL - inflammatory bowel disease - immunosuppressive medications - prior pelvic RT - contra-indications for MRI	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available ; ; Inclusion Criteria: - 1 Informed consent obtained prior to any protocol mandated study specific procedures in accordance with institutional policies. - 2 Either loco regionally recurrent or metastatic EBV positive RECIST evaluable nasopharyngeal carcinoma not amenable to curative treatment with no accepted effective standard of care therapeutic option. Addendum for phase 2 exploratory cohorts: subjects with PTLD or EBV lymphoma not amenable to curative treatment with no accepted effective standard of care therapeutic option. - 3 Not eligible for other approved or standard therapies - 4.Prior palliative radiation must have been completed at least 2 weeks prior to study Cycle 1 Day 0 - 5.Prior anti cancer systemic treatment must have been completed greater than 4 weeks prior to the first dose of VK 2019 or subjects must have recovered from all acute prior treatment related AEs - 6.Toxicities related to prior anti cancer therapy must have returned to Grade 1 or less. Peripheral neuropathy must be Grade 2 or less. Chronic but stable toxicities Grade > 1 (eg, dysphasia, G tube dependence, etc.) are permissible. - 7.Age ≥ 18 - 8.Absolute neutrophil count > 1500/µL (stable off any growth factor for at least 1 week of study drug administration) - 9.Hemoglobin > 9g/dL (transfusion to achieve this level is permitted) - 10.Platelet count > 75 x 103/ µL (transfusion to achieve this level is NOT permitted) - 11.Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) .Total serum bilirubin ≤ 1.5 x ULN - 12.Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min as calculated per Cockcroft Gault equation - 13.Urinary protein < 2+ by dipstick. If dipstick ≥ 2+, then a 24 hour urine collection can be done and the subject may enter only if urinary protein is < 1 g/24 hour - 14.Sexually active subjects must agree to utilize birth control method during treatment and for 18 weeks after the last dose of VK 2019. - 15.Eastern Cooperative Oncology Group (ECOG) performance status 2 or less. - 16.Ability to understand and the willingness to personally sign the written IRB approved informed consent document. Exclusion Criteria: - 1.Prior therapy restrictions. - 2.Concurrent treatment with systemic cancer directed therapy including complementary, alternative, herbal or nutritional supplement based treatments whose purpose is for anti cancer effect - 3.Severe or active symptomatic cardiopulmonary diseases, including unstable angina, congestive heart failure, or peripheral vascular disease within 12 months prior to study drug administration; and/or chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 4 weeks prior to study drug administration. Subjects with effectively treated conditions (eg, stenting for coronary artery disease) are eligible if stable for at least 4 weeks prior to study drug administration - 4.Metastatic disease with active central nervous system (CNS) involvement, defined as parenchymal brain involvement. Subjects with cranial nerve or base of skull involvement without the above are eligible. Subjects with CNS metastases that are stable on imaging at least 1 month following focal treatment with radiation are eligible - 5.Known history of human immunodeficiency virus (HIV) unless the HIV positive subjects has: 1. A stable regimen of highly active anti retroviral therapy (HAART) 2. No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections 3. A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR based test - 6.Serious uncontrolled medical disorder or active infection which would, in the opinion of the Investigator, impair the ability of the subject to receive protocol therapy or whose control may be jeopardized by the complications of this therapy - 7.NPC subjects: Have received a prior organ allograft or allogeneic bone marrow transplant. - 8.Current non prescription drug or alcohol dependence - 9.For all female subjects: pregnancy or breastfeeding - 10.All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment - 11.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the subject inappropriate for entry into the study - 12.Corrected QT by Fridericia's formula (QTcF) of > 470 ms average (mean) on triplicate ECG performed during screening	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a first in human, multicenter, open label, Phase 1a/b dose escalation and dose expansion study to establish the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and evaluate the safety and tolerability of QD oral dosing of HC 7366 in a dose escalating fashion in subjects with advanced solid tumors. Up to 36 subjects will be enrolled into the Phase 1a dose escalation part of the study. Every effort will be made to ensure approximately 50% of all subjects enrolled in this study will be subjects with the tumors of special interest such as squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and transitional cell carcinoma of the bladder (TCC). Subjects with other solid tumor types are also eligible provided study selection criteria are met and they do not exceed 50% of all enrolled subjects. The study will be conducted in the United States at approximately 3 to 5 sites. This Phase 1a/b study will follow a traditional 3+3 design. The starting dose level will be 10 mg QD, escalating to 20, 40, 75, 125, and 150 mg QD as safety allows. All doses are to be administered in the fasting state with water at least 1 hour before food or at least 2 hours after food. The Phase 1b dose expansion part will involve cohort expansion at up to 2 dose levels selected from the dose escalation data by the safety monitoring committee (SMC), to obtain additional safety and preliminary efficacy information. Each cohort in Phase 1b will enroll 15 subjects. The study will be expanded into a Phase 2 study via protocol amendment which will then assess the dose and tumor type(s) selected in Phase 1a/b as the most appropriate for further clinical development. Subjects will be dosed until unacceptable toxicity, disease progression per immune-related Response Evaluation Criteria in Solid Tumors (iRECIST), discontinuation of treatment for other protocol allowed reason (eg, subject refusal), any other administrative reasons, or after 2 years of treatment, whichever occurs first. For scheduling purposes, dosing will occur in 3 week cycles and computed tomography (CT) scans will be conducted once every 6 weeks with the first postbaseline scan after 6 weeks of dosing (precycle 3). ; ; Inclusion Criteria: 1. Have a signed an informed consent form prior to any study specific procedures or treatment 2. Be ≥18 years of age (male or female) at the time of consent 3. Have 1 of the following tumor types with qualifying characteristics, and have received at least 1 and no more than 5 prior lines of therapy: 1. SCCHN 2. CRC 3. NSCLC 4. TCC 5. Other solid tumors (eg, carcinoma of unknown primary) with the exception of rapidly progressing neoplasms (eg, pancreatic cancer, glioblastoma, hepatocellular carcinoma). Note: Subjects do not need to have progressed through all possible available therapies with known clinical benefit for their respective cancers to participate in this study. Note: Subjects with SCCHN, CRC, NSCLC, and TCC are a priority and should constitute as a whole, at least 50% of the enrolled population. Enrollment of all others will be capped when reaching a combined 50%, in order to maintain 18 slots for subjects with SCCHN, CRC, NSCLC, and TCC. 4. Have at least 1 radiologically measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 defined as a lesion that is at least 10 mm in longest diameter or lymph node that is at least 15 mm in short axis imaged by CT scan or magnetic resonance imaging and obtained by imaging within 28 days prior to study treatment. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions 5. Have resolution of all previous treatment related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (≤Grade 2) and alopecia. If the subject received major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention 6. If subjects were previously treated with immune checkpoint inhibitors, at least 4 weeks must have elapsed since the last dose, and toxicities resolved as above 7. Subjects must have at least one biopsiable lesion at baseline. Biopsies in this clinical study will conform to American Society of Clinical Oncology's Ethical Framework for Including Research Biopsies in Oncology Clinical Trials. Provided there are suitable and accessible lesions, no biopsy contraindications, minimal risk of complications and a positive informed decision, subjects are willing to provide fresh tissue for biomarker analysis, and, based on the adequacy of the tissue sample quality, for assessment of biomarker status. Two biopsies will be necessary: at baseline (within 15 days prior to study Day 1) and at the time of the first response assessment CT scan at Cycle 3/Day 1 (+7 days). Newly obtained biopsy specimens are preferred to archived samples and formalin fixed, paraffin embedded block specimens are preferred to slides 8. Have Eastern Cooperative Oncology Group performance status of 0 or 1 and sustained between screening and initiation of dosing on Day 1 9. Have no swallowing difficulties that would prevent compliance with oral dosing 10. Have not experienced >10% body weight loss in the previous 4 weeks 11. Have a serum albumin level >3 g/dL 12. Have life expectancy of 3 months or greater as determined by the treating physician 13. Have adequate organ function on Day 1, as defined by meeting all of the following criteria: 1. Total bilirubin ≤1.5 × upper limit of normal (ULN) OR direct bilirubin ≤ULN for subjects with total bilirubin levels >1.5 x ULN 2. Aspartate aminotransferase and alanine aminotransferase ≤2.5 × ULN or ≤5 × ULN for subjects with known hepatic metastases 14. Have adequate renal function on Day 1, as defined by creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL/min, as per the below Cockcroft Gault formula 15. Have adequate hematologic function on Day 1, as defined by meeting all of the following criteria: 1. Hemoglobin ≥9 g/dL (uncorrected by red blood cell transfusion or erythropoietin support) 2. Absolute neutrophil count ≥1.5 × 109/L 3. Platelet count ≥100 × 109/L 16. Have adequate coagulation function on Day 1, as defined by either of the following criteria: 1. International normalized ratio (INR) <1.5 × ULN OR for subjects receiving warfarin or low molecular weight heparin, the subject must, in the investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for these subjects may exceed 1.5 × ULN if that is the goal of anticoagulant therapy 2. Activated partial thromboplastin time <1.5 × ULN unless subject is receiving anticoagulant therapy, provided prothrombin time or partial thromboplastin time is within therapeutic range of intended use of anticoagulants 17. Have normal or adequately controlled pan-endocrine function (pituitary, adrenal, thyroid, pancreatic, gonadal). Subjects on hormonal supplementation must be stable at their treatment doses 18. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required 19. Female subjects of childbearing potential must be willing to use an adequate form of contraception from the signing of the ICF until 90 days after the last dose of study medication 20. Female subjects must agree not to breastfeed and not to donate ova starting at screening and throughout the study treatment, and for 90 days after the final administration of study drug 21. Male subjects with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or for the time their partner is breastfeeding throughout the study treatment and for 90 days after the final administration of study drug 22. Male subjects must not donate sperm during the treatment period and for at least 90 days after the final administration of the study drug 23. Male subjects with female partner(s) of child bearing potential must agree to use a condom with spermicide during the treatment period and for at least 90 days after the final administration of the study drug 24. Be willing and have the ability to comply with scheduled visits (including geographical proximity), treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: 1. Had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of study treatment or who has not recovered from adverse reactions due to a previously administered agent or major surgery 2. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment 3. Has a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor 4. Has known history of active tuberculosis 5. Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) 6. Has known active hepatitis B (eg, hepatitis B surface antigen reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [RNA] [qualitative]) infection 7. Has been diagnosed with severe acute respiratory syndrome coronavirus 2 infection confirmed by real time polymerase chain reaction (PCR) test as per the local guidelines at screening and positive by PCR within 7 days prior to the first dose of study treatment 8. Has a history of clinically severe autoimmune disease, or history of organ transplant 9. Has a history of retinitis or photosensitive skin disorders including (but not limited to) erythema multiforme, atopic eczema, psoriasis, viral exanthemata, pemphigus, and dermatitis herpetiformis 10. Has known additional malignancy that is progressing or required active treatment within the previous 5 years. Exceptions include basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy, superficial bladder cancer, or in situ cervical cancer. Subjects with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease free for at least 5 years 11. Has known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using systemic steroids for at least 7 days prior to study treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability 12. Has a history of interstitial lung disease, pneumonitis within 12 months prior to screening, or current pneumonitis 13. Has an active infection requiring systemic therapy 14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator 15. Has a clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome, symptomatic or uncontrolled arrhythmia, congestive heart failure, baseline electrocardiogram (ECG) abnormalities, including, but not limited to, QTc prolongation to greater than 470 ms, or any Class III or IV cardiac disease as defined by the New York Heart Association Functional Classification 16. Has overt or latent disorders of the exocrine pancreas (such as acute or chronic pancreatitis of any etiology) or chronic (including autoimmune) gastrointestinal disorders such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, lupus, scleroderma, Sjogren's syndrome, and polyarteritis nodosa 17. Has a known psychiatric or substance abuse disorder(s) that would interfere with informed consent or cooperation with the requirements of the study 18. Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through 90 days after the final administration of the study drug 19. Is a first degree relative of the investigator, staff, or study sponsor.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
Despite improvements in outcomes for patients with localized Ewing sarcoma, patients with relapsed metastatic Ewing sarcoma continue to have poor outcomes with current chemotherapy options. A large body of preclinical data supports a role for IGF-1R inhibition in the treatment of Ewing sarcoma. More recently, clinical trials of IGF-1R monoclonal antibodies have demonstrated single- agent activity in patients with relapsed Ewing sarcoma. Ganitumab (AMG 479) is a fully human monoclonal antibody directed against IGF-1R. We are proposing this single-agent expanded access IND to provide our patient the opportunity to benefit from this treatment after having developed progressive disease after multiple lines of prior therapy. ; ; Inclusion Criteria: Diagnosis: Confirmed translocation-positive Ewing sarcoma Organ Function Requirements: Serum creatinine < 1.4 Adequate liver function - Total bilitubin <1.5x upper limit of normal for age - SGPT (ALT) < 5x upper limit of normal for age Adequate cardiac function > 50% by echocardiogram Bone Marrow - Absolute neutrophil count > 750 - Platelet count > 75 Exclusion Criteria: - Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained. Lactating females are not eligible unless they have agreed not to breastfeed their infants for the duration of protocol therapy. Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapy. - Patients with known pre-existing diabetes mellitus will be excluded from study.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
Patients entered into the study will receive ASTX727 orally up to 3 to 8 days prior to receiving Lutathera treatment to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the receptor locus. ; ; Inclusion criteria 1. Be willing and able to provide written informed consent for the trial. 2. Be aged 18 or over at the day of signing consent 3. Histologic or cytologic confirmed diagnosis of neuroendocrine tumour 4. Have archival tissue block available or willing to have fresh tissue biopsy if blocks not available 5. Have disease that can be readily biopsied by ultrasound guidance (n=5) 6. Ki67 < 55% (only patients with well differentiated grade 1-3 NETs will be included in the study as patients with poorly differentiated grade 3 NETs have a prognosis of less than 6 months) 7. Progression or intolerance to first line therapy including somatostatin analogues 8. ECOG Performance status 0 - 2 9. No tumoural uptake on [68Ga]-DOTA-TATE or uptake less than background liver 10. Measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions 11. Adequate organ function as outlined in the protocol 12. Women of childbearing potential must be willing to use a highly effective method of contraception as outlined in the protocol for the course of the study through 6 months after the last dose of Investigational Medicinal Product (IMP). Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjects 13. Sexually active males must agree to use an adequate method of contraception as outlined in the protocol starting with the first dose of IMP through 6 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject Exclusion criteria 1. Previous treatment with either study medication and/or known hypersensitivity to the study medication 2. Serious concurrent medical illness, including serious active infection 3. History of organ transplant 4. Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority. 5. Has a known history of active Bacillus Tuberculosis (TB). 6. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. 7. Bleeding or thrombotic disorders or subjects at risk for severe haemorrhage 8. Is currently participating and receiving therapy or has participated or is participating in a study of an IMP or used an investigational device within 4 weeks of the first dose of IMP. 9. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Principal Investigator (PI). 11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 12. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through to 6 months after the last dose of IMP. 13. Has received a live vaccine within 30 days of first dose of ASTX727 administration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. 14. Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS 15. Other clinically significant co-morbidities that could compromise the subject's participating in the study	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
The purpose of this study is to assess the feasibility, safety and efficacy of GD2/CD70 bi-specific CAR-T cell therapy in patients with GD2 and/or CD70 positive tumor. Another goal of the study is to learn more about the function of the GD2/CD70 bi-specific CAR-T cells and their persistency in patients. ; ; Inclusion Criteria: 1. Patients with tumors received standard first-line therapy and judged to be non-resectable, metastatic, progressive or recurrent. 2. The expression status of GD2 or CD70 antigens in the tumor tissue will be determined for eligibility. Positive expression is defined by GD2 and PMSA antibody staining results based on immunohistochemistry or flow cytometry analyses. 3. Body weight greater than or equal to 10 kg. 4. Age: ≥1 year and ≤ 75 years of age at the time of enrollment. 5. Life expectancy: at least 8 weeks. 6. Prior Therapy: There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must be resolved to grade 2 or less. 7. Participant must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection. 8. At least 7 days must have elapsed since the completion of therapy with a biologic agent, selected targeted agent or a metronomic non-myelosuppressive regimen. 9. At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody. 10. At least 1 week since any radiation therapy at the time of study entry. 11. Karnofsky/jansky score of 60% or greater. 12. Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent. 13. Pulse Ox greater than or equal to 90% on room air. 14. Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN. 15. Renal function: Patients must have serum creatinine less than 3 times upper limit of normal. 16. Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion). 17. Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease does not have hematologic toxicity. 18. For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent. Exclusion Criteria: 1. Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, or greater than grade 2 hematologic toxicity. 2. Untreatable central nervous system (CNS) metastasis: Patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible. 3. Previous treatment with other genetically engineered GD2 or CD70-specific CAR T cells. 4. Active HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) infection or uncontrolled infection. 5. Patients who require systemic corticosteroid or other immunosuppressive therapy. 6. Evidence of tumor potentially causing airway obstruction. 7. Inability to comply with protocol requirements. 8. Insufficient CAR T cells availability.	{ "inclusion_biomarker": [ [ "GD2 expression" ], [ "CD70 expression" ] ], "exclusion_biomarker": [] }
This phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). DDR deficiency refers to a decrease in the ability of cells to respond to damaged DNA and to repair the damage, which can be caused by genetic mutations. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving avelumab together with M6620 may help to control DDR deficient metastatic or unresectable solid tumors. ; ; Inclusion Criteria: - Subjects must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective - Subjects will be eligible for this study based on the presence of actionable aberrations in one or more of the following DNA damage response (DDR) genes: ARID1A, ATM, ATR, ATRX, BAP1, BARD1, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCM, MRE11A, MSH2, NBN (NBS1), PALB2, RAD51, RAD51C, RAD51D, SMARCB1, and VHL, or other related genes at the discretion of the principal investigator in consultation with the MD Anderson Cancer Center Institute for Personalized Cancer Therapy Precision Oncology Decision Support (PODS) group. Variant interpretation for actionability will be performed by PODS - Subjects with germline defects in DDR genes are eligible for this trial - The collection of archival tumor tissue (within 1 year prior to study enrollment) will be mandatory. Tumor biopsies on cycle 1 day 15 will be mandatory. Subjects will not be put at undue risk to obtain the biopsy at cycle 1 day 15 (C1D15). A biopsy at C1D15 will not be required if it poses a serious/severe complication risk greater than 2%. All other biopsy time points are not mandatory but will be strongly encouraged where feasible. These include at baseline and at disease progression. Archival and fresh tissue requests can be waived in exceptional circumstances with principal investigator (PI) approval and only where rationale is documented - Subjects must have received at least 1 line of systemic therapy in the advanced/metastatic setting. Subjects with diseases without known effective options, and subjects who had declined standard of care therapy prior to study introduction are also eligible - Subjects enrolling in the dose escalation should have progressed on or be intolerant to all therapies known to confer a clinical benefit. Subjects must not have refused all available therapies - Subjects who have received prior therapy with immune checkpoint inhibitors (ICIs) are eligible for this trial. Subjects with a standard-of-care option for an immune checkpoint inhibitor are eligible - Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, or patients may have bone metastatic disease evaluable by Prostate Cancer Working Group 3 (PCWG3) for subjects with metastatic castration-resistant prostate cancer (CRPC), or according to tumor evaluation criteria best suited and accepted for the tumor type to be evaluated - Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Subjects must have a life expectancy >= 12 weeks - Absolute neutrophil count >= 1.5 x 10^9/L - Platelets >= 100 x 10^9/L - Hemoglobin >= 9 g/dL or >= 5.6 mmol/L - Total bilirubin =< 1.5 X the institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/ alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) =< 2.5 X institutional ULN or =< 5 X institutional ULN in the presence of liver metastases - Serum creatinine =< 2 X ULN or estimated creatinine clearance >= 30 mL/min according to the Cockcroft-Gault formula - Female patients of childbearing potential must have a negative serum or urine pregnancy test at screening (and again at baseline just prior to first administration of study drugs) - Female patients of non-childbearing potential must meet at least 1 of the following criteria: - Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months, with no alternative pathological or physiological cause; - Have undergone a documented hysterectomy and/or bilateral oophorectomy - Have medically confirmed ovarian failure All other female patients (including female patients with tubal ligation) are considered to be of childbearing potential - Women of childbearing potential and fertile men must agree to use adequate contraception when sexually active from signing of the informed consent form for the full study until at least 6 months after the last study drug administration. Patients must agree to utilize 2 reliable and acceptable methods of contraception simultaneously. A man is considered fertile after puberty unless permanently sterile by bilateral orchiectomy. Men taking part in this study are advised not to father a child during and up to 6 months after treatment; prior to treatment, advice should be sought for conserving sperm due to the chance of irreversible infertility as a consequence of treatment. Female partners of childbearing potential from male study patients have to use adequate contraception / birth control between signing of the informed consent and 6 months after the last administration of the study drug if the male study patient is not sterilized. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control. Highly effective (failure rate of less than 1% per year) contraception methods, when used consistently and correctly, include: - Combined (estrogen and progestin containing: oral, intravaginal, transdermal) and progestin-only (oral, injectable, implantable) hormonal contraception associated with inhibition of ovulation - Intra-uterine device or intrauterine hormone-releasing system - Bilateral tubal occlusion or vasectomized partner (provided that partner is the sole sexual partner and has received medical assessment of the surgical success) - Sexual abstinence (reliability to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient) Male patients with a female partner of reproductive potential must use a condom and ensure that an additional form of contraception is also used during treatment and until 6 months after last study drug administration. Patients must agree to utilize 2 reliable and acceptable methods of contraception simultaneously - Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study - Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures - Human immunodeficiency virus (HIV)-infected (HIV1/2 antibody-positive) patients may participate IF they meet all the following eligibility requirements: - They must be on an anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on this same regimen; the most recent undetectable viral load must be within the past 12 weeks - They must have a CD4 count >= 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/ mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy-induced bone marrow suppression - For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy - They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of enrolment - They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months Exclusion Criteria: - Anticancer systemic therapy or radiotherapy within 4 weeks or 5 half-lives, whichever is shorter prior to starting the study agents. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed 2 weeks prior to study enrollment, and no clinically significant toxicities are expected (e.g., mucositis, esophagitis) - Known symptomatic brain metastases requiring steroids. Patients with previously treated diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable - Current use of immunosuppressive medication at the time of study enrollment, EXCEPT for the following permitted steroids: - Intranasal, inhaled, topical steroids, eye drops, or local steroid injection (e.g., intra-articular injection) - Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent - Steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication) - Subjects who had major surgery within 4 weeks prior to study enrollment - Known prior severe hypersensitivity to investigational products or any component in their formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5 grade >= 3) - Active infection requiring systemic therapy - Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis, and pulmonary fibrosis - Active or prior autoimmune disease that may deteriorate when receiving an immunostimulatory agent. Patients with type I diabetes, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible - Prior organ transplantation including allogenic stem cell transplantation - Diagnosis of myelodysplastic syndrome (MDS) - Vaccination within 4 weeks of study enrollment and while on trial is prohibited except for the administration of inactivated vaccines - Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 month prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II) or a serious cardiac arrhythmia requiring medication - Other acute or chronic medical or psychiatric conditions including but not limited to recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results, and in the judgement of the Investigator, would make the patient inappropriate for entry into this study - Pregnant female patients, breastfeeding female patients, fertile male patients, and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study, and for at least 6 months after the last dose of study drug administration - Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV ribonucleic acid (RNA) if anti-HCV antibody screening test is positive) - Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ bladder cancer, or other cancer for which the patient has been disease-free for >= 2 years - Persisting toxicity related to prior therapy (NCI CTCAE v5 grade > 1); however, alopecia and sensory neuropathy grade =< 2, or other grade =< 2 AEs not constituting a safety risk, based on the investigator's judgement, are acceptable - Subjects receiving treatment with strong inhibitors or inducers of CYP3A4 that cannot be discontinued before start of investigational treatment and for the duration of study - Subjects with ongoing toxicity (any grade) and/or resolved ICI toxicity (grade 3 or higher only)	{ "inclusion_biomarker": [ [ "ARID1A aberration" ], [ "ATM aberration" ], [ "ATR aberration" ], [ "ATRX aberration" ], [ "BAP1 aberration" ], [ "BARD1 aberration" ], [ "BRCA1 aberration" ], [ "BRCA2 aberration" ], [ "BRIP1 aberration" ], [ "CDK12 aberration" ], [ "CHEK2 aberration" ], [ "FANCA aberration" ], [ "FANCC aberration" ], [ "FANCD2 aberration" ], [ "FANCE aberration" ], [ "FANCF aberration" ], [ "FANCM aberration" ], [ "MRE11A aberration" ], [ "MSH2 aberration" ], [ "NBS1 aberration" ], [ "PALB2 aberration" ], [ "RAD51 aberration" ], [ "RAD51C aberration" ], [ "RAD51D aberration" ], [ "SMARCB1 aberration" ], [ "VHL aberration" ], [ "ARID1A defect (germline)" ], [ "ATM defect (germline)" ], [ "ATR defect (germline)" ], [ "ATRX defect (germline)" ], [ "BAP1 defect (germline)" ], [ "BARD1 defect (germline)" ], [ "BRCA1 defect (germline)" ], [ "BRCA2 defect (germline)" ], [ "BRIP1 defect (germline)" ], [ "CDK12 defect (germline)" ], [ "CHEK2 defect (germline)" ], [ "FANCA defect (germline)" ], [ "FANCC defect (germline)" ], [ "FANCD2 defect (germline)" ], [ "FANCE defect (germline)" ], [ "FANCF defect (germline)" ], [ "FANCM defect (germline)" ], [ "MRE11A defect (germline)" ], [ "MSH2 defect (germline)" ], [ "NBS1 defect (germline)" ], [ "PALB2 defect (germline)" ], [ "RAD51 defect (germline)" ], [ "RAD51C defect (germline)" ], [ "RAD51D defect (germline)" ], [ "SMARCB1 defect (germline)" ], [ "VHL defect (germline)" ] ], "exclusion_biomarker": [] }
HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20 insertion mutation. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10376 in Chinese advanced Non-Small Cell Lung Cancer (NSCLC) patients. ; ; Inclusion Criteria: 1. Men or women greater than or equal to 18 years 2. Locally advanced or metastatic NSCLC patients confirmed by histology or cytology, for which standard treatment is invalid, unavailable or intolerable 3. Pathological, tumor tissue samples can be used to test EGFR/HER2 Exon 20 insertion mutation by central laboratory for subjects 4. At least one measurable lesion in accordance with RECIST 1.1 5. Eastern Cooperative Oncology Group (ECOG) performance status: 0~1 6. Estimated life expectancy >12 weeks 7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit. 8. Females must have the evidence of non-childbearing potential 9. Signed and dated Informed Consent Form Exclusion Criteria: 1. Treatment with any of the following: - Previous or current treatment with EGFR Exon 20 insertion inhibitors, HER2 Exon 20 insertion inhibitors or EGFR/HER2 Exon 20 insertion inhibitors - Any cytotoxic chemotherapy, anticancer Chinese medicine and targeted small molecule inhibitors within 14 days of the first dose of HS-10376 - Any investigational agents and large molecule antibodies within 28 days of the first dose of HS-10376 - Local radiotherapy for palliation within 2 weeks of the first dose of HS-10376, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose of HS-10376 - Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of HS-10376 2. Inadequate bone marrow reserve or serious organ dysfunction 3. Uncontrolled pleural, ascites or pericardial effusion 4. Untreated, symptomatic or active central nervous system metastases 5. Severe or poorly controlled hypertension 6. Immunodeficiency disease and active infectious disease 7. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications 8. History of hypersensitivity to any active or inactive ingredient of HS-10376 or to drugs with a similar chemical structure or drugs belonging to the same category of HS-10376 9. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator 10. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator 11. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study 12. History of neuropathy or mental disorders, including epilepsy and dementia	{ "inclusion_biomarker": [ [ "EGFR Exon 20 insertion" ], [ "HER2 Exon 20 insertion" ] ], "exclusion_biomarker": [] }
Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options. To request access, use Responsible Party contact information provided in this record.. ;NA; Inclusion Criteria: - To request more information use Responsible Party contact information provided in this record Exclusion Criteria: - To request more information use Responsible Party contact information provided in this record	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast cancer harboring a PIK3CA mutation in Japan, whose disease has progressed on or after aromatase inhibitor (AI) treatment regardless of prior CDK4/6 inhibitor use. ; ; Inclusion Criteria: - Japanese man or postmenopausal woman - Participant has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory. - Participant has identified PIK3CA mutation (as determined by a Novartis designated laboratory) - Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory - Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH or SISH) test is required by local laboratory testing - Participant has measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 - Participant has advanced breast cancer - Participant has ECOG performance status 0 or 1 Exclusion Criteria: - Participant with symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment - Participant has received prior treatment; - with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor for Cohort 1 and 3 - with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR, AKT inhibitor or CDK 4/6 inhibitor for Cohort 2 - Participant has a known hypersensitivity to alpelisib or fulvestrant, or to any of the excipients of alpelisib or fulvestrant - Participant with inflammatory breast cancer at screening - Participant is concurrently using other anti-cancer therapy - Participant has had surgery within 14 days prior to starting study drug or has not recovered from major side effects - Participant with an established diagnosis at screening of diabetes mellitus type I or not controlled type II (based on FPG and HbA1c) - Participant has currently documented pneumonitis /interstitial lung disease - History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis - Participant with unresolved osteonecrosis of the jaw - Participant has a history of severe cutaneous reactions Other protocol-defined inclusion/exclusion criteria may apply	{ "inclusion_biomarker": [ [ "PIK3CA mutation", "ER positive", "HER2 negative" ], [ "PIK3CA mutation", "PgR positive", "HER2 negative" ] ], "exclusion_biomarker": [] }
BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the national EXPLORE ALK cohort (GFPC 03-2019), a non-interventional, national, multi-center cohort of ALK-rearranged NSCLC patients. BioExALK study will be proposed to every patient included in the Explore ALK GFPC 03-2019 study. Biological analysis will be performed on tumor tissue at diagnosis and at the time of disease progression when available and on circulating tumor DNA (ctDNA). For plasma testing, after obtained patient consent, blood samples will be taken and analyzed at the Léon Bérard Center (Lyon). Biological analysis on tissue obtained at diagnosis and at disease progression will be collected and be sent for centralized analysis to the Rouen University Hospital. ; ; Inclusion Criteria: - Stage IIIB/IV NSCLC non eligible to locoregional treatment with curative intent - ALK rearrangement confirmed by IHC and/or FISH or NGS according to local methods - Patient included in the EXPLORE ALK study - Age > or = 18 years - Patient treated with first-line new generation ALKi - Patient agrees to sign an informed consent form and to collect blood samples at inclusion, first tumor evaluation and progression and for whom tumor biopsy at diagnosis is available - Patient enrolled in the french National Health Insurance program or with a third- party payer Exclusion Criteria: - Patients who do not wish to participate in Bioexalk - Patients under guardianship	{ "inclusion_biomarker": [ [ "ALK rearrangement" ] ], "exclusion_biomarker": [] }
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 25% mutation to the genes listed can be enrolled to a non-actionable treatment arm. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102). ; ; Inclusion Criteria: - Willing to be registered into the pomalidomide (POMALYST®) Risk Evaluation and Mitigation Strategy (REMS®) program - Enrolled in the MMRF002 Molecular Profiling Protocol (NCT02884102) with report less than 120 days old - Disease free of prior malignancies for ≥ 3 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma "in situ" of the cervix or breast, or prostate cancer not requiring therapy - High risk patients with relapsed refractory multiple myeloma (RRMM), who have: - received at least one prior but no more than 3 prior therapies - exposed to both a PI and an IMiD - had early relapse after initial treatment Early relapse as defined by at least one of the following: (Relapse is defined as the IMWG uniform response) 1. Relapse within 3 years of initiation of induction chemo therapy for post autologous stem cell transplantation (ASCT) followed by maintenance, or 18 months if unmaintained after ASCT 2. Within 18 months of initial non-ASCT based therapy - Patients must have progressed after their most recent treatment and require therapy for myeloma - Females of reproductive potential must have a negative pregnancy test at baseline, be non-lactating, and willing to adhere to scheduled pregnancy testing - Females of reproductive potential and males must practice and acceptable method of birth control - Laboratory values obtained ≤ 14 days prior to registration: - Absolute neutrophil count (ANC) ≥ 1000/ul - Hemoglobin (Hgb) ≥ 8 g/dl - Platelet (PLT) ≥ 75,000/ul - Total bilirubin <1.5 x upper limit of normal (ULN) or if total bilirubin is >1.5 x ULN, the direct bilirubin must be ≤ 2.0 mg/dL - Aspartate aminotransferase (AST) <3 x ULN - Creatinine Clearance ≥ 30 mL/min Measurable disease of Multiple Myeloma (MM) as defined by at least one of the following: - Serum monoclonal protein ≥ 0.5 g by protein electrophoresis - ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis - Serum immunoglobulin free light chain (FLC) ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio - Monoclonal bone marrow plasmacytosis ≥30% (evaluable disease) - Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2 - Ability to take aspirin, warfarin, or low molecular weight heparin Sub-Protocol Inclusion Criteria: Refer to each respective Sub Protocol for additional inclusion criteria. Exclusion Criteria: Patients will be ineligible for this study if they meet any one of the following criteria: - Aggressive multiple myeloma requiring immediate treatment as defined by: - Lactate dehydrogenase (LDH) > 2 times ULN - Presence of symptomatic extramedullary disease or central nervous system involvement - Hypercalcemia >11.5 mg/dl - Acute worsening of renal function (CrCl < 30 ml/min) directly related to myeloma relapse - Any neurological emergency related to myeloma - Clinical symptoms of hyperviscosity related to monoclonal protein - Involved serum free light chain > 100 mg/dL (1000 mg/L) in the setting of prior diagnosis of cast nephropathy - Infection requiring systemic antibiotic therapy or other serious infection within 14 days of enrolment - Known hypersensitivity or development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide, pomalidomide or similar drug. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of the agents - Prior Ixazomib/Pomalidomide/Dexamethasone combination therapy - Pregnant or breast-feeding females - Serious medical or psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse compliance, interfere in the completion of treatment per protocol, or follow-up evaluation - Active hepatitis A, B or C viral infection or known human immunodeficiency virus (HIV) infection - Concurrent symptomatic amyloidosis or plasma cell leukemia - POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes] - Residual side effects to previous therapy > Grade 1 prior to initiation of therapy (Alopecia any grade and/or neuropathy Grade 2 without pain are permitted) - Prior allogeneic or ASCT within 12 weeks of initiation of therapy. Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD) - Prior experimental therapy within 14 days of protocol treatment or 5 half-lives of the investigational drug, whichever is longer - Prior anticancer therapy within 14 days of initiation of protocol therapy (Dexamethasone/ 40mg/day) for a maximum of 4 days before screening is allowed - Prior major surgical procedure or radiation therapy within 4 weeks of the initiation of therapy (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy). - Known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or Gastro Intestinal (GI) absorption of drugs administered orally - Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months - Other co-morbidity, which would interfere with patient's ability to participate in trial or that confounds the ability to interpret data from the study Sub-Protocol Exclusion Criteria: Refer to each respective Sub Protocol for additional exclusion criteria.	{ "inclusion_biomarker": [ [ "CDKN2C mutation" ], [ "FGFR3 mutation" ], [ "KRAS mutation" ], [ "NRAS mutation" ], [ "BRAF V600E" ], [ "IDH2 mutation" ], [ "T(11;14)" ] ], "exclusion_biomarker": [] }
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic). Larotrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ; ; Inclusion Criteria: - At least 16 years of age - Locally-advanced or metastatic malignancy with an NTRK1, NTRK2, or NTRK3 gene amplification identified through molecular assays (such as IHC and any next-generation sequencing [NGS] platform, reference lab NGS, or in house NGS platform) as routinely performed at The University of Texas MD Anderson Cancer Center or other similarly-certified laboratories. The minimum level of amplification is 7 copies. This rationale of amplification level is based on data from MOCLIA at The University of Texas MD Anderson Cancer Center - Must have received prior standard therapy appropriate for tumor type and stage of disease, or, in the opinion of the investigator, is unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy - Must have at least one measurable lesion as defined by RECIST v1.1. Subjects with primary CNS tumors should meet the following criteria: - Must have received prior treatment including radiation and/or chemotherapy, with radiation completed > 12 weeks prior to cycle 1 day 1 (C1D1) of therapy, as recommended or appropriate for the tumor type - Must have >= 1 site of bi-dimensionally measurable disease (confirmed by magnetic resonance imaging [MRI] and evaluable by RANO), with the size of at least one of the measurable lesions >= 1 cm in each dimension - Must have imaging study within 28 days before enrollment. If on steroid therapy, the dose must be stable for at least five days immediately before and during the imaging study - Eastern Cooperative Oncology Group (ECOG) score =< 3. If enrolled with primary CNS tumor to be assessed by RANO, Karnofsky performance score (KPS) >= 70 % - Archived tumor tissue. If archival tissue is unavailable, an on-study tumor biopsy should be attempted if it can be safely performed - Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) or < 5 x ULN if liver function abnormalities are due to underlying malignancy - Total bilirubin < 2.5 x ULN, except in cases of biliary obstruction. Subjects with a known history of Gilberts disease and an isolated elevation of indirect bilirubin are eligible - Serum creatinine < 2.0 x ULN or estimated glomerular filtration rate >= 30 mL/minute using the Cockcroft-Gault formula - Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation - Willingness of men and women of reproductive potential to use two effective birth control methods, one used by the subject and another by his/her partner, for the duration of treatment and for 3 months following study completion Exclusion Criteria: - Investigational agent or anticancer therapy within 2 weeks prior to the planned start of larotrectinib or five half-lives, whichever is shorter, and without clinically significant toxicities from that therapy - Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting TRK. However, subjects who received less than 28 days of such treatment and discontinued because of intolerance or toxicity are eligible - Symptomatic or unstable brain metastases that needs corticosteroid usage. Subjects with asymptomatic brain metastases or primary CNS tumors are eligible - Uncontrolled concurrent malignancy that would limit assessment of efficacy. Allowed diseases may include, but are not limited to in situ cancers of cervix, breast, or skin, superficial bladder cancer, limited-stage prostate cancer, and basal or squamous cancers of the skin - Active uncontrolled systemic bacterial, viral, or fungal infection, unstable cardiovascular disease or other systemic disease that would limit compliance with study procedures. Unstable cardiovascular disease is defined as: - Persistently uncontrolled hypertension defined as systolic blood pressure (BP) > 150 mmHg and/or diastolic BP > 100 mmHg despite antihypertensive therapy - Myocardial infarction within 3 months of screening - Stroke within 3 months of screening - Inability to discontinue treatment with a strong cytochrome P450 (CYP450), 3A4 (CYP3A4) inhibitor or inducer prior to start of treatment - Pregnancy or lactation	{ "inclusion_biomarker": [ [ "NTRK1 amplification" ], [ "NTRK2 amplification" ], [ "NTRK3 amplification" ] ], "exclusion_biomarker": [] }
In this study, the purpose of this study is to investigate whether prophylactic medical compression therapy in breast cancer patients receiving docetaxel adjuvant chemotherapy could reduce the incidence and severity of lymphedema in the upper limbs that received axillary lymph node resection (sentinel lymph node biopsy or axillary lymph node dissection). ;NA; Inclusion Criteria: 1. Patients who underwent radical mastectomy and sentinel lymphctomy or axillary lymphectomy after diagnosis of unilateral breast cancer 2. Patients who are scheduled for adjuvant chemotherapy including Docetaxel after surgery 3. Patients aged 19 to 70 4. Patients who can understand the contents of this study and obtain consent Exclusion Criteria: 1. Patients with a history of breast-related surgery prior to this breast cancer surgery 2. Patients with metastases to other organs 3. Patients who have undergone neoadjuvant chemotherapy or have previously received radiation therapy 4. Patients with systemic diseases that may not be able to conduct clinical research 5. Patients with skin diseases who cannot receive medical compression treatment	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma. ; ; Inclusion Criteria: 1. Age between 18 to 70 years old (including 18 and 70) 2. Diagnosed as marginal zone lymphoma 3. No receiving chemotherapy before enrollment 4. Indications for treatment: 1) symptoms related to tumor; 2) end-organ function damage; 3) large mass; 4) continuous or rapid progress of disease; 5) patient's willingness 5. Having at least one measurable lesions 6. World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) 0-1 7. Life expectancy no less than 3 months 8. enough main organ function 9. Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study 10. Agreeing to sign the written informed consents Exclusion Criteria: 1. Diagnosed as central nervous system lymphoma 2. World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) ≥2 3. Other malignant tumor history or active malignant tumor need be treated 4. Serious surgery and trauma less than two weeks 5. Systemic therapy for serious acute/chronic infection 6. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months 7. Active tuberculosis. Patients suspected of active TB need to be examined for chest X-ray, sputum and clinical symptoms and signs 8. HIV-positive, AIDS patients and untreated active hepatitis（HBV/HBV and HCV） 9. Patients with a history of deep vein thrombosis or pulmonary embolism less than 12 months 10. Patients with a history of mental illness 11. Researchers determine unsuited to participate in this trial	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety， tolerability and efficacy of FS-1502. ; ; Inclusion Criteria: 1. Age ≥18 years at the time of study registration (men and women eligible); 2. Phase Ia dose-escalation study: Patients with HER2-expressing advanced malignant solid tumors who had failed to standard therapy(including surgery, chemotherapy, radiation therapy or biotherapy) , or can not receive standard therapy, or no standard therapy is available. 1. HER2 expression: IHC3+, IHC2+/FISH+ 2. HER2 expression: IHC1+, IHC2+/FISH- Phase Ib dose-expanded study: Histologically or cytologically confirmed HER2-positive patients with advanced breast cancer who had previously received at least 2 line therapy and had failed anti-HER2 therapy. Details as follows: 1. HER2 positive (defined as IHC3+ or IHC2+/FISH+); 2. For patients with advanced breast cancer who had previously failed anti-HER2 therapy and had received at least 2-line therapy, postoperative adjuvant therapy which could be considered as a treatment line number if disease progression during treatment and within 12 months after completion of treatment. 3. Provide evidence of disease progression or intolerable toxicity as confirmed by the investigator or medical history recorded prior to enrollment. 4. The enrollment can be based on written HER2 test report from certified local lab, and if patients had no HER2 test report, they should provide sufficient paraffin sections or fresh tumor tissue specimens which should be sent to the local lab or the central laboratory for testing and confirmation. Pivotal clinical study: Patients with locally advanced or relapsed metastatic breast cancer who have been histologically or cytologically confirmed to be HER2-positive and who have received two or more lines of anti-HER2 therapy in the past. Details as follows: 1. Her2-positive patients: Patients with IHC3+ or IHC2+ and FISH positive patients should provide enough tumor tissue samples within 5 years for the central laboratory to confirm HER2 status. Patients with HER2-positive patients are considered to be eligible for inclusion in this study; If the specimens provided are undetectable or are not available, a positive HER2 test from a local laboratory approved by the NMPA may be reported for entrainment. 2. Previous treatment with two or more lines of anti-HER2 therapy, neoadjuvant therapy or adjuvant therapy can be used as a treatment line number if the disease progresses during or within 12 months after treatment. 3. Evidence of investigator-confirmed or documented disease progression or intolerance of toxicity prior to enrollment. 3. The ECOG performance status must be 0 or 1. 4. Expected survival for at least 12 weeks. 5. Has adequate organ and bone marrow function: absolute neutrophil count (ANC) ≥ 1.0x1E9/L(without colony stimulating factor within 7 days); hemoglobin ≥ 90g/L (without red blood cell infusion within 14 days); platelet count ≥ 100x1E9/L(without thrombopoietin or thrombopoietin receptor agonists within 7 days nor platelet infusion within 14 days); Total bilirubin ≤ 1.5x upper limit normal (ULN), or ≤ 3x ULN if with Gilbert syndrome; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; AST and ALT ≤ 5x ULN if liver metastasis; Serum creatinine < 1.5x ULN and creatinine clearance ≥ 50mL/min (Cockroft-Gault formula calculation); Serum potassium ≥3.5 mmol/L；albumin ≥ 3g/dL; left ventricular ejection fraction (LVEF) >50%；urinary protein ≤1+ or 24-hour urinary protein dose < 1.0g. 6. Has at least one non-intracranial measurable lesion by RECIST version 1.1. 7. Male or female patients with fertility must agree to use effective contraceptive methods during the study period and within 3 months of the last dose of study therapy, such as dual barrier contraceptive methods, condoms, oral or injectable contraceptives, and intrauterine devices. 8. Ability to understand and voluntarily sign written informed consent. Exclusion Criteria: 1. Patients who received chemotherapy, targeted therapy, radiotherapy, etc., 14 days or within 5 half-lives periods, whichever is shorter, prior to the start of dosing. Patients who received major surgery, tumor immunotherapy, or monoclonal antitumor therapy within 4 weeks prior to the start of dosing. 2. Patients who have participated in other clinical trials 4 weeks before the start of study drug administration or within 5 half-lives periods, whichever is shorter. 3. Patients previously treated with anti-HER2 ADC drugs. 4. Patients with central nervous system metastasis. 5. Clinically uncontrolled mass pleural effusion, pericardial effusion, or abdominal effusion (2 weeks before first administration). 6. Non-recovery of toxic effects from previous antitumor therapy (> NCI-CTCAE 5.0 grade 1) alopecia, neurotoxicity, or other toxicity that had become chronic as assessed by the investigator and did not affect the safety of the investigational medication was admitted to NCI-CTCAE 5.0 grade 2 or below. 7. Patients with corneal epitheliopathy (other than mild punctiform keratopathy or existing eye diseases affecting the evaluation of ocular toxicity after trial administration) or who were unwilling to stop wearing contact lenses during the study. 8. Patients take medications that prolong the QTc interval (mainly Ia, Ic, Class III antiarrhythmic drugs) or have risk factors that prolong the QTc interval, such as uncorrectable hypokalemia, hereditary long QT syndrome; 9. Cardiac function and disease conform to one of the following conditions: 1. Three 12-lead electrocardiogram (ECG) measurements were performed at the research center during the screening period, and three mean values were calculated according to the QTc formula adopted by the instrument, QTc > 470 ms; 2. New York Heart Association (NYHA)Grade ≥ 2 for congestive heart failure; 3. arrhythmia of clinical significance grade ≥ 2. 4. History of myocardial infarction or severe arteriovenous thrombosis within 6 months. 10. Pregnant or lactating women; 11. Known allergy to any excipients of FS-1502; 12. Active infections requiring systemic treatment; 13. Persons with active hepatitis B (HBV surface antigen positive with HBV DNA exceeding 1000 IU/ml or meeting the research Center criteria for diagnosis of active hepatitis B infection) or hepatitis C (HCV RNA positive), human immunodeficiency virus infection (HIV positive); 14. Had been diagnosed with any other malignancies within the 5 years prior to study participation, other than early malignancies that have undergone radical treatment (carcinoma in situ), such as adequately treated basal or squamous cell skin cancers or carcinoma in situ of the cervix; 15. Any other clinically significant disease or condition that the investigator believes may affect protocol compliance or affect the patient's signing of the ICF.	{ "inclusion_biomarker": [ [ "HER2 expression" ], [ "HER2 positive" ] ], "exclusion_biomarker": [] }
This is an open-label, multicenter, dose-escalation and parallel-group expansion Phase II clinical trial to evaluate the efficacy, safety and tolerability of KN026 in combination with palbociclib and fulvestrant in women or male with HER2-positive metastatic breast cancer .The subjects will receive 20 mg/kg IV Q2W+ palbociclib 100/125 mg/day orally+/-Fulvestrant 500 mg IM until progressive disease, unacceptable toxicity or death. ; ; Inclusion Criteria: - Male or female subject >= 18 years; - Histologically or cytologically confirmed, metastatic or locally advanced unresectable HER2-positive; - Adequate organ function assessed within 7 days prior to first trial treatment - ECOG score 0 or 1; - Left ventricular ejection fraction (LVEF) ≥ 50% at baseline; - Life expectancy >3 months Exclusion Criteria: - Untreated active CNS metastasis or leptomeningeal metastasis; - Uncontrolled tumor-related pain; - Has received other anti-tumor treatment or an investigational drug within 28 days or within 5 times of half-life (whichever is shorter, and no less than 2 weeks) prior to the first trial treatment; - Major surgery for any reason within 28 days; - Curative radiation within 3 months of the first dose of trial treatment; - History of uncontrolled intercurrent illness; - Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance	{ "inclusion_biomarker": [ [ "HER2 positive" ] ], "exclusion_biomarker": [] }
The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma. ;NA; Inclusion Criteria: - biopsy proved Natural Killer T-cell Lymphoma - newly diagnosed patients Exclusion Criteria: - patients with biopsy samples unavailable	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD). ; ; Inclusion Criteria: 1. Adults ≥19 years old. 2. Pathologically documented breast cancer that is unresectable or metastatic 3. Tumor with homologous recombination deficiency (HRD) defined by - Germline or Somatic BRCA1/2 mutation - Homologous recombination repair (HRR) genes mutation - HRD detected through RAD51 foci formation functional assay - HRR genes: ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L 4. Previously treated with a taxane, unless this treatment was contraindicated (whether in recurrent/metastatic setting or in neoadjuvant/adjuvant setting). 5. Previous treatment with platinum therapy in the advanced or metastatic setting is permitted, provided the patient did not have a progression during the platinum treatment. If the patient was treated with neoadjuvant or adjuvant platinum therapy, at least 6 months of disease-free interval is required after the last dose. 6. Documented radiologic progression (during or after most recent treatment or within 6 months after completing adjuvant therapy). - If the patients had relapsed within 6 months after adjuvant therapy, this will be counted as a systemic chemotherapy for advanced or metastatic disease. 7. At least 3 weeks has passed since last chemotherapy treatment 8. At least 2 weeks has passed since last hormone therapy or radiation therapy (including palliative radiation). 9. Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1 10. At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (magnetic resonance imaging [MRI] where CT is not feasible) and is suitable for repeated assessment as per RECIST v.1.1. 11. Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7.0 months after the last dose of study treatment. - This study recommend "Copper T intrauterine device" as a highly effective methods of contraception (<1% failure rate) 12. Adequate normal organ and marrow function measured within 28 days prior to administration of study treatment - Hemoglobin ≥9.0 g/dL - Absolute neutrophil count (ANC) ≥ 1.5 x 109/L - Platelet count ≥ 75 x 109/L - Serum bilirubin ≤ 2.0mg/dL [This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.] - AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN - Adequate renal function: Serum creatinine ≤1.5mg/dL or estimated creatinine clearance >60 mL/min 13. Negative urine pregnancy test within 7 days prior to registration in premenopausal patients. 14. Ability to understand and comply with protocol during study period 15. Patients should sign a written informed consent before study entry Exclusion Criteria: 1. Prior treatment PARP inhibitor 2. However, if the patient participated in a clinical trial evaluating adjuvant PARP inhibitor, patient is allowed to be included in the present study if the patient recurred 6 months after completing PARP inhibitor. No more than three line of previous systemic chemotherapy, excluding neo-adjuvant and adjuvant chemotherapy. (No limitation on hormone therapy. Hormone therapy is not counted as previous line) 3. If there is a standard treatment available for metastatic breast cancer. 4. History of another primary malignancy except for - Malignancy treated with curative intent and with no known active disease ≥3 years - contralateral breast cancer - Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease - Adequately treated carcinoma in situ without evidence of disease 5. Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled GI disease (e.g., Crohn's disease, ulcerative colitis) 6. History of leptomeningeal carcinomatosis 7. Brain metastases or spinal cord compression. - Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days 8. active infection or immunocompromised patients including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B , hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). - Subjects with simple HBV carrier, a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 9. Patients who have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study agents or their excipients. 10. Female patients who are pregnant or breastfeeding. 11. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.	{ "inclusion_biomarker": [ [ "BRCA1 mutation (germline)" ], [ "BRCA2 mutation (germline)" ], [ "BRCA1 mutation (somatic)" ], [ "BRCA2 mutation (somatic)" ], [ "ATM mutation" ], [ "BARD1 mutation" ], [ "BRIP1 mutation" ], [ "CDK12 mutation" ], [ "CHEK1 mutation" ], [ "CHEK2 mutation" ], [ "FANCL mutation" ], [ "PALB2 mutation" ], [ "PPP2R2A mutation" ], [ "RAD51B mutation" ], [ "RAD51C mutation" ], [ "RAD51D mutation" ], [ "RAD54L mutation" ] ], "exclusion_biomarker": [] }
This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. ; ; Inclusion Criteria: - Patients must have a histologically confirmed diagnosis non-prostate GU cancer - Patients must have Clinical Laboratory Improvement Act (CLIA) testing and fit one of the following groups: - Confirmed presence of a cancer-associated alteration considered pathogenic/likely pathogenic by FM and/or the Genetics Review Panel in one or more of the following genes: BRCA1, BRCA2, ATM, BAP1, MSH2, PALB2, and BRIP1 or in one or more of the DNA-repair genes tested in the FoundationOne FoundationOneCDx (F1CDx) panel including the following genes (Foundation One mutation analysis results performed prior to enrollment on this study may be accepted for eligibility review and in the event that a patient cannot undergo a biopsy and tumor is not available, Foundation Medicine liquid biopsy may be performed): ABL1, ATR, ATRX, BARD1, BRD4, CCND1, CHEK1, CHEK2, DOT1L, FANCC, FANCE, FANCG, FANCL, IKBKE, MEN1, MLH1, MSH2, MSH6, MUTYH, NPM1, PMS2, POLD1, POLE, RAD51, SMARCB1, STK11, TP53 - Note: FoundationOneCDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens - Patients with benign or variants of unknown significance as determined by FoundationOne FoundationOneCDx (F1CDx) panel and Genetics Review Panel review will be included to be followed for survival - Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam - Evidence of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) during treatment or after the most recent dose of therapy with at least one platinum-based regimen of chemotherapy and/or an immune-checkpoint inhibitor (atezolizumab, pembrolizumab, nivolumab, avelumab or durvalumab) (2-week washout from chemotherapy and 4-weeks washout from monoclonal antibodies is required) - Age >= 18 years. Because no dosing or adverse event data are currently available on the use of olaparib in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials - Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (or Karnofsky >= 70%) - Leukocytes >= 3,000/mcL - Absolute neutrophil count >= 1,500/mcL - Platelets >= 100,000/mcL - Total bilirubin =< 1.5 x upper limit of normal (ULN) (for subjects with documented Gilbert's disease total bilirubin =< 3.0 mg/dL) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (for subjects with liver metastasis AST/ALT =< 5 x ULN) - Creatinine clearance >= 50 mL/min/1.73 m^2 - Hemoglobin >= 10 g/dL; transfusions are allowed - Prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed or the patient is on direct oral anticoagulant (DOA) - Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of olaparib - Pre-clinical data indicate that olaparib adversely affects embryofetal survival and development. Therefore, women of child-bearing potential and their partners should agree to use two (2) highly effective forms of contraception throughout study participation and for at least one (1) month after the last dose of olaparib. Male study participants should avoid fathering a child or donating sperm during the study and for three (3) months after the last dose of olaparib. - Note: Olaparib is a PARP inhibitor with the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib, breastfeeding should be discontinued if the mother is treated with olaparib - Ability to understand and the willingness to sign a written informed consent document or patients with impaired decision making capacity (IDMC) if they are represented by a legally authorized representative (LAR) - Patients must provide archival tumor sample for mutation analysis or be willing to undergo mandatory screening biopsy. In the event that the patient cannot undergo biopsy and tumor is not available, Foundation Medicine liquid biopsy will be performed - Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1. Postmenopausal is defined as: - Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments - Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50 - Radiation-induced oophorectomy with last menses > 1 year ago - Chemotherapy-induced menopause with > 1 year interval since last menses - Surgical sterilization (bilateral oophorectomy or hysterectomy) - Patients is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations Exclusion Criteria: - Patients who have had prior treatment with olaparib or any other PARP inhibitor (PARPi) - Patients with myelodysplastic syndrome/acute myeloid leukemia; or baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicated - Persistent toxicities (>= Common Terminology Criteria for Adverse Events [CTCAE] grade 2) with the exception of alopecia, caused by previous cancer therapy - Patients who are receiving any other investigational agents. Patients may be on other clinical trials or treatment during screening to determine eligibility - Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. A scan to confirm the absence of brain metastases is not required. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days - History of allergic reactions attributed to compounds of similar chemical or biologic composition of olaparib - Patients receiving any medications or substances that are inhibitors or inducers of CYP3A are ineligible. A washout period prior to starting olaparib for patients on CYP3A inhibitors is 2 weeks; and the required washout period for CYP3A inducers is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents - Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference texts such as the Physicians' Desk Reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product - Pregnant women are excluded from this study because olaparib is a PARP inhibitor agent with the potential for teratogenic or abortifacient effects - Any chronic or concurrent acute liver disease - History of stroke, transient ischemic attack (TIA), or myocardial infarction, within 6 months prior to enrollment - Uncontrolled concurrent disease or illness including but not limited to: - Ongoing or active infection - Symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia - Unstable or untreated cardiac conditions or ejection fraction of < 50% as determined by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) - Uncontrolled diabetes mellitus - Psychiatric illness/social situations that would limit compliance with study requirements - Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study - Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) - Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids - Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), stage 1, grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for >= 5 years. Patients with a history of localized triple negative breast cancer or localized resected prostate cancer may be eligible, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease - Resting electrocardiogram (ECG) with corrected QT (QTc) > 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome - Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 2 weeks prior to study treatment - Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery - Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)	{ "inclusion_biomarker": [ [ "BRCA1 alteration" ], [ "BRCA2 alteration" ], [ "ATM alteration" ], [ "BAP1 alteration" ], [ "MSH2 alteration" ], [ "PALB2 alteration" ], [ "BRIP1 alteration" ], [ "ABL1 alteration" ], [ "ATR alteration" ], [ "ATRX alteration" ], [ "BARD1 alteration" ], [ "BRD4 alteration" ], [ "CCND1 alteration" ], [ "CHEK1 alteration" ], [ "CHEK2 alteration" ], [ "DOT1L alteration" ], [ "FANCC alteration" ], [ "FANCE alteration" ], [ "FANCG alteration" ], [ "FANCL alteration" ], [ "IKBKE alteration" ], [ "MEN1 alteration" ], [ "MLH1 alteration" ], [ "MSH2 alteration" ], [ "MSH6 alteration" ], [ "MUTYH alteration" ], [ "NPM1 alteration" ], [ "PMS2 alteration" ], [ "POLD1 alteration" ], [ "POLE alteration" ], [ "RAD51 alteration" ], [ "SMARCB1 alteration" ], [ "STK11 alteration" ], [ "TP53 alteration" ] ], "exclusion_biomarker": [] }
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC). ; ; Inclusion: - Disease diagnosis: - Part 1: - GEA: Unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA (IHC 3+ or 2+ with or without gene amplification based upon local assessment or central assessment) - BTC: Unresectable, locally advanced, recurrent or metastatic HER2-expressing BTC (including intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], or gallbladder cancer [GBC]) (IHC 3+ with or without gene amplification; or IHC 0, 1+ or 2+ with gene amplification, based upon central assessment) - CRC: Unresectable, locally advanced, recurrent or metastatic HER2-expressing CRC (IHC 3+ with or without gene amplification; or IHC 0, 1+ or 2+ with gene amplification, based upon central assessment). Patients will be required to be extended RAS (KRAS and NRAS) and BRAF wild-type based upon central assessment. - Part 2: - GEA: Unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA (IHC 3+, or IHC 2+ and FISH+ by central assessment) - BTC: Same as Part 1 - CRC: Same as Part 1 - Tumor measurements as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1: - Part 1: Measurable or non-measurable disease - Part 2: Measurable disease - An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 - Adequate organ function - Adequate cardiac left ventricular function, as defined by a LVEF >/= institutional standard of normal Exclusion: - Prior treatment with a HER2-targeted agent - Prior systemic anti-cancer therapy (including investigational products) except prior adjuvant/neoadjuvant therapy, which must be completed at least 6 months prior to first study treatment dosing. For subjects with BTC and CRC the following additional exceptions apply: - BTC: patients may have started therapy for advanced disease but may not have received more than one cycle of any standard gemcitabine-based chemotherapy regimen. - CRC: patients may have started therapy for advanced disease but may not have received more than one cycle of 5-FU-based chemotherapy (< 1 month of therapy). - Patients with certain contraindications to bevacizumab cannot be enrolled on the mFOLFOX6-2 with bevacizumab arm. - Palliative radiotherapy is allowed if completed at least 2 weeks prior to first study treatment dosing - Untreated known brain metastases (patients with treated brain metastases who are off steroids, off antiseizure medications, and stable for at least 1 month at the time of screening are eligible) - Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF). Patients with known myocardial infarction or unstable angina within 6 months prior to randomization are also excluded. - QTc Fridericia (QTcF) > 470 ms. For patients with longer QTcF on initial electrocardiogram (ECG), follow-up ECG may be performed in triplicate to determine eligibility - Peripheral neuropathy > Grade 1 per NCI-CTCAE v5.0 - Clinically significant interstitial lung disease - Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen - Active hepatitis B or hepatitis C infection or infection with Human Immunodeficiency Virus (HIV)-1 or HIV-2 (Exception: patients with well controlled HIV [e.g., CD4 > 350/mm3 and undetectable viral load] are eligible)	{ "inclusion_biomarker": [ [ "HER2 expression" ], [ "HER2 expression", "KRAS wildtype", "NRAS wildtype", "BRAF wildtype" ] ], "exclusion_biomarker": [] }
The main objective of this trial is to explore the activity of chlorambucil, an alkylating agent commonly used in chronic lymphocytic leukemia treatment, in metastatic patients, gBRCA, including VUS, or DDR mutated, previously treated with a platinum-containing chemotherapy. ; ; Inclusion Criteria: 1. Pathologically confirmed pancreatic adenocarcinoma 2. Age ≥ 18 years 3. ECOG PS 0-2 4. Stage IV disease 5. Identified genetic aberrations that are associated with homologous recombination deficiency (HRD) 1. Cohort A: Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious 2. Cohort B: BRCA1 or BRCA2 mutations that are considered to be of uncertain/unknown significance (VUS) 3. Cohort C: Patients with other identified genetic aberrations that are associated with HRD 6. Adequate PFS during previous platinum-based chemotherapy for at least 4 months before progression 7. Screening laboratory values: Leukocytes > 3000/mmc Thrombocytes > 150000/mmc Hemoglobin > 10 g/dl Creatinine <2.0 times upper normal limit (unless normal creatinine clearance). Total bilirubin < 2.0 times upper normal limit (unless due to Gilbert's syndrome). Alanine aminotransferase (ALT) < 3.0 times upper normal limit. 8. Able to take oral medication 9. Progression during or after platinum-based chemotherapy 10. Other prior chemotherapy apart from first-line treatment for pancreatic cancer, are allowed, including maintenance treatment with PARP inhibitors 11. More than 2 weeks since prior chemotherapy end 12. Signed written informed consent 13. QTc <450 msec or QTc <480 msec for patients with bundle branch block Exclusion Criteria: 1. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to screening, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities 2. Active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy 3. Vaccination with vaccines called "live", since this treatment causes a drop of immunity defenses and a serious infection could result fatal. 4. History of seizure, head trauma and treatment with anti-epileptogenic drugs 5. Hypersensitivity to chlorambucil or to any excipients, in particular lactose 6. Recent radiotherapy (at least 4 weeks) or previous treatment with other cytotoxic agents 7. BRCA-mutated advanced pancreatic cancer who did not undergo maintenance with olaparib after platinum-based chemotherapy 8. Mismatch repair (MMR)/high levels of microsatellite instability (MSI-H), or high levels of tumor mutational burden (TMB) pancreatic cancer who did not undergo immunotherapy with pembrolizumab monotherapy or any other anti-PD1 agent 9. Concomitant PARP inhibitors therapy 10. Life expectancy less than 3 months, in the opinion of the investigator 11. Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible 12. Symptomatic duodenal stenosis 13. CT contrast medium allergy and claustrophobia to RM investigation 14. Any significant medical condition laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study 15. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study 16. Any condition that confounds the ability to interpret data from the study 17. Any familiar, sociologic or geographic conditions that can potentially interfere with the adhesion to the protocol or to the follow-up 18. Pregnant or nursing. Adequate contraception is defined as oral hormonal birth control, intrauterine device, and male partner sterilization (if male partner is sole partner for that subject) and the double barrier method (condom or occlusive cap plus spermicidal agent). 19. Concurrent treatment with other experimental drugs	{ "inclusion_biomarker": [ [ "gBRCA1 deleterious mutation" ], [ "gBRCA2 deleterious mutation" ], [ "BRCA1 uncertain significance" ], [ "BRCA2 uncertain significance" ], [ "Genetic aberrations associated with HRD" ] ], "exclusion_biomarker": [ [ "BRCA mutation" ], [ "Mismatch repair" ], [ "microsatellite instability-high" ], [ "tumor mutational burden-high" ] ] }
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors. ;NA; Inclusion Criteria: - Men or women greater than or equal to 18 years old. - Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements. In the United States, this test must be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Exclusion Criteria: - Primary brain tumor. - Spinal cord compression, or untreated, or symptomatic, or active brain metastases, or leptomeningeal disease from non-brain tumors. - Myocardial infarction within 6 months of study day 1. - Gastrointestinal (GI) tract disease causing the inability to take oral medication.	{ "inclusion_biomarker": [ [ "KRAS p.G12C" ] ], "exclusion_biomarker": [] }
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV as monotherapy and in combination with pembrolizumab in patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. The study includes patients with head and neck, cervical, anal, vulvar, or penile cancer. ;NA; Inclusion Criteria - All Patients: - Male or female patients ≥18 years of age - Histologically confirmed incurable or metastatic solid tumors that are HPV16+ (performed during screening locally or centrally, or based on documented historic test results) - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 - At least 1 measurable lesion according to RECIST 1.1 - Must have a lesion that can be biopsied with acceptable clinical risk and agree to have a fresh biopsy at Screening and on Cycle 2 Day 8 (+/- 2 days) - Patients must agree to venous access for leukapheresis and be willing to have a central line inserted if venous access is an issue - Adequate organ function and bone marrow reserve performed within 14 days prior to leukapheresis Inclusion Criteria - Part 2: • Patients must not have been treated with immune check-point inhibitors Exclusion Criteria - All Patients: - Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to leukapheresis. - Systemic treatment with either corticosteroids (>10 mg of prednisone or the equivalent per day) or other immunosuppressive medications within 14 days prior to leukapheresis - Patients treated with non-corticosteroid based immunosuppressive agents within the last 6 months prior to leukapheresis - Patients with active, known, or suspected autoimmune disease may not be eligible and should be discussed with the Sponsor - Patients with >Grade 1 AEs related to previous treatment with anticancer or investigational therapy that do not resolve at least 2 weeks prior to leukapheresis, except Grade 2 neuropathy, ototoxicity, mucositis, fatigue, alopecia, or endocrine disorders managed with hormone replacement - Known HIV infection, active hepatitis B or hepatitis C, or active mycobacterium tuberculosis infection - Has known active central nervous system metastases - Have active interstitial lung disease and any history of myocarditis - Major surgery within 2 weeks of leukapheresis Exclusion Criteria - Part 1B: - Known hypersensitivity to pembrolizumab - History of any Grade 3 immune-related AE (irAE) from prior immunotherapy Exclusion Criteria - Part 2: • Prior treatment with an immune check-point inhibitor	{ "inclusion_biomarker": [ [ "HPV16 positive" ] ], "exclusion_biomarker": [] }
This phase I trial studies the biological effects of DS-8201a on patients with HER2 positive cancer that has spread to other places in the body (advanced). DS-8201a works by binding to a protein called HER2 that is present on the surface of tumor cells. This allows DS-8201a to kill the tumor cells by damaging their deoxyribonucleic acid (DNA), resulting in tumor cell death. This study looks at how DS-8201a may affect the levels of certain proteins and immune cells in tumors and how well the drug works against tumor cells by examining cells from a small piece tumor taken before and after DS-8201a is given. ; ; Inclusion Criteria: - Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective - Patients must have measurable or evaluable disease - Age >= 18 years of age - Patients must have HER2-positive or HER2-expressing tumors as defined by Clinical Laboratory Improvement Act (CLIA)-certified labs. Patients must have either: - A tumor HER2 immunohistochemistry (IHC) score of 1+ or greater (as determined by a CLIA-certified IHC test, per criteria specified) or - A tumor with HER2 amplification (as determined by CLIA-certified in situ hybridization (ISH) or a CLIA-certified next-generation sequencing assay) - Patients with HER2 mutations are eligible, as are patients with HER2-positive breast cancer - Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%) - Absolute neutrophil count >= 1,500/mcL (within 8 days of enrollment) - Platelets >= 100,000/mcL (within 8 days of enrollment) - Leukocytes >= 3,000/mcL (within 8 days of enrollment) - Hemoglobin >= 9 g/dL (>= 8.0 g/dL for gastric cancer [GC] only) (within 8 days of enrollment) - Serum albumin >= 2.5 g/dL (GC only) (within 8 days of enrollment) - Total bilirubin =< 1.5 x institutional upper limit of normal (=< 3 x upper limit of normal in the presence of documented Gilbert's syndrome or liver metastases at baseline) (within 8 days of enrollment) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal OR =< 5 x institutional upper limit of normal for patients with liver metastases at baseline (within 8 days of enrollment) - Creatinine =< 1.5 x institutional upper limit of normal OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above 1.5 x institutional normal (within 8 days of enrollment) - No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment - No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment - International normalized ratio (INR)/prothrombin time (PT) and either partial thromboplastin or activated partial thromboplastin time (aPTT) =< 1.5 x upper limit of normal (ULN) - Ability to understand and the willingness to sign a written informed consent document - Willingness to provide blood samples for research purposes - Patients must have a lesion or lesions amenable to biopsy and must be willing to undergo 3 core needle biopsy procedures for research purposes - Patients must have left ventricular ejection fraction (LVEF) >= 50% by either an echocardiogram (ECHO), multigated acquisition (MUGA), or cardiac MRI scan within 28 days prior to enrollment - Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements: - They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective - They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/uL over the past 2 years, unless it was deemed related to the cancer and/or immunotherapy-induced bone marrow suppression - For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/ul during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy - They must have an undetectable viral load and a CD4 count >= 250 cells/uL within 8 days of enrollment - They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for >= 1 month after treatment of the brain metastases - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - The effects of DS-8201a on the developing human fetus are unknown. For this reason and because HER2 antibodies conjugated to topoisomerase 1 inhibitor agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation and for at least 7 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a administration - Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol < 40 pg/mL [< 147 pmol/L] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method - Subjects must not freeze, donate, or retrieve for their own use ova or sperm starting at screening, throughout the study period, and for at least 4.5 months after the final study drug administration. Preservation of sperm or ova should be considered prior to enrollment in this study - Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a Exclusion Criteria: - Patients who have had: - Chemotherapy (including antibody drug therapy, retinoid therapy, hormonal therapy for cancer) within: - 4 weeks or five half-lives, whichever is shorter, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel or - 6 weeks for nitrosoureas or mitomycin C or - Immunotherapy, including monoclonal antibody therapy, within 4 weeks - Patients with any of the following pulmonary-related illnesses: - A history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or for whom suspected ILD/pneumonitis cannot be ruled out by imaging at screening - Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD] grade 3-4 per Global Initiative for Obstructive Lung Disease [GOLD] criteria, restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (i.e., Rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior pneumonectomy. - Patients who have had radiation therapy within 4 weeks (or palliative stereotactic radiation therapy within 2 weeks) - Patients who have had a major surgery within 4 weeks - Patients who are receiving any other investigational agents - Patients with a medical history of myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association class II to IV), or with troponin levels consistent with myocardial infarction (as defined according to the assay manufacturer) 28 days prior to enrollment - History of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a (e.g., other topoisomerase I inhibitors) or the inactive ingredients in the drug product - Patients who have a history of severe hypersensitivity reactions to other monoclonal antibodies - Patients with a Fridericia's formula-corrected QT interval (QTcF) prolongation to > 470 ms (females) or > 450 ms (males) based on average of the screening triplicate 12-lead electrocardiogram (ECG) - Patients with spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms - Patients with an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals - Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade =< 1 or baseline. Subjects with chronic grade 2 toxicities (e.g., grade 2 chemotherapy-induced neuropathy) may be eligible per the discretion of the investigator after consultation with the sponsor medical monitor or designee. Subjects should no longer be symptomatic nor require treatment with corticosteroids or anticonvulsants and must have recovered from the acute toxic effect of radiotherapy - Patients with substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation of the subject or evaluation of the clinical study in the opinion of the investigator - Patients with uncontrolled intercurrent illness - Patients with psychiatric illness/social situations that would limit compliance with study requirements - Pregnant women are excluded from this study because DS-8201a is a HER2 antibody conjugated to a topoisomerase 1 inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a - Patients are not allowed to receive chloroquine/hydroxychloroquine. Patients receiving chloroquine/hydroxychloroquine require a washout of > 14 days	{ "inclusion_biomarker": [ [ "HER2 positive" ], [ "HER2 expression" ], [ "HER2 amplification" ], [ "HER2 mutation" ] ], "exclusion_biomarker": [] }
Nivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype mAb that binds PD-1 on activated immune cells and disrupts engagement of the receptor with its ligands PD-L1 (B7 H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the host antitumor response. In early clinical trials, nivolumab has demonstrated activity in several tumor types, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). Nivolumab is in clinical development for the treatment of patients with NSCLC, RCC, melanoma, squamous cell carcinoma of the head and neck (SCCHN) and other tumors (eg, glioblastoma multiforme, mesothelioma, small cell lung cancer, gastric). Nivolumab is approved in the United States (US), European Union, and other countries for the treatment of patients with unresectable or metastatic melanoma, advanced NSCLC with progression on or after platinum-based chemotherapy, advanced RCC whose disease progressed on an antiangiogenic therapy, classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin treatment, and recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. The proposed study will evaluate the efficacy and safety of preoperative administration of Nivolumab or Nivolumab combined with nab-paclitaxel and carboplatin in neoadjuvant setting and administration of Nivolumab in adjuvant setting in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of the tumor immune microenvironment and circulating immune cells in these patients. Data obtained in this study will provide valuable information for planning further prospective clinical trials of anti-PD-1 and other immunotherapies in NSCLC, both in the peri-operative and advanced disease setting. Ultimately, it is highly desirable to discover prospective biomarkers of response and toxicity to allow patients with NSCLC who are most likely to derive benefit to receive anti-PD-1 treatment, and conversely to minimize the risk of toxicity and ineffective treatment for patients who are unlikely to benefit. ;NA; Inclusion Criteria: - Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue - Lung function capacity capable of tolerating the proposed lung surgery - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 - Available tissue of primary lung tumor Exclusion Criteria: - Presence of locally advanced, inoperable or metastatic disease - Participants with active, known or suspected autoimmune disease - Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer. Several EGFR and/or HER2 mutations exist in the cancer cells. Two mutations observed in NSCLC are called EGFR- or HER2exon20ins and EGFR C797X. The study treatment, BAY2927088, works by blocking the mutated EGFR protein and also its ex20ins version which are present in NSCLC. It is also believed to work against HER2 and HER2ex20ins mutations. Researchers think this may help stop the further spread of NSCLC cancer. This is the first time that researchers will study BAY2927088 in humans. In this study, the researchers want to learn more about using BAY2927088 in participants who have NSCLC with EGFR and/or HER2 mutations including EGFRex20ins and/or HER2ex20ins mutations. The main aims of this study are to find for BAY2927088 - how safe BAY2927088 is - how it affects the body (also referred to as tolerability) - how BAY2927088 moves into, through and out of the body - the maximum amount of BAY2927088 that the participants can take without too many side effects. The researchers will also study the action of BAY2927088 against the cancer. The study will have three parts: Dose Escalation, Backfill, and Dose Expansion. Each participant of the first, so called dose escalation part, will be assigned to one of specific sequential dose groups for BAY2927088. The amount of BAY2927088 that is given increases stepwise from one group to the next. The second may be initiated at any dose that has already been tested during the first part and found to be safe and to have either reached a predicted efficacious exposure range or to have induced an objective response. The first part and second part will run concurrently. The participants of the third, so called dose expansion part, will receive the most appropriate dose of BAY2927088 found in the first and second parts. The third part may be initiated in parallel with the first and second part based on emerging data. During the study, the participants will take the study treatment in 3 week periods called "cycles". They will in general take BAY2927088 once daily until their cancer gets worse, until they have medical problems, until they leave the study or until the study is terminated. Participants will have around 5 visits in each cycle. During the study, the study team will: - take blood and urine samples - take regular CT or MRI scans to check if the participants' cancer has gotten better or worse - check the participants' overall health and heart health - ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. ;NA; Inclusion Criteria: - Documented histologically or cytologically confirmed locally advanced NSCLC, not suitable for definitive therapy or recurrent or metastatic NSCLC at screening (small cell or mixed histologies are excluded). - Documented disease progression after treatment with at least one prior systemic therapy for advanced disease. Participants who do not have standard of care access due to any reason, are intolerant to, or are not eligible for standard treatments, may also be eligible. - Adequate archival tumor tissue (ideally taken after last targeted treatment and not older than 6 months) has to be available, either from primary or metastatic sites. If archival material is not available, a fresh tumor biopsy should be performed if feasible and if the procedure poses no significant risk for the participant. - Measurable disease by RECIST v1.1 with at least one lesion not chosen for biopsy during the screening period (if a biopsy is taken during screening) that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements. A biopsied lesion should not be used as a target lesion for RECIST 1.1 tumor assessments. Previously irradiated lesions must have shown progression to be considered measurable. - Documented activating EGFR and/or HER2 mutation assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States [US] sites) or an equally accredited (outside of the US) local laboratory - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. - Minimum life expectancy of 12 weeks. - Adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 days before the first dose of study treatment: 1. Hemoglobin ≥ 9.0 g/dL. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within 2 weeks prior to testing. 2. Platelets ≥ 100 × 10^9 cells/L. 3. Absolute neutrophil count ≥ 1.5 ×10^9 cells/L. Criteria must be met without the use of hematopoietic growth factors (e.g., G-CSF) within 2 weeks prior to testing. - Adequate kidney function as assessed by following laboratory test to be conducted within 7 days before the first dose of study treatment: a. Estimated glomerular filtration rate (eGFR) > 60 mL/min per 1.73 m^2 according to the Modification of Diet in renal Disease Study Group (MDRD) formula. - Adequate liver function as assessed by following laboratory tests to be conducted within 7 days before the first dose of study treatment: 1. Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for participants with documented Gilbert-Meulengracht Syndrome, or for participants with hyperbilirubinemia considered due to liver metastasis). 2. Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor). Exclusion Criteria: - Treatment with an EGFR tyrosine kinase inhibitor (TKI) ≤ 8 days or 5x the terminal phase, elimination half-lives, whichever is shorter, prior to the first dose of study drug. - Treatment with a systemic anti-cancer treatment (excluding EGFR TKIs as described above) ≤ 14 days prior to the first dose of study drug. - Radiation therapy, stereotactic radiosurgery (SRS) and palliative radiation ≤ 14 days prior to the first dose of study drug. - Treatment with immunotherapy ≤ 28 days prior to the first dose of study drug. - Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Participants with chronic, but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor. - Any history of primary brain or leptomeningeal disease (symptomatic or asymptomatic), presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local treatment (such as radiotherapy or surgery). - History of spinal cord compression or brain metastases with the following exceptions: 1. Participants with treated brain metastases that are asymptomatic at screening and who are off or receiving low-dose of corticosteroids (≤10 mg prednisone or equivalent) for at least 7 days prior to first dose of BAY 2927088 are eligible to enroll in Dose Escalation and Backfill. 2. Participants with treated brain metastases that are asymptomatic at screening are eligible in Dose Expansion if all of the following criteria are met: - there is no evidence of progression (new or enlarging brain metastases) for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. - Participants must be off or receiving low-dose of corticosteroids (≤10 mg prednisone or equivalent) for 7 days prior to first dose of BAY2927088. 3. Participants with history of spinal cord compression >3 months from definitive therapy and stable by imaging (MRI or CT) during the screening period and clinically asymptomatic. - History of congestive heart failure (CHF) Class >II according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment (e.g. ventricular arrhythmias, atrial fibrillation) or any clinically important abnormalities in rhythm, conduction or morphology or resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec) - Participants with: 1. Known human immunodeficiency virus (HIV), except as noted below: Participants with history of HIV infection are eligible at the Investigator's discretion provided that: • CD4+ T-cell (CD4+) counts are ≥ 350 cells/uL • The participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to the start of study drug and has an HIV viral load less than 400 copies/mL prior to start of the study treatment • The ART being used does not contain strong inducers or inhibitors of CYP3A4, and is not anticipated to cause overlapping toxicities with study drug • The participant has not had an opportunistic infection within the past 12 months 2. Active Hepatitis B infection (positive for Hepatitis B surface antigen [HbsAg]) and Hepatitis B virus [HBV] DNA). 3. Active Hepatitis C infection (positive anti-HCV Antibody and quantitative HCV RNA results greater than the lower limits of detection of the assay). NOTE: Participants with history of chronic HBV or HCV infection are eligible at the Investigator's discretion provided that the disease is stable and sufficiently controlled under treatment. - Use of strong CYP3A4 inhibitors and inducers from 14 days prior to first administration of study drug. Strong CYP3A4 inhibitors and inducers are prohibited during the study and until Safety FU (follow up) visit.	{ "inclusion_biomarker": [ [ "EGFR activating mutation" ], [ "HER2 activating mutation" ] ], "exclusion_biomarker": [] }
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2. ; ; Inclusion Criteria: 1. Advanced solid tumors that has progressed beyond standard of care OR 2. ER+ HER2- BC that has progressed following treatment with a CDK4/6 inhibitor OR 3. Endometrial and gastric cancer that has progressed after at least 2 prior therapies (including one prior platinum therapy) OR 4. Platinum refractory or platinum resistant ovarian cancer CCNE1 amplified tumors that have progressed beyond standard of care Exclusion Criteria: 1. Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis. 2. Have received the following anticancer therapy: a. Previous therapy with CDK2i, PKMYT1i, or WEE1i, except in Part 1A where up to 10 patients who previously received PKMYT1i, or WEE1 inhibitor will be permitted. 3. Have central nervous system (CNS) metastases or spinal cord compression that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease. 4. Have known intracranial hemorrhage and/or bleeding diatheses. 5. Have clinically active ongoing ILD of any etiology, including drug-induced ILD, and radiation pneumonitis within 28 days prior to initiation of study treatment. 6. Have any unresolved toxicities from prior therapy greater than CTCAE Grade 1 or that have not resolved to baseline at the time of starting the study. 7. Have mean resting QTcF > 450 msec, a history of prolonged QT syndrome or Torsades de pointes, or a familial history of prolonged QT syndrome. 8. Have clinically significant, uncontrolled, cardiovascular disease including congestive heart failure Grade III or IV according to the New York Heart Association classification; myocardial infarction or unstable angina within the previous 6 months, uncontrolled hypertension, or clinically significant, uncontrolled arrhythmias, including bradyarrhythmia that may cause QT prolongation (eg, Type II second degree heart block or third-degree heart block). 9. Have a history of another primary malignancy other than completely resected carcinomas in situ) that has been diagnosed or required therapy within 2 years prior to initiation of study treatment. 10. Have active, uncontrolled infection (viral, bacterial, or fungal), including tuberculosis, hepatitis B virus (HBV), hepatitis C virus, AIDS-related illness, or COVID-19 infection (symptoms and a positive test result). 11. Requires treatment with a prohibited medication or herbal remedy that cannot be discontinued at least 2 weeks before the start of study drug administration. 12. Have planned major surgical procedure within 14 days of the first dose of study drug (procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures). 13. Unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, or other study procedures and study restrictions. 14. Patient is a woman who is not postmenopausal or surgically sterile, and is unwilling to abstain from sexual intercourse or employ highly effective contraception OR is a man who is not surgically sterile, and is unwilling to abstain from sexual intercourse or employ highly effective contraception 15. Patient is a pregnant female	{ "inclusion_biomarker": [ [ "HR positive", "HER2 positive" ], [ "CCNE1 amplification" ] ], "exclusion_biomarker": [] }
This phase II trial studies how well pembrolizumab works before surgery in treating patients with mismatch repair deficient solid cancers that have spread to nearby tissue or lymph nodes (locally advanced). Cancer is caused by changes (mutations) to genes (DNA) that control the way cells function, and some of these mutations can cause tumor cells to grow quickly and out of control. Microsatellite instability-high (MSI-H) tumors are made up of cancer cells that have a greater than normal number of genetic markers called microsatellites. These cancers may have defects in the ability to correct mutations that occur when DNA is copied in the cell. Similarly, mismatch repair deficient tumors (dMMR) may have difficulty repairing some type of genetic mutation during cellular replication that may affect tumor's response to cancer therapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ; ; Inclusion Criteria: - Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of solid cancer - Solid cancer that is deficient in mismatch repair (dMMR) or microsatellite instability high (MSI-H) as determined by one of three methods: - Immunohistochemistry determined dMMR by complete loss of MLH1, PMS2, MSH2 or MSH6 - Polymerase chain reaction (PCR) determined microsatellite instability at > 30% of tested microsatellites - Next-generation sequencing determined MSI-H based upon instability at multiple microsatellites as determined by the specific next generation sequencing panel - Locally advanced cancer defined as either an unresectable primary cancer or a resectable primary cancer with a high chance of recurrence (defined as an estimated greater or equal to 20% chance of recurrence by the treating physician). A resectable primary may include locoregional disease, as long as all disease is felt by the treating physician to be in a resectable distribution - The participant (or legally acceptable representative if applicable) provides written informed consent for the trial - Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (unless discussed and approved by study principal investigator [PI]) - Have available archival tumor tissue. Availability will be met as long as a request to obtain formalin-fixed, paraffin embedded (FFPE) tissue blocks (preferred) or slides has been made (unless discussed and approved by study PI) - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the date of signing study consent - A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: - Not a woman of childbearing potential (WOCBP) OR - A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least (120 days [corresponding to time needed to eliminate any study treatment(s) plus 30 days (a menstruation cycle) for risk of genotoxicity]) after the last dose of study treatment - Absolute neutrophil count (ANC) >= 1500/uL (within 14 days prior to the start of study treatment) - Platelets >= 100 000/uL (within 14 days prior to the start of study treatment) - Hemoglobin >= 8.0 g/dL or >= 5.6 mmol/L (within 14 days prior to the start of study treatment) - Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks - Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN (within 14 days prior to the start of study treatment) - Creatinine clearance (CrCl) should be calculated per institutional standard - Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for participants with total bilirubin levels > 1.5 x ULN (within 14 days prior to the start of study treatment) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (=< 5 x ULN for participants with liver metastases) (within 14 days prior to the start of study treatment) - International normalized ratio (INR) OR prothrombin time (PT) activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants (within 14 days prior to the start of study treatment) Exclusion Criteria: - A woman of childbearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) - Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks of study treatment. Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to =< grade 1 or baseline. Participants with =< grade 2 neuropathy may be eligible - If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment - Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease - Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug - Has a known additional malignancy that is progressing or has required active treatment within the past 1 year. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) or other similar good prognosis cancer with recurrence rates expected to be < 10% that have undergone potentially curative therapy are not excluded - Known metastatic sites of disease. Note: locoregional lymph nodes or tumor deposits are not considered metastatic disease - Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients - Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment - Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis - Has an active infection requiring systemic therapy - Has a known history of human immunodeficiency virus (HIV) - Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection. Note: no testing for hepatitis B and hepatitis C is required unless mandated by local health authority - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial - Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment	{ "inclusion_biomarker": [ [ "mismatch repair deficient" ], [ "Microsatellite instability-high" ], [ "MLH1 loss" ], [ "PMS2 loss" ], [ "MSH2 loss" ], [ "MSH6 loss" ] ], "exclusion_biomarker": [] }
To study the radioactive uptake of [68Ga]P137 in the lesion sites of PCa patients and evaluate the ability of [68Ga]P137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa). ; ; Inclusion Criteria: - Men over 18 years of age need to undergo [68Ga]P137 PET/CT examination for suspected prostate cancer. - The patients can fully understand and voluntarily participate in this experiment, and sign the informed consent. Exclusion Criteria: - Significant hepatic or renal dysfunction; - Patients with malignant tumors other than prostate cancer within 2 years; - Ready to pregnant; - The patient can not tolerate all clinical tests.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab [DA-EPOCH+/-R]) with the addition of targeted therapy (tafasitamab) for the treatment of patients with newly diagnosed Philadelphia chromosome negative (Ph-) B acute lymphoblastic leukemia (B-ALL). Chemotherapy drugs, such as those in EPOCH+/-R, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Tafasitamab is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Adding tafasitamab to the DA-EPOCH+/-R regimen may work better than DA-EPOCH+/-R alone in treating newly diagnosed Ph- B-ALL. ; ; Inclusion Criteria: - Adults (age 18 years and older) with newly-diagnosed CD19+ Ph- B-ALL - In the opinion of the treating investigator, patients must be an unsuitable candidate for a pediatric-inspired regimen, reasons for which may include (but not be limited to) older age (e.g., >= 40 years), practical/logistical barriers to or toxicity concerns from administration of a pediatric-inspired regimen - Marrow or blood involvement detectable by MFC - Total bilirubin =< 2.0 x upper limit of normal (ULN) (unless attributed to Gilbert's disease or other causes of inherited indirect hyperbilirubinemia, at which point total bilirubin must be =< 4.0 x ULN) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5.0 x institutional ULN. (Note: Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is =< 5.0 x ULN and ALT/AST are =< 8.0 x ULN) - Calculated creatinine clearance of > 30 ml/min, as measured by the Modification of Diet in Renal Disease (MDRD) equation, will be eligible - As patients with ALL frequently have cytopenias, no hematologic parameters will be required for enrollment or to receive the first cycle of treatment. However, adequate recovery of blood counts will be required to receive subsequent cycles - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. (Performance status of 3 will be allowed if poor performance status is thought to be directly secondary to ALL) - Ability to give informed consent and comply with the protocol - Anticipated survival of at least 3 months, independent of ALL Exclusion Criteria: - Burkitt lymphoma/leukemia - No prior systemic therapy for ALL except to control acute symptoms and/or hyperleukocytosis (e.g., corticosteroids, cytarabine, etc.) - No isolated extramedullary or known parenchymal central nervous system (CNS) disease - Known hypersensitivity or intolerance to any of the agents under investigation - Other medical or psychiatric conditions that in the opinion of the investigator would preclude safe participation in the protocol - May not be pregnant or nursing - Pregnancy test is only required in women, unless they are highly unlikely to conceive (defined as [1] surgically sterilized, or [2] postmenopausal [i.e., a woman who is > 50 years old or who has not had menses for >=1 year], or [3] not heterosexually active)	{ "inclusion_biomarker": [ [ "CD19 positive", "Philadelphia chromosome negative" ] ], "exclusion_biomarker": [] }
This study aims to describe the treatment patterns in clinical practice in adult patients with mNSCLC with a BRAF V600E mutation. This study will also describe Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) for treatments prescribed in routine practice for mNSCLC with BRAF V600E mutation. Adverse events (AEs) related to treatment management will also be described. ;NA; Inclusion Criteria: - Age ≥ 18 years at the time of first-line treatment initiation for mNSCLC, - Patients who initiated a first systemic treatment for mNSCLC in the metastatic setting from 01 December 2017 and before their study entry date (retrospectively enrolled patients), or Patients who initiated a first systemic treatment for mNSCLC (metastatic setting) at or after their study entry date (prospectively enrolled patients), - Confirmed diagnosis of Stage IV mNSCLCat any time before study inclusion Stage IV M1a, M1borM1c, as per the American Joint Committee on Cancer (AJCC cancer) staging manual, - Confirmed presence of BRAF V600E mutation - via tumor biopsy, metastasectomy, or liquid biopsy - at anytime before study inclusion, - Signed ICF or non-opposition to study participation,according to local regulations. Patients eligible for prospective QoL data collection must, in addition to the above mentioned criteria, meet ALL of the following criteria to be eligible for the study: - Patients who initiate a first or second systemic treatment line for mNSCLC (metastatic setting) with a BRAF V600E mutation at or after their study entry date Exclusion Criteria: - Concurrent or another previous malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, in-situcarcinoma of the cervix, Bowen's disease or Gleason ≤ 6 prostate cancer, - Previous, ongoing, or planned participation in a clinical trial involving an interventional drug as a first-or second-line systemic treatment for mNSCLC.	{ "inclusion_biomarker": [ [ "BRAF V600E" ] ], "exclusion_biomarker": [] }
This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied. ; ; Inclusion Criteria: 1. Part A: Histological or cytological proof of advanced KRASm NSCLC, CRC or PDAC; PART B: Histological or cytological proof of advanced KRASm PDAC. 2. Age => 18 years; 3. Able and willing to give written informed consent; 4. WHO performance status of 0 or 1 5. Able and willing to undergo blood sampling for PK and PD analysis; 6. Able and willing to undergo tumor biopsies prior to start (or have undergone a biopsy within 2 months of inclusion), while on study treatment and upon progression of disease; 7. Life expectancy => 3 months and no deterioration or hospitalizations within 2 weeks leading to C1D1, allowing adequate follow up of toxicity evaluation and antitumor activity; 8. Evaluable disease according to RECIST 1.1 criteria; (PART A and PART B); 9. Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration and agree to use effective contraceptive methods, as defined in section 5.9.3, through-out the treatment period, and for 4 months after the study treatment 10. Adequate organ system function. Exclusion Criteria: 1. Part A: No excluded genotypes Part B: Excluded genotypes (including co occurring mutations): - NRAS (except G12A/C) - RASQ61 - KRASG13 - BRAF Class 1, 2, or unclassified - PIK3CA - STK11 - KEAP1 2. Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment; 3. Patients currently using concomitant medication that are strong inhibitors or inducers of CYP3A4; 4. History of another malignancy Exception PART A: Patients who have been disease-free for at least 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent completely resected second malignancies are eligible. Exception PART B: Adequately treated carcinoma in situ of the cervix and adequately treated basal cell carcinoma of the skin. 5. Symptomatic or untreated leptomeningeal disease 6. Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy (for at least 4 weeks) are allowed to enroll. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive antiepileptic drugs or corticosteroids. 7. Patients who have had previous treatment with any targeted drug combination known to interfere RAS/MEK/MAPK pathway components. 8. Toxicities related to prior treatments > grade 1 (excluding alopecia) 9. History of interstitial lung disease or pneumonitis 10. Woman who are breast feeding; 11. Patients who have undergone any major surgery within the last 4 weeks prior to starting study drug or who would not have fully recovered from previous surgery. 12. Radio- or chemotherapy within the last 4 weeks prior to receiving the first dose of investigational treatment; except a palliative dose of radiation of 8 Gy, which is allowed up to one week before study start and should not be applied to the target lesion. 13. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients; 14. Patients with a known history of or uncontrolled hepatitis B (HBV) or C (HCV); 15. Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair study compliance; 16. Patients with cardiac comorbidities (myocardial infarct within 6 months of study start, NYHA class ≥ III, congestive heart failure or instable angina pectoris), uncontrolled hypertension (systolic blood pressure > 160 mm Hg and/or diastolic pressure > 90 mm Hg), prolonged QT interval(> 440 ms for men, > 460 ms for women) or patients who have had a stroke within 6 months prior to start study. 17. Other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality active infections that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study. 18. Patients with pulmonary embolisms or deep venous thrombosis (DVT) within 3 months prior to start 19. Known hypersensitivity to one of the study drugs or excipients. 20. Baseline diarrhea and/or any condition that would impair absorption of oral agents 21. Patient with a history or findings of central or branch retinal artery or venous occlusion with significant vision loss or other retinal diseases that cause current visual impairment or would likely cause visual impairment over the time period of the study, as assessed by an ophthalmologist.	{ "inclusion_biomarker": [ [ "KRAS mutation" ] ], "exclusion_biomarker": [ [ "NRAS mutation" ], [ "RAS Q61" ], [ "KRAS G13" ], [ "BRAF class 1 mutation" ], [ "BRAF class 2 mutation" ], [ "BRAF unclassified mutation" ], [ "PIK3CA mutation" ], [ "STK11 mutation" ], [ "KEAP1 mutation" ] ] }
This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation. ; ; Inclusion Criteria: - Subjects must have a history of primary brain tumor (including but not limited to glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic ganglioglioma (AG), and anaplastic pleomorphic xanthoastrocytoma (PXA)). - Subjects must have a BRAF-V600 mutation identified in previous tissue analysis (may be IHC or PCR based). Allowable mutations include V600E, V600K, V600R, and V600D. - Subjects must be taking dabrafenib at a dose of at least 50mg twice daily (adults only) and / or trametinib at a dose of at least 1mg daily (adults only) for at least 7 days prior to surgery as prescribed by their treating physician. Note: Pediatric patients may be taking any dose of dabrafenib and / or trametinib as prescribed by their treating physician for at least 7 days prior to surgery. - Subjects must be undergoing surgery for clinical purposes. - Written informed consent - a signed informed consent and/or assent (as age appropriate) for study participation will be obtained according to institutional guidelines. Exclusion Criteria: - Subjects who are receiving any other investigational agents or chemotherapeutic agents. - Subjects for whom collection of blood, spinal fluid, or tissue samples is unsafe or clinically inadvisable.	{ "inclusion_biomarker": [ [ "BRAF V600E" ], [ "BRAF V600K" ], [ "BRAF V600R" ], [ "BRAF V600D" ] ], "exclusion_biomarker": [] }
transoral Robotic surgery for rECurrent tumours of the Upper aerodigestive Tract ; ; Inclusion Criteria: - Aged over 18 - Previous HNC treated with radiotherapy - Undergoing TORS as part of their management for recurrent disease - Surgery performed on or before July 31st 2018. Exclusion Criteria: - TORS used in a diagnostic setting only - Nasopharyngeal and thyroid cancers	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on hematopoietic stem cell mobilization in poor mobilization patients with hematological malignancies. All eligible patients will receive EAP regimen treatment, then the number of CD34+ cells and white blood cells will be monitoring. When the collection standard is met, hematopoietic stem cell collection will be started. ;NA; Inclusion Criteria: 1. According to the diagnostic criteria of the Italian transplantation working group, patients with hematological malignancies diagnosed as "confirmed poor mobilization" or "predicted poor mobilization". 2. Patients with auto-HSCT indication. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0~2. 4. Patients should be within age range of ≥18 and ≤75 years old. 5. Life expectancy ≥ 3 months. 6. Patients must be able to sign informed consent. Exclusion Criteria: 1. Patients with severe cardiac, hepatic or renal insufficiency, such as: - Cardiac function class II or higher or severe arrhythmia; - Serum direct bilirubin (DBIL)>2× upper limit of normal (ULN); - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2× ULN; - Serum creatinine clearance rate≤50%. 2. Patients with active infection. 3. History of allergy to Etoposide (VP-16), Cytarabine (Ara-C), or PEG-rhG-CSF. 4. Women who are pregnant or breastfeeding. 5. Have received live vaccine and attenuated live vaccine within 4 weeks before enrollment. 6. For any other reasons, the patients are believed not suitable for participation in this study by investigators	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors). ;NA; Inclusion Criteria: - Patients who voluntarily join the study and sign the informed consent form; - Aged 18 to 75 years (when signing informed consent); Eastern cooperative oncology group（ ECOG） score: ≤2 ; patients with malignant peripheral nerve sheath tumors （MPNST）who are expected to survive ≥12 weeks; - NF1 patients (including patients with MPNST) who are judged by the investigator as incomplete surgical resection, require systemic treatment, and have measurable lesions; Note: NF1 diagnostic criteria meets at least one of the following: 1. Genetic examination confirmation: test positive for NF1 germline mutation in a Clinical Laboratory Improvement Amendments （CLIA）-certified laboratory (positive NF1 germline mutation must be confirmed by the central laboratory of this project, or an NF1 mutation test report issued by a CLIA-certified laboratory; 2. Clinical and imaging examination confirmation: According to the clinical National Institute of Health (NIH) consensus criteria, at least two of the following NF1 diagnostic criteria are met: 1. Six or more café-au-lait macules (≥0.5cm in prepubertal patients or ≥1.5 cm in post pubertal patients) 2. Freckling in axilla or groin 3. ≥2 neurofibromas of any type, or ≥1 plexiform neurofibromas 4. Optic glioma 5. Two or more Lisch nodules 6. A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex) 7. A first-degree relative with NF1 - Patients who are confirmed by direct measurement or according to the Response Evaluation Criteria in Solid Tumors（RECIST） 1.1 standard that there is at least one evaluable lesion, and the diameter of the lesion is greater than 3 cm, and the lesion can be seen in three consecutive sections; - The main organs function well and meet the following standards: 1. Blood routine examination standard (no blood transfusion and no hematopoietic stimulating factor drugs used for correction within 7 days before the examination): a. White blood cell count (WBC) ≥3.5×109/L b. Hemoglobin (HGB) ≥90 g/L; c. The absolute value of neutrophils (NEUT) ≥ 1.5×109/L; d. Platelet count (PLT) ≥ 100×109/L. 2. The biochemical inspection shall meet the following standards: a. Albumin (ALB) ≥35g/L; b. Total bilirubin (TBIL) ≤ 1.5× the upper limit of normal (ULN), and patients with Gilbert syndrome are ≤ 2.5× ULN; c. Alanine-based transferase (ALT) and aspartate-based transferase (AST) ≤2.5×ULN; d. Serum creatinine (CR) ≤1.5×ULN or creatinine clearance (CCR) ≥50ml/min (application of standard Cockcroft-Gault formula); 3. The coagulation function test shall meet the following standards: International normalized ratio (INR)≤1.5×ULN (have not received anticoagulant therapy); 4. Thyroid function examination must meet the following standards: Thyroid-stimulating hormone (TSH)≤ULN; if abnormal, Triiodothyronine （T3） and thyroxine（T4）levels should be examined, and T3 and T4 levels are normal. 5. Heart color Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%. - Female patients of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; serum pregnancy test within 7 days before study entry Negative, and must be a non-lactating subject; male patients should agree to adopt avoidance measures during the study period and within 6 months after the end of the study period; - Patients enrolled in the second stage need to be pathologically confirmed to be enrolled in cohort 1, cohort 2 or cohort 3. Exclusion Criteria: - Combined diseases and medical history: 1. Patients who have other malignant tumors within 3 years before the first medication or are currently suffering from other malignancies. The following two situations can be enrolled: other malignant tumors treated by a single operation; achieving 5 consecutive years of disease-free survival (DFS); 2. With factors that affect oral medications (such as dysphagia, chronic diarrhea and intestinal obstruction, etc.) 3. Unreliable toxic reactions higher than Common Terminology Criteria for Adverse Events(CTCAE) v5.0 level 1 caused by any previous treatment, excluding hair loss; 4. Received major surgical treatment or obvious traumatic injury within 28 days before the first medication; 5. Long-term unhealed wounds or fractures caused by surgery or trauma; 6. Arterial/venous thrombosis occurred within 6 months before the first medication, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; 7. With a history of psychotropic drug abuse and cannot be quit or have mental disorders; 8. There are risk factors for prolonging the corrected QT interval（QTc）interval, such as uncorrectable hypokalemia, hereditary long QT syndrome, or taking drugs that prolong the QTc interval (mainly class Ia, Ic, and III antiarrhythmic drugs) ； 9. Past or current retinal vein stenosis, retinal detachment, central retinal vein occlusion, glaucoma, grade 1 cataract, related symptoms caused by the disease are not considered as exclusion criteria; 10. Interstitial pneumonia, including clinically significant radiation pneumonia; 11. Patients with any severe and/or uncontrollable disease, including: 1. Unsatisfactory blood pressure control (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); 2. Suffering from grade ≥2 myocardial ischemia or myocardial infarction, arrhythmia (including male QTc ≥450 ms (male), QTc ≥470 ms (female)) and grade ≥2 congestive heart failure (New York Heart Association ( NYHA) classification, appendix 2); 3. Active or uncontrolled serious infection (≥CTCAE v5.0 Grade 2 infection); 4. Active hepatitis: hepatitis B reference: HBsAg is positive, and the HBV DNA test value exceeds the upper limit of normal; hepatitis C reference: HCV antibody is positive, and the HCV virus titer test value exceeds the upper limit of normal; Note: Those who meet the criteria for entry, hepatitis B surface antigen-positive or core antibody-positive patients, and hepatitis C patients need to continue antiviral therapy to prevent virus activation; 5. Renal failure requiring hemodialysis or peritoneal dialysis; 6. A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 7. Poor diabetes control (fasting blood glucose (FBG)> 10 mmol/L); 8. Urine routines suggest that urine protein is ≥++, and the 24-hour urine protein quantification is confirmed to be >1.0 g; 9. Those who suffer from epilepsy and need treatment; - Tumor-related symptoms and treatment: 1. Have received surgery, chemotherapy, radiotherapy or other anti-cancer therapies within 4 weeks before the first medication (the washout period will be calculated from the end of the last treatment); Note: Those who have received local radiotherapy in the past can be included in the group if the following conditions are met: the end of radiotherapy is more than 4 weeks from the beginning of the study treatment (brain radiotherapy is more than 2 weeks); and the target lesion selected for this study is not in the radiotherapy area; Or the target lesion is located in the radiotherapy area, but the progress has been confirmed. 2. Have received National Medical Products Administration(NMPA) approved Chinese patent medicines with anti-tumor indications (including compound cantharidin capsules, Kangai injections, Kanglaite capsules/injections, Aidi injections, Brucea javanica oil injections). /Capsules, Xiaoaiping Tablets/Injections, Huachansu Capsules, etc.) treatment; - Research and treatment related: 1. Patients who have previously received one of the following treatments: a. Patients who have received NF1 drug treatment within 3 months before enrollment, and the related side effects have not yet recovered to below grade 1 (except for hair loss). Note: Patients who are receiving NF1 drug treatment must recover from the acute toxicity of the current NF1 treatment to less than or equal to Grade 1 (refer to CTCAE v5.0) before entering this study; b. Patients Received tipifarnib, pirfenidone, peg-interferon, sorafenib or other VEGFR inhibitor or biological treatments within 14 days before receiving study drug treatment ; c. Receiving strong Cytochrome P450 3A4 enzyme（CYP3A4） inhibitors (amprenavir, atazanavir, boceprevir, clarithromycin, cornivatan, delavirdine, diltiazem, erythromycin) within 14 days before receiving study drug treatment , Fursanavir, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mibefradil, Miconazole, Nefazodone, Nefinavir, Posaconazole, Ritonavir, saquinavir, tilarrevir, telithromycin, verapamil, voriconazole, etc.) or strong inducers (carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, Patients with primidone, rifabutin, rifampicin, rifapentin, etc.), except for external use on the skin; 2. Unable to perform Magnetic Resonance Imaging(MRI) examination and/or there are contraindications for MRI examination, such as prosthesis, orthotics or orthodontics, which will interfere with the volume analysis of the target Plexiform neurofibroma( PN) on MRI; - Patients who need to take more than the recommended dose of vitamin E daily; - Patients who have participated within 4 weeks before the first medication and used other anti-tumor clinical trial drugs or wihtin 5 half-lives; - According to the judgment of the investigator, there are situations that seriously endanger the safety of the patients or affect the completion of the study.	{ "inclusion_biomarker": [ [ "NF1 mutation (germline)" ] ], "exclusion_biomarker": [] }
This is a first-in-human, Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PT199 (an Anti-CD73 mAb) alone and in combination with a PD-1 inhibitor, in patients with locally advanced or metastatic solid tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate. ; ; Inclusion Criteria: 1. 18 years or older and able to sign informed consent and comply with the protocol 2. At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors 3. Histologically or cytologically confirmed unresectable advanced or metastatic solid tumors previously treated with all available systemic standard therapy or for which treatment is not available or not tolerated, or for subjects enrolling in parts B and C (combination therapy groups) only anti PD-1 therapy is indicated as standard of care therapy. 4. Able to provide a formalin fixed, paraffin embedded (FFPE) tumor tissue sample (archival tissue or fresh biopsy). To be assessed for CD73 and other biomarkers (PD-L1) expression. - Biopsy must be excisional, incisional, or core. Needle aspiration is insufficient. - Archival tissue is acceptable if biopsy was completed within 6 months. - Biopsy is optional in part A (monotherapy dose escalation). 5. ECOG performance status of 0 or 1 6. Adequate organ function confirmed at screening and within 7 days of initiating treatment, as evidenced by: - Absolute neutrophil count (ANC) ≥ 1.5 × 109/L - Hemoglobin (Hgb) ≥ 9 g/dl (RBC and Platelets transfusion are not allowed within 2 weeks of C1D1). - Platelets (plt) ≥ 75 × 109/L - AST/SGOT and ALT/SGPT ≤ 2.5 × Upper Limit of Normal (ULN) or ≤ 5.0 × ULN if liver metastases are present - Total bilirubin ≤ 1.5 × ULN - Calculated creatinine clearance ≥ 50 mL/min (Cockcroft Gault formula) 7. Resolution of all acute adverse events resulting from prior cancer therapies to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE V5.0) Grade ≤ 1 or baseline (except alopecia or neuropathy) 8. Negative serum pregnancy test within 72 hours before starting study treatment in all pre-menopausal women and women < 24 months after the onset of menopause (had a menstrual period in past 24 months) and are of childbearing potential (women who underwent hysterectomy or bilateral oophorectomy do not need a pregnancy test) 9. Must agree to use effective contraceptive methods to avoid pregnancy (including male and female participants and partners of study subjects) during the study and until at least 6 months after ceasing study treatment. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception Exclusion Criteria: 1. Women who are pregnant or lactating 2. Women of child-bearing potential (WOCBP) who do not use adequate birth control 3. Autoimmune disease requiring systemic treatment within the past twelve months 4. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to study treatment. Corticosteroids doses equivalent to Prednisone 10mg per day or less are allowed. 5. Patients with a history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or has a history of interstitial lung disease. 6. Patients with untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed (e.g., evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain/CNS metastases) Note: Patients with treated brain metastases that are off corticosteroids and have been clinically stable for 28 days are eligible for enrollment. 7. Patients with a known concurrent malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, carcinoma in situ of the cervix or other noninvasive or indolent malignancy that has previously undergone potentially curative therapy. 8. Patients who have received an investigational product, < 5 half-lives duration. 9. Patients who have previously received immune checkpoint inhibitor therapy and discontinued treatment because of immune-related adverse events 10. Patients who have allergies or hypersensitivity reactions to immune checkpoint inhibitor therapy or any of the inactive ingredients 11. Prior T-cell, NK cell, or CD73 inhibitor therapy (Prior Checkpoint inhibitor anti PD-1 and anti PD-L1 therapies are allowed) 12. Patients that have received a live-virus vaccination within 30 days of planned treatment start (exception Janssen JNJ-78436735 COVID-19 vaccine). 13. Impaired cardiac function or significant diseases, including but not limited to any of the following: - LVEF < 45% as determined by MUGA scan or ECHO - Congenital long QT syndrome - QTcF ≥ 480 msec on screening ECG - Unstable angina pectoris ≤ 3 months prior to starting study drug - Acute myocardial infarction ≤ 3 months prior to starting study drug 14. Patients with uncontrolled hypertension or blood pressure of ≥ 150 mmHg systolic and/or ≥ 90 mmHg diastolic at Screening. 15. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia [triglycerides > 500 mg/dL], or active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol 16. Patients who have received chemotherapy, ≤ 5 half-lives or 3 weeks, whichever is shorter (6 weeks for nitrosourea or mitomycin-C), targeted therapy, or immunotherapy within 4 weeks prior to starting study drug 17. Patients who have ≥ Grade 3 neuropathy 18. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy 19. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy 20. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants (Other anticoagulants such as anti-thrombin or factor X are allowed). 21. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion and Sponsor approval 22. Evidence of active infection with Hepatitis B or Hepatitis C that is not adequately controlled. (For patients with known prior history of Hepatitis B or Hepatitis C, enrollment may be allowed per investigator's discretion and Sponsor approval.) 23. Has a history or current evidence of any medical or psychiatric condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial. For example, conditions that depend on the establishment of collateral circulation, such as peripheral arterial vascular disease, myocardial infraction recovery period, etc	{ "inclusion_biomarker": [ [ "CD73 expression" ], [ "PD-L1 expression" ] ], "exclusion_biomarker": [] }
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer. ; ; Inclusion Criteria: 1. Willing and able to participate in the study and provide written informed consent 2. Be ≥ 18 years of age on the day of signing the ICF 3. Patients must have thyroid cancer that expresses ICAM-1 and that meets one of the following diagnoses: 1. ATC BRAF wild-type at any stage, including newly diagnosed 2. ATC BRAF mutant after failure of or inability to tolerate BRAF-specific therapy 3. PDTC that has failed any of the following treatments: surgery RAI, chemotherapy, radiation therapy, and/or targeted therapies 4. Measurable disease by CT or PET/CT per RECIST v1.1 5. ECOG performance status 0 to 2 (see Appendix 2; Section 14.2) 6. Life expectancy greater than 8 weeks 7. Adequate hepatic, renal, bone marrow, cardiac, and coagulation function, defined as the following: 1. Estimated creatinine clearance ≥ 50 mL/minute 2. ALT and AST ≤ 2.5 × upper limit of normal (ULN); patients with hepatic metastases, ALT and AST ≤ 5 × ULN 3. Serum total bilirubin < 1.5 mg/dL unless the patient has known Gilbert's Syndrome, then total bilirubin ≤ 3 mg/dL 4. Serum albumin ≥ 2.5 g/dL 5. Hemodynamically stable and left ventricular ejection fraction ≥ 45% 6. Hematological parameters i. Absolute neutrophil count > 1000/µL without myeloid growth factor support for ≥ 1 week ii. Absolute lymphocyte count ≥ 100/µL iii. Platelet count ≥ 50 × 10e3/µL without platelet transfusion for ≥ 1 week iv. Hemoglobin concentration > 8 g/dL without red blood cell transfusion for ≥ 2 weeks 8. Has met the minimum washout time for previous cancer treatments (Section 5.5.3) before undergoing apheresis or LDC, and in the Investigator's judgement, the patient is able to safely undergo the procedure 9. Absolute lymphocyte count ≥100/mm3 prior to apheresis (incorporated into inclusion criterion #7) 10. Females of reproductive potential (defines as all females physiologically capable of becoming pregnant) must agree to use 1 highly effective method of contraception and 1 additional effective method (as defined in Section 6.3 ) from at least 28 days before enrollment/apheresis and for at least 1 year after the infusion of AIC100 CAR T Cells. 11. Females of reproductive potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test result at Screening 12. Detectable ICAM-1 expression by IHC (incorporated into inclusion criterion #3) Exclusion Criteria: 1. Women who are pregnant or breastfeeding 2. Clinically significant, active, uncontrolled, systemic infection; the following are not exclusionary: 1. Patients with HIV must have been on effective antiretroviral therapy for ≥ 4 weeks prior to enrollment; must have an HIV viral load < 400 copies/µL; no acquired immunodeficiency syndrome related opportunistic infections in the previous 12 months; and a CD4+ cell count ≥ 350 cells/µL 2. Patients with chronic HBV infection must on antiviral therapy and have an HBV viral load below the limits of detection 3. Patients with chronic HCV infection must have completed therapy and have an HCV viral load below the limits of detection 3. Prior treatment with investigational gene therapy or CAR T cell therapy 4. Presence of active and clinically relevant central nervous system disorder such as epilepsy, stroke, or symptomatic or uncontrolled brain metastases 5. Evidence of another malignancy within 2 years prior to Screening (except in-situ non melanoma skin cancers, localized controlled prostate cancer, adequately treated Stage 1 uterine cancer that has a low risk of recurrence, or any other malignancies with similar outcome) 6. Patients who are seropositive for HIV or who have an uncontrolled HBV or HCV infection (incorporated into exclusion criterion #2) 7. Active autoimmune disease (including but not limited to systemic lupus erythematosus, Sjögren's Syndrome, RA, psoriasis, multiple sclerosis, inflammatory bowel disease) requiring immunosuppressive therapy within 4 weeks prior to eligibility confirmation, with the exception of conditions requiring thyroid replacement therapy 8. Patients with severe chronic diseases of the kidney, liver, heart, lung; or any other serious illness that, in the opinion of the Investigator, may affect the patient's treatment, follow up, or assessments, including but not limited to uncontrolled clinically significant neurological or psychiatric disorders or metabolic diseases 9. Patients who need long-term use of systemic corticosteroids > 10 mg/day prednisone or equivalent 10. Allergy to any of the chemotherapy drugs given during lymphodepletion or known hypersensitivity to any component of AIC100 CAR T Cells, including excipients (Section 7.1) 11. Receipt of a COVID-19 vaccine within 4 weeks before Screening	{ "inclusion_biomarker": [ [ "ICAM-1 expression", "BRAF wild-type" ], [ "ICAM-1 expression", "BRAF mutation" ] ], "exclusion_biomarker": [] }
This open-label phase II trial studies how well niraparib works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The trial is designed to assess the efficacy and safety of niraparib in patients with HR mutation/ alteration whose disease progressed on prior immunotherapy and/or BRAF-targeting therapy. ; ; Inclusion Criteria: - Have genetic homologous recombination (HR) mutation/ alteration including ARID1A/B, ARID2, ATM, ATR, ATRX, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCD2, MRN11A, PALB2, RAD50, RAD51, RAD54B - Disease must have progressed on the standard systemic therapies or they could not have tolerated the standard therapies. - ECOG PS >/=1 - Have measurable metastatic disease according to RECIST 1.1 - Prior systemic cytotoxic therapy up to 1 regimens is allowed; There is no limit on the number of prior immunotherapy or targeted therapy regimens. - All adverse events associated with prior treatment must have resolved to ≤ Grade 1 prior to day 1 of the study drug administration. Exclusion Criteria: - Previously treated with a PARP inhibitor - Symptomatic brain metastasis or active brain lesions ≥6 mm size or those - Require steroid treatment for brain lesions or leptomeningeal disease - Systemic cancer therapy within 14 days prior to day 1 of the study drug administration - Any major surgery ≤ 3 weeks of starting the study and patient must have recovered from any effects of any major surgery - Investigational therapy administered ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational - Prior radiotherapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy - Medical history of immunocompromised condition - Systemic treatment of another type of cancer ≤ 2 years prior to registration - Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)	{ "inclusion_biomarker": [ [ "ARID1A mutation" ], [ "ARID1B mutation" ], [ "ARID2 mutation" ], [ "ATM mutation" ], [ "ATR mutation" ], [ "ATRX mutation" ], [ "BARD1 mutation" ], [ "BRCA1 mutation" ], [ "BRCA2 mutation" ], [ "BAP1 mutation" ], [ "BRIP1 mutation" ], [ "CHEK2 mutation" ], [ "FANCD2 mutation" ], [ "MRN11A mutation" ], [ "PALB2 mutation" ], [ "RAD50 mutation" ], [ "RAD51 mutation" ], [ "RAD54B mutation" ], [ "ARID1A mutation" ], [ "ARID1B mutation" ], [ "ARID2 mutation" ], [ "ATM mutation" ], [ "ATR mutation" ], [ "ATRX mutation" ], [ "BARD1 mutation" ], [ "BRCA1 alteration" ], [ "BRCA2 alteration" ], [ "BAP1 alteration" ], [ "BRIP1 alteration" ], [ "CHEK2 alteration" ], [ "FANCD2 alteration" ], [ "MRN11A alteration" ], [ "PALB2 alteration" ], [ "RAD50 alteration" ], [ "RAD51 alteration" ], [ "RAD54B alteration" ] ], "exclusion_biomarker": [] }
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment. ; ; Inclusion Criteria: - Has diagnosis of AML according to the World Health Organization (WHO) 2008 classification with ≥5% blasts in bone marrow, with or without extramedullary disease - Is in first relapse or refractory to first-line high-dose chemotherapy with no more than 1 attempt (1 to 2 cycles of induction chemotherapy) at remission induction - prior HSCT is permitted - Has presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood as defined in the protocol - Is between 1 month and 21 years of age at the time the Informed Consent/Assent form is signed - Has protocol-defined adequate performance status score - Has fully recovered from the acute clinically significant toxicity effects of all prior chemotherapy, immunotherapy, or radiotherapy, per protocol guidelines - Has protocol-defined adequate renal, hepatic and cardiac functions - If of reproductive potential, is permanently sterile or agrees to use highly effective birth control upon enrollment, during the period of therapy, and for 6 months following the last dose of study drug or cytarabine, whichever is later - If female of child-bearing potential, tests negative for pregnancy and agrees not to breast feed - Participant/legal representative is capable of understanding the investigational nature of the study, potential risks, and benefits, and the patient (and/or legal representative) signs a written assent/informed consent - Meets protocol-specified guidelines before inclusion in the continuation therapy phase Exclusion Criteria: - Has been diagnosed with isolated central nervous system relapse, certain kinds of leukemia, or with myeloid proliferations related to Down syndrome - Has uncontrolled or pre-defined significant cardiovascular disease as detailed in the protocol - Has systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient must be off vasopressors and have negative blood cultures for at least 48 hours prior to the start of systematic protocol therapy. - Has known active clinically relevant liver disease (e.g., active hepatitis B or active hepatitis C) - Has known history of human immunodeficiency virus (HIV) - Has history of hypersensitivity to any of the study medications or their excipients - Is receiving or is anticipated to receive concomitant chemotherapy, radiation, or immunotherapy other than as specified in the protocol - Has any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise subject safety or compliance, interfere with consent/assent, study participation, follow up, or interpretation of study results - Is currently participating in another investigative interventional procedure (observational or long-term interventional follow-up is allowed) - Is otherwise considered inappropriate for the study by the Investigator	{ "inclusion_biomarker": [ [ "FLT3 ITD" ] ], "exclusion_biomarker": [] }
Multicenter, retrospective and prospective, cohort, observational study evaluating the clinical efficacy and tolerability of Eribulin as second-line treatment in accordance with the indications authorized by AIFA in patients with triple negative advanced breast cancer in a real world setting. ; ; Inclusion Criteria: - Performance status according to ECOG equal to 0-2 - Locally advanced or triple negative metastatic breast cancer (HR- and HER2-) confirmed histologically - Progressing after first-line chemotherapy for advanced disease - Previous anthracyclines and taxanes therapy (in an adjuvant, neoadjuvant or metastatic), unless the patient is ineligible to receive such treatments - Treatment with Eribulin mesylate since 2017, in accordance with AIFA indications - Adequate haematological, renal and hepatic function, as per clinical practice - Written informed consent Exclusion Criteria: - Breast cancer HER2 + or HR + - Treatment with Eribulin in the context of clinical studies - Patients unsuitable for treatment with Eribulin - Diagnosis of other malignancies in the two years prior to enrollment, with one exception of adequately treated localized basal cell or squamous cell carcinomas of the skin o cervical carcinomas undergoing curative treatment	{ "inclusion_biomarker": [ [ "HR negative", "HER2 negative" ] ], "exclusion_biomarker": [ [ "HER2 positive" ], [ "HR positive" ] ] }
Diffuse intrinsic pontine gliomas (DIPGs), which diffusely occupy the pons of brainstem, are the deadliest primary brain cancer in children. Biopsy for pathology plus radiotherapy remains the current standard-of-care treatment that is minimal effective. Thus, the median overall survival after diagnosis is just 10 months. Recent studies have identified a lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3), as a feature mutation in DIPGs. Several preclinical studies have already demonstrated H3.3-K27M as a promising target for immunotherapy. The researched vaccine is a cancer-treatment vaccine containing an H3.3-K27M targeted neoantigen peptide, that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells. The main goal of this study is investigating the safety and preliminary efficacy of the vaccine in treating newly-diagnosed DIPGs when the vaccine is administered in combination with the standard-of-care treatment. ;NA; Inclusion Criteria: A. First entry criteria 1. Age ≥ 5 years old; 2. Newly-diagnosed patients with DIPG appearance on MRI image; 3. HLA-A2 subtype; 4. The expected survival time exceeds 24 weeks; 5. The KPS score is greater than 50; B. Second entry criteria 1. The KPS score is greater than 50; 2. DIPG is diagnosed histologically on tumor tissue obtained by biopsy or surgical resection; 3. H3.3K27M mutation is detected on tumor tissue obtained by biopsy or surgical resection ; 4. Adequate organ functions that meet the following criteria: The absolute number of neutrophils: ≥1500/mm3 Platelet count: ≥75000/uL Hemoglobin: ≥80 g/L Creatinine≤1.5×ULN Bilirubin≤1.5×ULN ALT≤3×ULN AST≤3×ULN 5. Ability to comprehend and sign an informed consent form. Exclusion Criteria: 1. With past medical history of malignant tumors (except being asymptomatic for more than 3 years); 2. History of allergy to chemotherapeutics or radiosensitizers for the treatment of cancer in central nervous system and head/neck; 3. History of allergy to the vaccine and its ingredients; 4. Comorbidity with HIV infection and/or acute phase of hepatitis B/C; 5. Any progressive diseases that hinder participation in the trial; 6. With unstable cardiovascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia et.al.; 7. History of uncontrolled mental illnesses; 8. Inability to comprehend or sign informed consent form or abide by the research procedures; 9. Other conditions believed to hinder participation in this trial at investigator' discretion.	{ "inclusion_biomarker": [ [ "HLA-A2 subtype" ], [ "H3.3 K27M" ] ], "exclusion_biomarker": [] }
The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further, the response of the cancer to the treatment will be determined. ;NA; Inclusion Criteria: Part A - single-agent dose-escalation: - Patients with histologically confirmed solid tumors or NHL. Patients with tumors known to be positive for deoxyribonucleic acid damage repair (DDR) defects (such as ataxia-telangiectasia mutated [ATM] deleterious mutation or low ATM expression) can be included. J-arm of Part A - single-agent dose-escalation in Japanese: - Japanese patients with histologically confirmed solid tumors. Patients with tumors known to be positive for DDR defects (such as ATM deleterious mutation or low ATM expression) can be included. Part A.1 - single-agent dose-escalation with alternative dosing schedule: - Patients with histologically confirmed solid tumors or NHL known to be positive for ATM loss and/or ATM deleterious mutations will be included. The biomarker status of patients in Part A.1 will be evaluated before general screening and only patients with the presence of the putative biomarkers of DDR deficiency will be recruited into general screening. Part B - single-agent expansion: - Patients with DDR deficiency biomarker-positive advanced solid tumors of the following histologies: i) CRPC; ii) HER2-negative BC that is hormone-receptor positive (estrogen-receptor positive, progesterone-receptor positive, or both) or TNBC; iii) CRC, and iv) gynecological tumors (ovarian, primary peritoneal, and fallopian tube cancers, endometrial cancer, or cervical cancer). - Patients with histologically confirmed advanced solid cancer, regardless of the cancer type, or NHL and loss of ATM protein by IHC. - The biomarker status of patients in Part B will be evaluated before general screening and only patients with the presence of the putative biomarkers of DDR deficiency will be recruited into general screening. Part A.1 And Part B: - Patients must be able to provide either samples of archival tumor tissue not older than 6 months or a fresh tumor biopsy during general screening. Part B.1 - single-agent expansion with alternative dosing schedule: - Patients with histologically confirmed R/R MCL. These patients do not undergo biomarker testing to determine eligibility. The provision of baseline tumor tissue (archival or fresh) is strongly encouraged. If archival tissue ≤ 6 months old is unavailable, a fresh baseline biopsy may be obtained if safe and feasible. The following inclusion criteria apply to ALL (dose-escalation and expansion) patients: - Patients with tumors resistant or refractory to standard treatment and in which, in the opinion of the investigator, experimental treatment with BAY1895344 may be of benefit. Furthermore, no standard therapy would confer clinical benefit to the patient. Patients in the MCL cohort of Part B.1 are to be relapsed or refractory to standard treatments. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. For MCL patients: ECOG of 0 to 2. - Patients must have adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 (+2) days before the first dose of study drug. Note that the below values are to be independent of red blood cell transfusions or granulocytes colony-stimulating factor (G-CSF) (i.e., no red blood cell or platelets transfusion within 28 days prior to the screening complete blood count [CBC] result, or administration of G-CSF is to occur within 14 days prior to the CBC result). Requirements for MCL patients are indicated below. - a. Hemoglobin ≥ 9 g/dL. Patients with chronic erythropoietin treatment consistent with institutional guidelines can be included. For MCL patients: ≥ 8 g/dL; red blood cell transfusions during the screening period are allowed, and patients with chronic erythropoietin treatment consistent with institutional guidelines can be included - b. Absolute neutrophil count (ANC) ≥ 1.5 X 10^9/L (≥ 1500/mm^3). For MCL patients: ANC ≥ 1.0 X 10^9/L. Patients with ANC ≤ 1.0 X 10^9/L due to marrow infiltration may receive G-CSF during screening to bring pretreatment ANC levels to ≥ 1.0 X 10^9/L - c. Platelet count ≥ 100 X 10^9/L (≥100,000/mm^3). For MCL patients: ≥ 75 X 10^9/L Exclusion Criteria: - Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study - History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class >II, unstable angina (angina symptoms at rest), new-onset angina (within the past 6 months before study entry), myocardial infarction within the past 6 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted) - Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C - Known human immunodeficiency virus (HIV)-infected persons are not eligible if any of the following criteria apply： - CD4+ T-cell count less than 350 cells/μL - History of AIDS-defining opportunistic infection within the past 12 months - On established antiretroviral therapy (ART) for less than 4 weeks or presenting with a viral load of more than 400 copies/mL prior to enrollment - On ART or prophylactic antimicrobials that are expected to cause significant drug-drug interactions or overlapping toxicities with study intervention - Patients who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment. Patients with chronic HBV or HCV infection are eligible at the investigator's discretion provided that the disease is stable and sufficiently controlled under treatment. - Infections of Common Terminology Criteria for Adverse Events Version (CTCAE) Grade 2 not responding to therapy or active clinically serious infections of CTCAE Grade > 2 - Metastatic solid brain, spinal, or meningeal tumors or central nervous system (CNS) lymphoma manifestations (including meningeosis lymphomatosa and parenchymal lymphoma lesions) unless the patient is > 3 months from definitive therapy, has a stable imaging study within 4 weeks prior to the first dose of study drug and is clinically stable with respect to the tumor at the time of study entry. Patients with asymptomatic brain metastases must not be on steroid therapy. Patients with neurological symptoms should undergo a CT / MRI scan of the brain or spinal column to exclude new or progressive brain, meningeal, or spinal metastases or CNS lymphoma manifestations. - History of organ allograft transplantation. For MCL patients: Those who received an allogeneic stem cell transplant may participate provided that engraftment has occurred, there is no evidence of GVHD, and the patient is not taking immune suppressants. MCL patients who received an autologous stem cell transplant may participate once they have recovered from the procedure. - Treatment with anticancer chemotherapy or immunotherapy during the study or within 3 weeks before the first dose of study drug. For small-molecule drugs, a period of at least 3 half-lives before the first dose of study drug is acceptable. Mitomycin C or nitrosoureas should not be given within 6 weeks before the first dose of study drug. - Treatment with systemic steroids (methylprednisolone dose ≥10 mg/day or equivalent dose). For MCL patients: Treatment with systemic corticosteroids > 20 mg/day prednisone equivalent (unless patient has been taking a stable dose for >3 weeks and has shown tumor progression).	{ "inclusion_biomarker": [ [ "ATM deleterious mutation" ], [ "ATM low expression" ], [ "ATM loss" ], [ "DDR deficiency", "estrogen-receptor positive" ], [ "DDR deficiency", "progesterone-receptor positive" ], [ "DDR deficiency", "estrogen-receptor positive", "progesterone-receptor positive" ] ], "exclusion_biomarker": [] }
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of docetaxel and cisplatin combined with Nimotuzumab in the treatment of recurrent and metastatic nasopharyngeal carcinoma ;NA; Inclusion Criteria: - biopsy proved nasopharyngeal carcinoma; - stage IVc according to Union for International Cancer Control (UICC) edition VIII,or recurrent disease after chemotherapy and/or radiotherapy; - 18 years or older; without other malignancy; - proper functioning of the major organs. Exclusion Criteria: - allergic to docetaxel or cisplatin or Nimotuzumab ; - female within gestation period or lactation; - patients received drug of other clinical trail within 3 months	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1 ; ; Inclusion Criteria: Part A 1. Subject must be at least 18 years old and must have histologically confirmed, unresectable, locally advanced, or metastatic PD-L1-expressing solid cancer not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest. Any level of PD-L1 expression assessed by using any Food and Drug Administration (FDA) approved PD-L1 immunohistochemistry (IHC) assay is accepted. The assessment should have been performed on the most recent available tissue from a site of metastatic disease (if possible). 2. Subject must have evaluable or measurable disease. Part B 1. Subject must be at least 18 years old and must have histologically confirmed, unresectable, locally advanced or metastatic PD-L1-expressing solid cancer (defined below) not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest. PD-L1 expression must be assessed at screening by the study's central laboratory, using VENTANA SP263 PD-L1 assay on a tissue from a site of metastatic disease (if possible). For this purpose, recent archived tissue suitable for PD-L1 expression assessment by IHC (obtained after the last treatment and within 6 months) or fresh biopsy material can be used. The PD-L1 assessment must show at least 5% vCPS (visually estimated Combined Positive Score) for eligibility. - Arm 1: Histologically confirmed recurrent or metastatic NSCLC not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest. NOTE: subjects with driver mutations are only eligible if they have received all appropriate targeted therapies. - Arm 2: Histologically confirmed recurrent or metastatic SCCHN (oral cavity, oropharynx, hypopharynx, or larynx) not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest. Subjects who refuse radical resection are eligible. NOTE: squamous cell carcinoma of any other primary anatomic location in the head and neck, subjects with SCCHN of unknown primary, and subjects with skin squamous cell carcinoma (SCC) of the head and neck are not eligible for this arm. The tumor must be platinum resistant or the subject ineligible for platinum therapy due to hypersensitivity or concerns with ototoxicity. - Arm 3: Subjects with any other relapsed or refractory PD-L1 positive solid tumor not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest, who received PD-1/PD-L1 treatment. Subjects with PD-L1 positive solid tumor types, for which PD-1/PD-L1 treatment is not approved, could be enrolled at the Investigator's discretion and after discussion with the Medical Monitor. 2. Subject must have at least 1 measurable tumor lesion according to RECIST 1.1. Parts A and B 3. Subject must have Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1. 4. Prior treatment must include a CPI (i.e., PD-1 inhibitors, PD-L1 inhibitors with or without CTLA-4 inhibitors) if there is an approved CPI for the specific cancer type. Subjects may also have received CPIs in an investigational setting. Subjects who have not received a CPI and where there is no approved CPI for the specific cancer type could be enrolled at the Investigator's discretion and after discussion with the Medical Monitor. 5. Subject must have adequate bone marrow function (NOTE: administration of blood products and growth factors is not allowed within 2 weeks prior to screening laboratory tests): - absolute neutrophil count (ANC) ≥ 1,500/μL - platelet count ≥ 100,000/μL - hemoglobin ≥ 8.0 g/dL 6. Subject must have adequate renal function, based on estimated creatinine clearance (eCrCl) ≥ 50 mL/min, calculated by the Cockcroft-Gault equation. NOTE: At the Investigator's discretion, the eCrCl result < 50 mL/min may be verified by measured creatinine clearance (mCrCl) based on the 24-hour urine collection. Subjects with mCrCl ≥ 50 mL/min will be eligible irrespective of the eCrCl result calculated by the Cockcroft-Gault equation. 7. Subject must have adequate hepatic function, as determined by: - total bilirubin (or direct bilirubin for subjects with Gilbert's disease) < 1.5 × upper limit of normal (ULN) - aspartate aminotransferase (AST) ≤ 3 × ULN (or ≤ 5 × ULN if liver metastasis) - alanine aminotransferase (ALT) ≤ 3 × ULN (or ≤ 5 × ULN if liver metastasis) 8. Subject must have adequate serum albumin (albumin ≥ 2.5 g/dL) 9. Women of reproductive potential must have a negative highly sensitive pregnancy test within 72 hours before the start of treatment. Women who are postmenopausal (> 1 year since last menstrual cycle) or permanently sterilized (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy) may be considered as not of reproductive potential. 10. Subjects of reproductive potential must agree either to abstain continuously from heterosexual intercourse or to use a highly effective birth control method from signing the informed consent until 30 days after the last dose of MT-6402 for females and until 90 days after the last dose of MT-6402 for males. Exclusion Criteria: Part A 1. Subjects without available tissue from a site of metastatic disease or easily biopsiable lesion (biopsy sites of non significant risk, in the opinion of the Investigator) or unwilling to consent to biopsy. Part B 1. Subjects without easily biopsiable lesions (biopsy sites of non significant risk, in the opinion of the Investigator) or unwilling to consent to biopsy. Parts A and B 2. History or current evidence of another neoplastic disease, except cervical carcinoma in situ, superficial noninvasive bladder tumors, curatively treated Stage I to II non melanoma skin cancer or any previous cancer curatively treated > 2 years before the start of treatment. 3. Active autoimmune disease currently under treatment or required systemic treatment within 2 years (replacement therapy, e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed). Subjects who have not required systemic treatment of an auto-immune disease for at least 2 years may be enrolled if permission is provided after discussion with the Medical Monitor. 4. Ongoing > Grade 1 immune related toxicity caused by prior CPI therapy (i.e., PD-1 inhibitors, PD-L1 inhibitors, or CTLA-4 inhibitors). Subjects with stable endocrinological AEs, e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus, must have been on a stable dose of supplemental therapy for at least 2 weeks before screening to be eligible for this study. 5. Evidence of active noninfectious ≥ Grade 2 pneumonitis or current evidence of ≥ Grade 3 other underlying pulmonary disease. 6. Received any of the following PD-L1 inhibitors within the following time periods prior to the first dose of MT-6402: atezolizumab - 12 months; durvalumab - 7 months; avelumab - 2 months. 7. Any concurrent cancer treatment, apart from local treatment of non-target lesions for palliative intent (e.g., local surgery or radiotherapy). 8. Prior radiation therapy within 4 weeks before the start of study treatment. NOTE: A lesion in a previously irradiated area can only be considered target lesion if there has been radiographical disease progression since the end of radiation therapy. 9. Received approved or investigational treatment for the disease under study (except PD L1 inhibitors where exclusion criterion 6 applies) within 4 weeks before the start of treatment. For small molecules (MW < 0.9 kDa), the washout is 5 half-lives, but at least 2 weeks. 10. Subjects who have had allogeneic tissue or solid organ transplantation. 11. Current evidence of new or growing central nervous system (CNS) metastases during screening. Subjects with known asymptomatic CNS metastases will be eligible if they meet all the following criteria: 1. Had radiotherapy or another appropriate therapy for the CNS metastases. 2. Have stable CNS disease on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before screening compared with prior neuro imaging. 12. Major surgical procedure (as defined by the Investigator) within 28 days prior to the start of study treatment. 13. History or current evidence of significant cardiovascular disease before the start of treatment, including but not limited to the following conditions: 1. Angina pectoris requiring anti-anginal medication, (chest pain: Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥ 2) 2. Clinically significant valvular disease. 3. Myocardial infarction within 12 months prior to the start of treatment. 4. Arterial thrombosis or pulmonary embolism within 3 months before the start of treatment. 5. History of Grade ≥ 2 symptomatic congestive heart failure (CHF) or New York Heart Association (NYHA) criteria Class ≥ II. 6. Left ventricular ejection fraction (LVEF) < 55%, assessed preferably by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan if ECHO is not available, within 28 days before starting study treatment. 7. High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate > 100/min at rest and upon repeated testing, significant ventricular arrhythmia (CTCAE Grade ≥ 2 [ventricular tachycardia], or higher-grade atrioventricular [AV]-block [second degree AV-block Type 2 [Mobitz 2] or third-degree AV-block]) or left ventricular bundle branch block. Subjects receiving digoxin, calcium channel blockers, or beta adrenergic blockers are eligible at the Investigator's discretion after consultation with the Medical Monitor if the dose has been stable for ≥ 2 weeks before the start of treatment with MT-6402. 8. Any of the following within 3 months before the start of treatment: pericarditis (any CTCAE Grade), pericardial effusion (CTCAE Grade ≥ 2), non-malignant pleural effusion (CTCAE Grade ≥ 2) or malignant pleural effusion (CTCAE Grade ≥ 3) (subjects with pleural effusion that is manageable and stable > 3 months prior to study are eligible). 9. QT interval correction for heart rate using Fridericia's formula (QTcF) ≥ 470 ms (average from 3 QTcF values on the triplicate 12-lead electrocardiogram [ECG]) at screening. In subjects with right bundle branch blocks, additional corrections will be performed to calculate the QT equivalent JT, and depending on the result the subject may be eligible with the agreement of the Medical Monitor. 14. Current evidence of uncontrolled human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening. Serology testing is not required if seronegativity is documented in the medical history, and if there are no clinical signs suggestive of HIV or hepatitis infections, or suspected exposure. The following exceptions apply for subjects with positive viral serology: 1. Subjects with HIV and an undetectable viral load and CD4 + T-cell (CD4+) counts ≥ 350 cells/mL may be enrolled, but must be taking appropriate opportunistic infection prophylaxis, if clinically relevant. 2. Subjects with positive HBV serology are eligible if they have an undetectable viral load and the subject will receive antiviral prophylaxis for potential HBV reactivation per institutional guidelines. 3. Subjects with positive HCV serology are eligible if quantitative polymerase chain reaction (PCR) for plasma HCV RNA is below the lower limit of detection. Concurrent antiviral HCV treatment per institutional guidelines is allowed. 15. Current treatment requiring systemic steroids at doses > 10 mg/day prednisone equivalent. 16. Subjects with a history of hypersensitivity or serious toxic reactions to kanamycin or other aminoglycosides. 17. Subjects with unintentional weight loss > 10% of their body weight over the preceding 2 months or less before screening. 18. Female subjects who are pregnant or breastfeeding. 19. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Medical Monitor, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.	{ "inclusion_biomarker": [ [ "PD-L1 expression" ] ], "exclusion_biomarker": [] }
BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is the most common type, which is an important biomarker for predicting the prognosis and precise treatment efficacy of metastatic colorectal cancer (mCRC). The prognosis of metastatic colorectal cancer with BRAF V600E mutation is very poor, with OS of about 6-9 months. Previous studies have shown that single anti-BRAF inhibitor are ineffective, while multi-target inhibitions of Ras-Raf -MEK pathway is a possible effective strategy for BRAF V600E-mutant mCRC. Currently, the proven effective regimens include the VIC regimen (Vemurafenib + cetuximab + Irinotecan) and BEACON regimen (Encorafenib+ cetuximab +/- Binimetinib) from the SWOGS1406 study. Furthermore, BRAF inhibitor +MEK inhibitor combined with PD-1 monoclonal antibody has been shown to be an effective strategy in BRAF V600E-mutant malignant melanoma, which promote the study of the regimens for the treatment of BRAF V600E-mutant mCRC. Increasing basic and clinical studies have shown that cetuximab has ADCC effect, induces immunogenic cell death, promotes immune cell infiltration and other immunomodulatory effects, and has a synergistic effect with PD-1 monoclonal antibody in colorectal cancer. Based on those theories, we conducted the phase I study to explore the safety and preliminary efficacy of the regimen of Vemurafenib (BRAFi) plus cetuximab (EGFRi) combined with PD-1 monoclonal antibody in BRAF V600E-mutant /MSS type mCRC. ;NA; Inclusion Criteria: 1. Male or female ≥ 18 years of age 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 3. Participants must have histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, with clinical confirmation of unresectable and/or metastatic disease that is measurable according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria 4. Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to screening and confirmed by central laboratory. And confirmation of MSS or pMMR status from immunohistochemistry or PCR or NGS; 5. Prior treatment with at least one systemic treatment (chemotherapy or target therapy) for mCRC, and prior treatment did not include cetuximab 6. Adequate organ and marrow function: - ①Hemoglobin (Hb) ≥ 90 g/L；Platelets (PLT) ≥ 75 x 10^9/L；Neutrophil ≥1.5 x 10^9/L - ②Total bilirubin ≤ 1.5 x upper limit of normal (ULN)；Aspartate aminotransferase (AST) ≤3 x ULN ；Alanine aminotransferase (ALT) ≤3 x ULN - ③Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance (determined as per Cockcroft-Gault) ≥ 50 mL/min at screening - ④INR, APTT, and PT≤ 1.5 x ULN - ⑤Serum albumin≥ 28 g/L - ⑥ECG showed no evident abnormality 7. Written informed consent Exclusion Criteria: 1. Known hypersensitivity or contraindication to any component of cetuximab or PD-1 monoclonal antibody or macromolecular protein reagent. 2. A history of other malignancies with a disease-free survival of less than 5 years, with the following exceptions: adequately treated basal or squamous cell skin cancer, carcinoma in-situ of the cervix, and gastrointestinal tumors treated curatively with endoscopic mucosectomy; 3. Any active autoimmune disease or a history of autoimmune disease 4. Use of immunosuppressive medications or glucocorticoid therapy ≤2 weeks prior to entry 5. Uncontrolled active infection requiring antibiotics 6. Known history of HIV infection or active hepatitis 7. Severe complications, including any of the following: - ①Massive gastrointestinal bleeding, perforation, or gastrointestinal obstruction - ②Symptomatic heart disease - ③Uncontrolled diabetes and hypertension - ④Uncontrolled diarrhea 8. Women who are pregnant or lactating and people who do not agree to avoid pregnancy 9. Patients with serious psychiatric that may interfere treatment. 10. Other conditions which are inappropriate to participate in the study confirmed by investigators.	{ "inclusion_biomarker": [ [ "BRAF V600E", "MSS" ], [ "BRAF V600E", "pMMR" ] ], "exclusion_biomarker": [] }
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo. ;NA; Inclusion Criteria: - At least 18 years of age at the time of signing informed consent. - Histologically confirmed EC including: endometrioid, serous, undifferentiated, and carcinosarcoma. - TP53 wt assessed by next generation sequencing (NGS), evaluated by a central vendor. - Completed a single line, at least 12 weeks of platinum-based therapy (not including adjuvant or neoadjuvant therapy for Stage I-III disease) and achieved confirmed partial or complete response (PR or CR) by imaging, according to RECIST version 1.1. The participants should have received treatment for: Primary Stage IV disease, defined as: - had a primary or later debulking surgery during first-line platinum-based therapy with R0 resection (R0 resection indicates a macroscopic complete resection of all visible tumor) and achieved CR after at least 12 weeks platinum-based therapy, OR - had a primary or later debulking surgery during first-line platinum-based therapy with R1 resection (R1 resection indicates incomplete removal of all macroscopic disease) and achieved PR or CR after at least 12 weeks platinum-based chemotherapy, OR - had no surgery and achieved PR or CR after at least 12 weeks platinum-based chemotherapy OR At first relapse (i.e., relapse after primary therapy including surgery and/or chemotherapy and/or immunotherapy for Stage I-IV disease), defined as: - had Stage I - III disease at diagnosis and received, at initial diagnosis, adjuvant chemotherapy and relapsed later. Participants should have PR or CR after at least 12 weeks of platinum-based chemotherapy compared with the start of this chemotherapy at the time of relapse, - had Stage I-III disease at diagnosis and did not receive adjuvant chemotherapy at initial diagnosis and relapsed later. Participants should have PR or CR after at least 12 weeks of platinum-based chemotherapy compared with the start of this chemotherapy at the time of relapse, OR - had Stage IV disease at diagnosis and received initially chemotherapy with or without surgery and relapsed later. At the time of relapse, participants should have PR or CR after at least 12 weeks of platinum-based chemotherapy compared with the start of this chemotherapy at the time of relapse. - Previous treatment with anti-programmed cell death protein 1(PD-1) or anti-programmed death-ligand 1(PD-L1) monoclonal antibody and concomitant biologic agents (e.g., bevacizumab, trastuzumab) is allowed. - Must be able to initiate study drug 3 to 8 weeks after completion of their final dose of chemotherapy. - Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. - Participants must have adequate bone marrow function and organ function within 2 weeks before starting study drug as defined by the following laboratory criteria: - Hepatic function: total bilirubin up to less than (<) 3upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to (<=) 2.5ULN in participants without liver metastasis. For participants with known liver involvement of their tumor: AST and ALT (<=) 5ULN - Hematopoietic function within 1 week: Absolute neutrophil count (ANC) greater than or equal to (>=) 1.510^9/liter (L); platelet count >= 100*10^9/L; hemoglobin >= 9.0 gram per deciliter (g/dL) per local laboratory results - Renal function: estimated creatinine clearance (CrCl) of >= 20 milliliter per minute (mL/min), calculated using the standard local formula, as applicable - In the opinion of the Investigator, the participant must: - Have a life expectancy of at least 12 weeks, and - Be fit to receive investigational therapy - Premenopausal females of childbearing potential must have a negative pregnancy test (serum β-human chorionic gonadotropin test) prior to the first dose of study drug. Female participants of childbearing potential must agree to use highly effective methods of contraception throughout the study and for 90 days following the last dose of study drug. - Written informed consent signed in accordance with federal, local, and institutional guidelines prior to the first screening procedure. Exclusion Criteria: - Participants meeting any of the following exclusion criteria are not eligible to enroll in this study: - Has any uterine sarcomas (carcinosarcomas - not excluded), clear cell or small cell carcinoma with neuroendocrine differentiation - Received a blood or platelet transfusion during the 2 weeks prior to Cycle 1 Day 1 (C1D1). Participants' hemoglobin must be assessed within 2 weeks of screening and at least 1 week post transfusion - Concurrent systemic steroid therapy higher than physiologic dose (> 10 milligram per day [mg/day] of prednisone or equivalent). Systemic steroid therapy as pre-medication for taxane is allowed - Insufficient time since or not recovered from procedures or anti-cancer therapy, defined as: - Not recovered from major surgery <= 28 days prior to Day 1 dosing. Minor procedures, such as biopsies, dental work, or placement of a port or intravenous (IV) line for infusion are permitted - Having ongoing clinically significant anti-cancer therapy-related toxicities CTCAE Grade > 1, with the exception of alopecia. In specific cases, participants whose toxicity has stabilized or with Grade 2 non-hematologic toxicities can be allowed following documented approval by the Sponsor's Medical Monitor - Palliative radiotherapy within 14 days of the intended C1D1. Palliative radiotherapy may be permitted for symptomatic control of pain from bone metastases, provided that the radiotherapy does not involve target lesions, and the reason for the radiotherapy does not reflect evidence of disease progression. - Any gastrointestinal dysfunctions that could interfere with the absorption of selinexor (e.g., bowel obstruction, inability to swallow tablets, malabsorption syndrome, unresolved nausea, vomiting, diarrhea CTCAE v 5.0 > grade 1). - Participants unable to tolerate two forms of antiemetics for at least 2 cycles will not be eligible for the trial. - Active, ongoing or uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week of screening. - Serious psychiatric or medical condition that could interfere with participation in the study or in the opinion of the Investigator would make study involvement unreasonably hazardous. - Previous treatment with an XPO1 inhibitor. - Stable disease or PD on the post-chemotherapy scan or clinical evidence of progression prior to randomization. - Participants who received any systemic anticancer therapy including investigational agents <= 3 weeks (or <= 5 half-lives of the drug [whichever is shorter]) prior to C1D1. - Major injuries or surgery within 14 days prior to C1D1 and/or planned major surgery during the on-treatment study period. - Other malignant disease with disease-free <= 3 years except: curatively treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, or ductal carcinoma in situ (DCIS) of the breast. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor, or other agents used in the study. - Active brain metastases (e.g., stable for < 8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsant therapy. Corticoid therapy is allowed if administered as stable dose for at least 1 month before randomization). - Females who are pregnant or lactating. - Any other life-threatening illness, active medical condition, organ system dysfunction, or serious active psychiatric issue which, in the Investigator's opinion, could compromise the participant's safety or the participant's ability to remain compliant with study procedures.	{ "inclusion_biomarker": [ [ "TP53 wt" ] ], "exclusion_biomarker": [] }
This study will be a single arm multicenter Phase II open-label, dose escalation study of asciminib in patients with CML-CP without T315I mutation who have had 1 prior TKIs for which they did not respond to treatment or were intolerant to treatment. ; ; Inclusion Criteria: Signed informed consent must be obtained prior to participation in the study 2. Chronic Myelogenous Leukemia (CML-CP,) no previous Accelerated Phase (AP) or Blast Crisis (BC) 3. ≥ 18 years of age 4. For CML-CP patients with treatment failure/resistance to first line (1L) Tyrosine Kinase Inhibitor (TKI,) BCR-ABL1IS at screening: 1. >10% if 1L treatment duration between 6 and 12 months 2. >1% if 1L treatment longer than 12 months 5. For CML-CP patients with treatment intolerance to 1L TKI, BCR-ABL1IS > 0.1% at screening 6. Previously treated with 1 Adenosine triphosphate- (ATP)-binding site TKI for at least 6 months of therapy 7. Intolerance of TKI therapy and/or resistance to TKI therapy (European Leukemia Network (ELN) 2020) Intolerance is defined as: - Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while on therapy, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal) - Hematologic intolerance: Patients with grade 3 or 4 toxicity (absolute neutrophil count [ANC] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses recommended by manufacturer Resistance/Failure is defined for CML-CP patients (CP at the time of initiation of last therapy) as follows . Patients must meet at least 1 of the following criteria: - Three months after the initiation of therapy: No Complete Hematological Response (CHR) or > 95% Philadelphia Chromosome Positive (Ph+) metaphases - Six months after the initiation of therapy: BCR-ABL1 ratio > 10% IS and/or >65% Ph+ metaphases - Twelve months after initiation of therapy: BCR-ABL1 ratio > 1% IS and/or >35% Ph+ metaphases - At any time after the initiation of therapy, loss of CHR, Complete Cytogenetic Response (CCyR) or Partial Cytogenetic Response (PCyR) - At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to study treatment - At any time after the initiation of therapy, confirmed loss of Major Molecular Response (MMR) in 2 consecutive tests, of which one must have a BCR-ABL1 ratio ≥ 1% IS - At any time after the initiation of therapy, new clonal chromosome abnormalities in Ph+ cells: CCA/Ph+ 8. Adequate end organ function within 12 days before the first dose of asciminib treatment. Patients with mild to moderate renal and hepatic impairment are eligible if: - Total bilirubin ≤ 3.0 x ULN without AST/ALT increase - Aspartate transaminase (AST) ≤ 5.0 x ULN - Alanine transaminase (ALT) ≤ 5.0 x ULN - Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN and ≤ 1.5 x ULN, value should be considered not clinically significant and not associated with risk factors for acute pancreatitis - Alkaline phosphatase ≤ 2.5 x ULN - Creatinine clearance ≥ 30 mL/min as calculated using Cockcroft-Gault formula Exclusion Criteria: - 1. Previous treatment with 2 or more ATP-binding site TKIs 2. Previous treatment with asciminib 3. Known presence of the T315I mutation at any time prior to study entry 4. Known second chronic phase of CML after previous progression to AP/BC 5. Previous treatment with a hematopoietic stem-cell transplantation 6. Patient planning to undergo allogeneic hematopoietic stem cell transplantation 7. Cardiac or cardiac repolarization abnormality, including any of the following: - History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG) - Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third-degree AV block) - QTcF at screening ≥450 msec (male patients), ≥460 msec (female patients) - Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: - Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia - Concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication. - Inability to determine the QTcF interval 8. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis 9. Participation in a prior investigational study within 30 days prior to randomization or within 5 half-lives of the investigational product, whichever is longer 10. Treatment with medications that meet one of the following criteria is not allowed and should be switched to an alternative at least one week prior to the start of treatment with study treatment: - Strong inducers of CYP3A for patients on the dose of 80 mg QD and 200mg QD - Strong inducers and inhibitors of CYP3A for patients on the dose of 200 mg BID 11. Pregnant or nursing (lactating) women 12. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception. - Highly effective contraception methods include: - Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception - Female sterilization (have had surgical bilateral oophorectomy (with or without hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before taking study treatment). In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment - Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject - Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception - In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment - Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before taking study medication. In the case of oophorectomy alone, women are considered post-menopausal and not of child-bearing potential only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. - Highly effective contraception for women should be maintained throughout the study and for at least 7 days after the last dose. 13. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 7 days after stopping study (only for patients treated with asciminib). A condom is required for all sexually active male participants on asciminib treatment to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, these male participants must not donate sperm for the time period specified above.	{ "inclusion_biomarker": [ [ "BCR-ABL1 mutation" ], [ "CCA/Ph positive" ] ], "exclusion_biomarker": [] }
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy and NKTR-255, and to see how well they work in treating patients with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are commonly found on diffuse large B-cell lymphoma and B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. Giving CD19/CD22-CAR T cells and chemotherapy in combination with NKTR-255 may work better in treating patients with diffuse large B-cell lymphoma or B acute lymphoblastic leukemia. ; ; For B acute lymphoblastic leukemia (ALL) 1. Confirmed diagnosis of relapsed or refractory B-cell ALL of one of the following types: - Chemotherapy refractory disease in subjects with B-ALL, defined as progression or stable disease after one line of therapy. - Recurrence of disease after achieving CR. 2. Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, PCR, FISH, or next generation sequencing) require verification of MRD positivity on two occasions at least 4 weeks apart. 3. Subjects with Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ALL) subjects are eligible if they progressed after receiving a tyrosine kinase inhibitor (TKI). 4. Subjects with recurrence of isolated CNS relapse after achieving complete remission (CR); if relapsed with MRD, will require verification of MRD positivity on two occasions at least 4 weeks apart. 5. CD19 positive expression- CD19 expression is required at any time since diagnosis. If patient has received anti-CD19 targeted therapy (i.e. Blinatumomab or CD19-CAR T cells), then CD19 expression must be subsequently demonstrated. CD19 expression may be detected by immunohistochemistry or by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject. In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples. 6. Subjects who have undergone autologous SCT with disease progression or relapse following SCT are eligible. Subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, they have elelino evidence of GVHD and have been without immunosuppressive agents for at least 30 days. 7. Subjects who have undergone prior anti-CD19 or anti-CD22 CAR therapy must be at least 30 days post CAR infusion and may not have eficence of persistnce of CAR T cells in blood smples (circulating levels of genetically modified cels of >/= 5% by flow cytometry. 8. Must have evaluable or measurable disease. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. 9. At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives. Exceptions: 1. There is no time restriction with regard to prior intrathecal chemotherapy (incl. steroids) provided there is complete recovery from any acute toxic effects; 2. Subjects who are on standard ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine or oral methotrexate) may be enrolled provided that chemotherapy is discontinued at least 1 week or 5 half-lives (whichever is shorter) prior to apheresis. 3. Subjects receiving steroid therapy at physiologic replacement doses (≤5 mg/day of prednisone or equivalent doses of other corticosteroids) only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis; 4. For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to apheresis, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation port. 10. Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia) 11. Age 18 or older 12. Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2; or Karnofsky ≥ 60% 13. Normal Organ and Marrow Function (supportive care is allowed per institutional standards, i.e. filgrastim, transfusion) 1. ANC ≥ 1000/uL* 2. Platelet count ≥ 50,000/uL* 3. Absolute lymphocyte count ≥ 300/uL* 4. Adequate renal, hepatic, pulmonary and cardiac function defined as: 5. Creatinine ≤ 2 mg/dL or creatinine clearance ≥ 60 mL/min 6. Serum ALT or AST ≤ 5x ULN (Elevated ALT/AST associated with leukemia or lymphoma involvement of the liver will not disqualify a subject; only one value required for eligibility). 7. Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome. 8. Cardiac ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an ECHO, MUGA or Cardiac MRI [performed within 180 days or after most recent anthracycline based treatment or mediastinal radiation therapy (whichever is most recent)] 9. No clinically significant ECG findings 10. No clinically significant pleural effusion 11. Baseline oxygen saturation > 92% on room air * A subject will not be excluded because of cytopenia if it is felt by the investigator to be due to underlying leukemia/lymphoma. 14. Subjects with CNS involvement are eligible as long as there are no overt signs or symptoms that in the evaluation of the investigator would mask or interfere with the neurological assessment of toxicity. 15. Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential) 16. Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative lymphodepletion regimen or 1 month after the last dose of NKTR_255, whichever is later. 17. Ability to give informed consent. Must be able to give informed consent. Subjects unable to give informed consent will not be eligible for this study. =ELIGIBILITY TO RECEIVE NKTR-255= - Received a CD19/CD22 CAR-T infusion - No persisting grade ≥1 CRS or greater than grade 1 fever within 12 hours preceding NKTR-255 infusion - No grade 4 CRS within 96 hours preceding NKTR-255 infusion - No persisting grade ≥ 2 neurotoxicity on the day of NKTR-255 infusion - No previous grade ≥ 3 neurotoxicity of > 48 hours duration at any time preceding NKTR-255 infusion - ANC ≥ 1000/µL - No intervention with tocilizumab and/or dexamethasone within 48 hours preceding NKTR-255 infusion - No active, serious, and uncontrolled infection(s) - No contraindications according to the PI's assessment - Life expectancy > 30 days Exclusion Criteria: 1. History of other malignancy, unless disease free for at least 3 years. At the discretion of the Principal Investigator, subjects in remission for 1-2 years prior to enrollment may be deemed eligible after considering the nature of other malignancy, likelihood of recurrence during one year following CAR therapy, and impact of prior treatment on risk of CD19/CD22-CAR T cells. Subjects in remission <1 year are not eligible. - Exception: Nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) is eligible. - Hormonal therapy in subjects in remission >1 year will be allowed. 2. Presence of fungal, bacterial, viral, or other infection that is uncontrolled. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment. 3. Known history of infection with any of the following: - HIV - Hepatitis B (HBsAg positive) - Hepatitis C virus (anti-HCV positive) A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing. 4. Presence of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement that in the judgment of the investigator may impair the ability to evaluate neurotoxicity. 5. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment 6. Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment 7. History of severe immediate hypersensitivity reaction to any of the agents used in this study 8. Women who are pregnant or breastfeeding 9. In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation. 10. Previous treatment with interleukin-2 or interleukin-15. 11. Confirmed diagnosis of relapsed/refractory biphenotypic BT cell ALL 12. Primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years	{ "inclusion_biomarker": [ [ "Philadelphia Chromosome positive" ], [ "CD19 expression" ] ], "exclusion_biomarker": [] }
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy. ;NA; Inclusion Criteria: - Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion - Previous treatment with a kinase inhibitor with known activity on TRK inhibition - Unable to participate in an ongoing selitrectinib clinical trial - Medically suitable for treatment with selitrectinib Exclusion Criteria: - Currently enrolled in an ongoing clinical study with a TRK inhibitor	{ "inclusion_biomarker": [ [ "NTRK1 fusion" ], [ "NTRK2 fusion" ], [ "NTRK3 fusion" ] ], "exclusion_biomarker": [] }
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-21668 in solid tumor patients. In dose escalation phase, biomarker status is not required, but in dose expansion phase patients are required to harbor PIK3CA mutation. ;NA; Inclusion Criteria: 1. Age ≥18 and ≤70 years, male and female patients; 2. Life expectancy ≥ 12 weeks; 3. ECOG performance score 0-1; 4. Locally advanced or relapsed/metastatic solid tumor patients, who had disease progression after standard therapy, intolerable to standard therapy or for whom no standard therapy exists, PIK3CA mutation status is required for dose expansion phase; 5. Evaluable lesion required for dose escalation phase and measurable lesion as per RECIST 1.1 required for dose expansion phase; 6. Adequate organ function; 7. Signed informed consent. Exclusion Criteria: 1. Prior use of PI3K、mTOR or AKT inhibitor; 2. Prior other malignant tumor; 3. Unstable, symptomatic primary CNS tumors/metastasis or leptomeningeal metastases ; 4. Type I or type II diabetes; 5. Inadequate wash-out of prior anti-cancer therapies; 6. Cardiac disorders; 7. Instable systemic diseases; 8. Acute or chronic pancreatitis; 9. Pregnancy or lactation; 10. Other protocol specified criteria.	{ "inclusion_biomarker": [ [ "PIK3CA mutation" ] ], "exclusion_biomarker": [] }
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of talazoparib when given in combination with palbociclib, axitinib, or crizotinib in treating patients with solid tumors that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). PARPs are proteins that help repair damaged DNA, the genetic material that serves as the body's instruction book. PARP inhibitors, such as talazoparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Palbociclib, axitinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving talazoparib in combination with palbociclib, axitinib, or crizotinib may help control locally advanced or metastatic solid tumors. ; ; Inclusion Criteria: - Pathogenic or likely pathogenic germline or somatic gene defect as determined by local assessment and classification in at least one of the following: - Defect in DNA damage response (DDR) genes such as: BRCA1/2, PALB2, RAD51C/D, or other related genes at the discretion of the principal investigator in consultation with the MD Anderson Cancer Center Institute for Personalized Cancer Therapy Precision Oncology Decision Support (PODS) group (Arms A-C) - Defect in MET, ALK or ROS1, e.g. MET mutations or amplifications, high MET expression, ALK translocations, ROS1 translocations (eligible for Arm C: talazoparib + crizotinib) - NOTE: Patients with metastatic castration-resistant prostate cancer can enroll in Arm B with talazoparib + axitinib without a specific and/or selected mutation - Patients who are eligible for more than one Arm will be assigned according to physician preference - Histological or cytological diagnosis of a solid tumor that is advanced/metastatic, intolerable to standard therapy, resistant to effective standard therapy, or for which no standard therapy is available - Availability of a fresh or recent tumor tissue sample from a diagnostic biopsy/surgery or a metastatic tumor biopsy; the sample must have been obtained within 12 months prior to study enrollment. When only bone disease is present, an archival tumor tissue sample obtained within 5 years prior to study enrollment may be accepted for non-prostate cancer patients and a fresh bone biopsy may be accepted for prostate cancer patients only NOTE: A fresh biopsy should be encouraged for all patients at time of enrollment even if a previous biopsy is available. Optional on-treatment and at-progression biopsies will be encouraged for all patients - Have measurable disease at study enrollment as defined by RECIST v1.1 with at least 1 measurable lesion that has not previously been irradiated; or patients may have bone metastatic disease evaluable by Prostate Cancer Working Group 2 (PCWG2) for subjects with metastatic castration-resistant prostate cancer (mCRPC), or according to the tumor evaluation criteria best suited and accepted for the tumor type being evaluated) - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1 - Absolute Neutrophil Count (ANC) >= 1,500/mm^3 or >= 1.5 x 10^9/L (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment) - Platelets >= 100,000/mm^3 or >= 100 x 10^9/L (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment) - Hemoglobin >= 9 g/dL (>= 5.6 mmol/L) (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment) - estimated creatinine clearance >= 60 mL/min will be required during dose-escalation phase, according to the Cockcroft-Gault formula - Where creatinine clearance (CLCR) (creatinine clearance) is measured in mL/min, age is expressed in years, weight in kilograms (kg), and SCR (serum creatinine) in mg/dL - Or as measured by 24h urine assessment NOTE: Patients with moderate renal impairment (30-59 mL/min) will be considered during the dose expansion phase. A reduced starting dose for talazoparib will be considered in these patients - Total serum bilirubin =< 1.5 x the upper limit of normal range (ULN) - Aspartate and Alanine aminotransferase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) =< 5 x ULN - Female Patients of childbearing potential must have negative serum pregnancy or urine pregnancy test at screening. Female patients of non-childbearing potential must meet at least one of the following criteria: - Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state - Have undergone a documented hysterectomy and/or bilateral oophorectomy - Have medically confirmed ovarian failure All other female patients are considered to be of childbearing potential - Evidence of a personally signed and dated informed consent document, within > 28 days prior to enrollment, indicating that the patient has been informed of all pertinent aspects of the study - Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures - Able to swallow the study drug, have no known intolerance to study drugs or excipients, and comply with study requirements Exclusion Criteria: - Prior anti-cancer therapy within 2 weeks prior to study enrollment or prior radiation therapy within 2 weeks prior to study enrollment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed at least 2 days prior to study enrollment and no clinically significant toxicities are expected (e.g. mucositis, esophagitis) - Major surgery within 4 weeks prior to study enrollment - Patients with known hypersensitivity to either talazoparib or the additional study drug to be received per treatment arm: palbociclib (Arm A), axitinib (Arm B), crizotinib (Arm C) - Diagnosis of myelodysplastic syndrome (MDS) - Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 2 weeks, and are neurologically stable. Of note, patients who required a single dose of corticosteroids on days receiving radiation treatment do not require a 2-week washout - Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation - Persisting toxicity related to prior therapy (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0 Grade > 1). However, alopecia and sensory neuropathy Grade =< 2, or other Grade =< 2 adverse events not constituting a safety risk, based on the investigator's judgement, are acceptable - Active infection requiring systemic therapy. Minor infections, e.g. periodontal infection or urinary tract infection (UTI), which may be treated with short term oral antibiotics are allowed - Patients with known uncontrolled human immunodeficiency virus (HIV) virus or acquired immunodeficiency syndrome. Note: Patients with history of controlled HIV virus will be considered eligible for this trial - Patients with uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening. Note: Patients with controlled hepatitis B or hepatitis C will be considered eligible for this trial - Clinically significant cardiovascular disease, including any of the following: - Myocardial infarction or symptomatic cardiac ischemia within 6 months before screening - Congestive heart failure New York Heart Association class III or IV - History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes) within 1 year before screening - History of Mobitz II second degree or third degree heart block unless a permanent pacemaker is in place - Hypotension as indicated by systolic blood pressure < 86 mm Hg at screening - Bradycardia as indicated by a heart rate of <45 beats per minute on the screening electrocardiogram - Uncontrolled hypertension as indicated by systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening - Current use of potent P-gp inhibitors within 7 days prior to enrollment: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil. - NOTE: Patients who have recently been on enzalutamide require a 28 day washout period due to longer elimination half-life of this therapy - Patients treated within the last 7 days prior to enrollment with: - Food or drugs that are known to be strong CYP (cytochrome P-450) 3A4 inhibitors (ie, amprenavir, atazanavir, boceprevir, clarithromycin, conivaptan, delavirdine, diltiazem, erythromycin, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, voriconazole, and grapefruit or grapefruit juice). Drugs that are known to be strong CYP3A4 inducers (ie, carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John's wort - Inability to swallow capsules, known malabsorption syndrome, or other conditions that may impair absorption of study drugs - Bisphosphonate or denosumab dosage that was not stable (i.e. not the same) for at least 2 weeks before study enrollment for patients receiving these therapies - Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the patient inappropriate for entry into this study - Medical, psychological, or social conditions that may interfere with the patient's participation in the study, or with the evaluation of the study results - Diagnosis of any other malignancy within 2 years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast, bladder, or cervix, or low grade (Gleason =< 6) prostate cancer on surveillance without any plans for treatment intervention (e.g. surgery, radiation, or castration), or other early-stage low risk cancers - Pregnant female patients; breastfeeding female patients; fertile male patients; and female patients of childbearing potential who are unwilling or unable to use 2 methods of contraception for the duration of the study and for at least 7 months after the last dose of study drugs for female patients or 4 months after the last dose of study drugs for male patients, whichever is later for the individual patient. Male patients are prohibited from sperm donation while enrolled in this study and for 4 months after the last dose of the study drugs. Highly effective methods of contraception are those that alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly. These methods include: - Established use of oral, inserted, or injected or implanted hormonal methods of contraception are allowed provided the patient remains on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness - Correctly placed copper containing intrauterine device (IUD) - Male condom or female condom used with spermicide (i.e. foam, gel, film, cream or suppository) - Male sterilization with appropriately confirmed absence of sperm in the postvasectomy ejaculate - Bilateral tubal ligation or bilateral oophorectomy	{ "inclusion_biomarker": [ [ "BRCA1 defect" ], [ "BRCA2 defect" ], [ "PALB2 defect" ], [ "RAD51C defect" ], [ "RAD51D defect" ], [ "MET mutation" ], [ "MET amplification" ], [ "MET overexpression" ], [ "ALK translocation" ], [ "ROS1 translocation" ] ], "exclusion_biomarker": [] }
This ComboMATCH phase II trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread to other places in the body (metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone. ; ; Inclusion Criteria: - A COMBOMATCH TREATMENT TRIAL EAY191 ELIGIBILITY CRITERIA: - The patient must be enrolled on the ComboMATCH Master Registration Trial EAY191 - Note: Patients must fulfill all eligibility criteria outlined in the ComboMATCH Registration Trial EAY191 at the time of registration to EAY191-N2. This includes submission of next-generation sequencing (NGS) data from one of the National Cancer Institute (NCI) credentialed designated laboratories for all potential patients prior to treatment trial assignment. Copy number and allele frequency cutoff as per the Registration protocol - Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH registration trial (EAY191) - Please note the current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trial Support Unit (CTSU) ComboMATCH Registration protocol page - Please note novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH Registration protocol - A COMBOMATCH TREATMENT TRIAL EAY191-N2 ELIGIBILITY CRITERIA: - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information - Age >= 18 - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 14 days prior to registration - Histologically or cytologically confirmed invasive breast carcinoma - Confirmed metastatic disease by either imaging or tissue diagnosis - Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and one additional lesion that can be biopsied (primary, metastatic both allowed) - Patients must have NF1 nonsense or frameshift mutation, or NF1 whole gene deletion detected in tumor as determined by the ComboMATCH screening assessment - The tumor must have been determined to be estrogen receptor (ER) and/or progesterone receptor (PgR) positive assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing. Patients with >= 1% ER or PgR staining by immunohistochemistry (IHC) are considered positive - The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines - Prior use of CDK4/6 inhibitor(i) is required - Prior use of fulvestrant regardless of duration is allowed and will determine treatment assignment - Up to one line of chemotherapy in metastatic setting is allowed - Absolute neutrophil count >= 1,500/mm^3 (within 14 days prior to registration) - Platelet count >= 100,000/ mm^3 (within 14 days prior to registration) - Hemoglobin level >= 10 g/dL (within 14 days prior to registration) - Measured or calculated creatinine clearance > 30 mL/min (within 14 days prior to registration) - Total bilirubin level =< institutional upper limit of normal (within 14 days prior to registration) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 5.0 x ULN - Left ventricular ejection fraction (LVEF) assessment must be performed within 6 weeks prior to registration (LVEF assessment performed by echocardiogram is preferred; however, multi-gated acquisition scan [MUGA] scan may be substituted based on institutional/situational preferences). The LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial - ELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO TRANSITION TO COHORT 2: - Patient's willingness to transition to Cohort 2 affirmed - The patient must have an ECOG performance status of 0-2 - Absolute neutrophil count >= 1,500/mm^3 (within 14 days prior to second registration) - Platelet count >= 100,000/ mm^3 (within 14 days prior to second registration) - Hemoglobin level >= 10 g/dL (within 14 days prior to second registration) - Total bilirubin level =< institutional upper limit of normal (ULN) (within 14 days prior to second registration) - AST and ALT must be =< 5.0 x ULN - Measured or calculated creatinine clearance > 30 mL/min (within 14 days prior to second registration) - The LVEF performed within the last 3 months must be >= 50% regardless of the cardiac imaging facility's lower limit of normal (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional/situational preferences) - Pregnancy test according to institutional standards done within 14 days before second registration must be negative (for patients of childbearing potential only) Exclusion Criteria: - Concurrent anticancer therapy - Active autoimmune disease requiring systemic treatment within the past 3 months, documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents - Active brain metastasis. Brain metastases that have been stable for at least 1 month after completion of treatment are not an exclusion criterion - History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous, chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration - Patients will be excluded if they currently have the following risk factors for RVO that are documented prior to the enrollment: - Uncontrolled glaucoma with intra-ocular pressures >= 21 mmHg - Serum cholesterol >= grade 2. - Hypertriglyceridemia >= grade 2 - Hyperglycemia (fasting) >= grade 2 - Patients with baseline QT corrected for heart rate (QTc) > 500 ms, either induced by medication or congenital long QT syndrome will be excluded due to known side effects of binimetinib - Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2 within 14 days prior to registration. Patients with nervous system disorders that resolve to =< Grade 1 prior to registration are eligible - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better - Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications - Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results - Pregnancy or lactation at the time of registration or intention to become pregnant during the study (Note: Pregnancy testing according to institutional standards for patients of childbearing potential must be performed within 14 days prior to registration) - For binimetinib, highly effective contraception should be used for at least 30 days after the last dose, and patients should not breastfeed for 3 days after the last dose - For fulvestrant, highly effective contraception should be used for 1 year after the last dose, and patients should not breastfeed for 1 year after the last dose - Use of any investigational product within 30 days prior to study entry - INELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO TRANSITION TO COHORT 2 - Not a candidate for binimetinib in the opinion of the treating investigator	{ "inclusion_biomarker": [ [ "NF1 nonsense mutation", "ER positive", "HER2 negative" ], [ "NF1 frameshift mutation", "ER positive", "HER2 negative" ], [ "NF1 deletion", "ER positive", "HER2 negative" ], [ "NF1 nonsense mutation", "PgR positive", "HER2 negative" ], [ "NF1 frameshift mutation", "PgR positive", "HER2 negative" ], [ "NF1 deletion", "PgR positive", "HER2 negative" ] ], "exclusion_biomarker": [] }
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile. ; ; Key Inclusion Criteria* Criteria for B-ALL: - Subject has unequivocal r/r CD19+ B-ALL that has been confirmed by morphology, flow cytometry, or a validated minimal residual disease assay. - Subjects with Philadelphia chromosome positive disease can be eligible if they are intolerant to tyrosine kinase inhibitor therapy or if they have r/r disease. Criteria for NHL: - Subject has unequivocal aggressive CD19+ r/r B-cell NHL that is confirmed by archived tumor biopsy tissue from last relapse after CD19-directed therapy and corresponding pathology report. Alternatively, if at least 1 tumor involved site is accessible at time of Screening, the subject's diagnosis is confirmed by pretreatment biopsy (excisional when possible) or by flow cytometry of fine needle aspirate. If a subject never had a CR, a sample from the most recent biopsy is acceptable. NHL subtypes included but are not limited to: - Diffuse large B-cell lymphoma (DLBCL) including Richter's transformation - FL including Grade 3 or transformed FL - High-grade B-cell lymphoma - Primary mediastinal lymphoma - Subject has measurable or detectable (for example positron emission tomography-positive) disease according to the Lugano Classification. - Subject must have received at least 2 prior chemotherapy-containing regimens, consistent with standard of care treatment guidance (e.g., NCCN), unless no second line therapy of known benefit exists for a given subject. Other than those specifically prohibited, other therapies are allowed until 7 days prior to initiation of LD. In that case, all Screening safety laboratories and disease assessments must be performed after the last dose of prior therapy. For Richter's transformation, only 1 prior line of therapy is required for the DLBCL component. - Subject has received no more than 7 systemic lines of anti-cancer therapy for the disease under study. - Subjects previously treated with CD19-directed autologous CAR T therapies have received no more than 2 lines of therapy after administration of their previous CAR T product. - Expansion cohort only: Subjects must have received autologous CD19-directed CAR T therapy and demonstrated clinical response to the treatment at Day 28 or later, followed by relapse. Criteria for both B-ALL and NHL: - Eastern Cooperative Oncology Group performance status score of 0 or 1. - An estimated life expectancy of at least 12 weeks according to the investigator's judgment. - Seronegative for human immunodeficiency virus antibody (i.e., intact immune function). - Subject has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as: 1. Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 (calculated using the CKD-EPI equation [Levey et al, 2009]). If there is a concern that eGFR calculation is not an accurate reflection of renal function, a 24-hour urine collection for creatinine clearance may be used at the investigator's discretion. 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels both ≤3 times of upper limit of normal (ULN), unless there is suspected disease in the liver. 3. Total bilirubin <2.0 mg/dL, except in subjects with Gilbert's syndrome. 4. Platelet count ≥50,000/μL and absolute neutrophil count of ≥1000/ μL. Platelet transfusions within 14 days of screening are not allowed except for subjects in B-ALL disease cohort with extensive bone marrow disease burden, in which case adequate bone marrow recovery after prior treatment is required to be documented. 5. C-reactive protein (CRP) <2x ULN; subjects with CRP elevation within 2x ULN, ruling out infectious cause will be required. 6. Left ventricular ejection fraction >45% as assessed by echocardiogram (ECHO) or multiple gated acquisition scan performed within 1 month before starting lymphodepleting chemotherapy. ECHO results performed within 6 months before Screening and at least 28 days after the last cancer treatment may be acceptable if the subject has not received any treatment with cardiotoxicity risks. 7. No clinically significant evidence of pericardial effusion or pleural effusion causing clinical symptoms and needing immediate intervention, based on the investigator's opinion. Any known effusion must be stable without need for drainage within 2 weeks of enrollment. 8. No clinically significant renal/pulmonary comorbidities. 9. Baseline oxygen saturation >92% on room air. Key Exclusion Criteria* Criteria for B-ALL: - Burkitt cell (L3 ALL) or mixed-lineage acute leukemia. - No active central nervous system (CNS) disease. Subjects with a history of CNS involvement must have a documented CR on at least 2 imaging studies at least 3 months apart (with no masses in parenchyma and no ocular involvement) and a negative cerebrospinal fluid cytology on at least 2 evaluations (one evaluation may be during the Screening Period and the other must be at least 3 months prior). Criteria for NHL: - No prior or active CNS disease. - Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression. - Active hemolytic anemia. Criteria for B-ALL and NHL: - Subject has had a malignancy, besides the malignancies of inclusion (B-ALL or NHL), that in the investigator's opinion, has a high risk of relapse in the next 2 years. In the case of Richter's transformation, subjects may be enrolled with ongoing chronic lymphocytic leukemia/small lymphocytic lymphoma. - Uncontrolled and serious fungal, bacterial, viral, protozoal, or other infection that has not resolved and does require therapeutic anti-microbial medications at least 7 days prior to LD. Subjects with elevated CRP must undergo infectious disease workup and the recommendations discussed with medical monitor to be considered on an individual basis. The CRP must be trending toward the normal range for the laboratory with the exception when it's deemed related to the underlying malignancy. - Any form of primary immunodeficiency (e.g., severe combined immunodeficiency disease). - Active hepatitis B or hepatitis C confirmed by PCR. Subject positive for inactive hepatitis B is allowed to enroll if on prophylactic treatment. 1. Subject is seropositive for hepatitis B antigen with confirmation. If confirmatory tests are negative, the subject can be enrolled. 2. Subject is seropositive for hepatitis C antibody unless antigen negative. If hepatitis C antibody test is positive, the subject must be tested for the presence of RNA by reverse transcription PCR and be hepatitis C virus-RNA negative. - Any known uncontrolled cardiovascular disease at the time of Screening that, in the investigator's opinion, renders the subject ineligible, including but not limited to: 1. Active ventricular or atrial dysrhythmia ≥ Grade 2, bradycardia ≥ Grade 2. 2. Myocardial infarction within 6 months before Screening. 3. Pulmonary embolism, deep vein thrombosis, or any other significant coagulopathy including disseminated intravascular coagulation. - History of hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening. In case of hypertensive crisis caused by omission of well-established treatment regimen, transient and promptly stabilized, enrollment must be discussed and agreed upon with sponsor and medical monitor. - History of severe immediate hypersensitivity reaction to any of the agents used in this study. - Presence of a CNS disorder that, in the opinion of the investigator, renders the subject ineligible for treatment. - Abnormal findings during the Screening Period or any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the subject's safety. - History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or any other known bone marrow failure syndrome. - Active uncontrolled autoimmune disease requiring active immunosuppression at the time of Screening (excluding subjects needing steroids for physiologic replacement). - Subject has received stem cell transplant within 90 days before Screening. - Subject has active GvHD symptoms. - Subject has received systemic biologic agent for treatment of disease under study within 28 days of LD or other systemic anti-cancer therapy within 10 days of LD Note: this criterion does not apply if the subject has clear evidence of disease progression after such an agent has been administered and all AEs have resolved to a Grade 2 or less in severity. This should be discussed with the medical monitor for confirmation. - Participation in noninterventional registries or epidemiological studies is not excluded. - Radiotherapy within 4 weeks before Screening should be discussed with monitor and determined on a case-by-case basis. - Presence of pleural/peritoneal/pericardial catheter, as well as biliary and ureteral stents (does not apply to intravenous lines). - Subject has received live vaccine within 4 weeks before Screening. Non-live virus vaccines are not excluded. - Subject has received CD19-directed therapy other than autologous CD19-directed CAR T therapy within 90 days of the anticipated start date of LD. - Additional criteria apply	{ "inclusion_biomarker": [ [ "CD19 positive" ] ], "exclusion_biomarker": [] }
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM). The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the recommended Phase 2 dose (RP2D). Participants will be on this combination treatment for 28-day cycles. They will continue with this treatment until disease progression or unacceptable toxicity. ; ; Inclusion Criteria: 1. Participants must have RRMM with measurable disease: a) Has measurable disease defined as one of the following: - Serum M-protein ≥0.5 g/dL (≥5 g/L). - Urine M-protein ≥200 mg/24 hours. - In participants without measurable M-protein in serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP), a serum free light chain (FLC) assay result with involved FLC level ≥10 mg/dL (≥100 mg/L), provided serum FLC ratio is abnormal. 2. Has undergone stem cell transplant or is considered transplant ineligible. 3. Has failed at least 3 prior lines of anti-myeloma treatments and is either refractory, or intolerant to at least 1 immunomodulatory drug ( IMiD); (ie, lenalidomide or pomalidomide [thalidomide excluded]), at least 1 proteasome inhibitor (ie, bortezomib, ixazomib or carfilzomib), and refractory to at least 1 anti-CD38 antibody and who have demonstrated disease progression with the last therapy. 5.Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. 6.Have recovered to Grade 1 or baseline from all toxicity associated with previous therapy or have the toxicity established as sequela. Exclusion Criteria: 1. Received treatment with systemic anticancer treatments within 14 days before the first dose of study drug. 2. Current participation in another interventional study, including other clinical trials with investigational agents (including investigational vaccines or investigational medical device for disease under study) within 4 weeks of the first dose of TAK-981 and throughout the duration of this trial. 3. Prior radiation therapy within 14 days of the first dose of TAK-981. 4. Major surgery within 4 weeks before C1D1. participants should be fully recovered from any surgically related complications. 5. Plasmapheresis within 28 days of randomization. 6. Diagnosis of primary amyloidosis, Waldenström's disease, monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (SMM), plasma cell leukemia POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), myelodysplastic syndrome, or myeloproliferative syndrome. 7. With disease where the only measurable parameter is plasmacytoma. 8. Second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the participant is not on active anticancer therapy. 9. Prior treatment with more than 1 anti-CD38 antibody. 10. Requires the use of drugs known to prolong the corrected QT interval (QTc) (during Phase 1b only). 11. History of QT interval with Fridericia's correction (QTcF) >480 ms. 12. History of human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C infection. 13. Systemic infection requiring systemic antibiotic therapy. 14. Active or history pneumonitis. 15. Receipt of any live vaccine (eg, varicella, pneumococcus) within 4 weeks of initiation of study drug. 16. Receiving strong or moderate Cytochrome P450 (CYP) 3A4/5 inhibitors or inducers. 17. History of unstable cardiac comorbidities in the following 6 months.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation ;NA; Inclusion Criteria: - Age>=18Y - Good Organ Function - Expected survival time ≥ 3 months - advanced melanoma with BRAF V600 mutation that have been diagnosed - ECOG score 0-1; Exclusion Criteria: - Previous treatment with BRAF inhibitors or MEK inhibitors - Symptomatic brain or meningeal metastases (unless the patient has beenon > treatment for 3 months, has no evidence of progress on imagingwithin 4 weeks prior to initial administration, and tumor-related clinicalsymptoms are stable). - Severe active infections requiring systemic anti-infective therapy - A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.	{ "inclusion_biomarker": [ [ "BRAF V600" ] ], "exclusion_biomarker": [] }
This is a Phase II study for patients with MIBG avid tumors. The study is to determine the response rate to <131>I-MIBG in patients with de novo, relapsed or refractory neuroblastoma or other MIBG avid malignant tumors 42 days post MIBG therapy. It will also be evaluating the tolerability and safety of the study agent by evaluating the hematopoietic and non-hematopoietic toxicity of <131>I-MIBG therapy. Tumor response will be evaluated by comparing the patient's disease pre-treatment against the patient's day +42 post <131>I-MIBG treatment. The evaluations may include the following: <131>I-MIBG scan, CT or MRI, urine catecholamine, bone marrow analyses and any other tests considered standard of care for cancer evaluation. To be eligible for participation, patients must have tumors that are MIBG avid. Patients must also have a stem cell source for autologous rescue in the event of protracted therapy associated cytopenias. Peripheral stem cell collections are preferred as the hematopoietic cell source. Bone marrow harvests for a hematopoietic cell source is an alternative. This study will provide data for future clinical trials utilizing <131>I-MIBG therapies. A room on H12 has been prepared with lead lined walls, and many radiation safety components to accomodate this treatment. <131>I metaiodobenzlguanidine (<131>I-MIBG) is a radiopharmaceutical that concentrates within adrenomedullary tissue. The agent was initially used for tumor imaging due to its capability to locate pheochromocytomas, neuroblastomas and other neuroendocrine tumors. <131>I-MIBG was subsequently used as an therapeutic agent for these tumor types. Phase I and II therapeutic trials targeting neuroblastoma have reported response rates of 10-50%. Toxicities observed have been mainly hematopoietic, with ~50% of patients receiving 15mCi/kg requiring stem cell reinfusion. Observed non-hematopoietic toxicities have been mild. Most recently, trials have been conducted combining the study agent with myeloablative chemotherapy and stem cell reinfusion have been performed with initial response rates of ~50%. ;NA; Inclusion Criteria: - Patients must be between 12 months and 65 years at the time of enrollment - Diagnosis: diagnosis of neuroblastoma or at the time of relapse by histology and/or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites - Disease Status: 1. The presence of refractory or progressive disease (PD) 2. For patients with neuroblastoma, the presence of mixed response (MR), or no response (NR) following the completion of A3973 or equivalent induction therapy, or the presence of a partial response (PR) with high Curie score (>2) following induction therapy. 3. Patients with de novo high risk neuroblastoma who have completed standard induction therapy and do not achieve a CR, VGPR, or PR with low Curie score post induction. - Patients must have evidence of MIBG avid disease as determined by diagnostic MIBG scan obtained within 4 weeks of study entry. - Patients who receive greater than 12 mCi/kg are required to have stem cell rescue products harvested prior to study treatment. - Performance Level and Life Expectancy: Patients must have a Lansky Play Scale17 of 60% (<16 yrs old), Karnofsky score 60% (>16 yrs old), or ECOG score of < or equal to 2 and a life expectancy of 2 months. - Patients may enter this study with or without salvage therapy for recurrent tumor. Patients must have fully recovered from the toxic effects of any prior therapy. - Organ Function requirements: Hematopoietic Criteria: 1. Hemoglobin- 10 gl/dl (transfusion allowed) 2. ANC- 550 / cu mm (off myeloid growth factors) 3. Platelets- > 50,000/cu mm. (transfusion allowed - however patients must not require more than two platelet transfusions per week). Renal Function: a. Serum Creatinine- < 2 x ULN for age. Hepatic Function: Total bilirubin <1.5 x ULN for age SGPT (ALT) and SGOT (AST) < 10 x ULN for age Cardiac Function: For children with NBL: Normal ejection fraction (>55%) documented by echocardiogram or radionuclide MUGA evaluation OR normal fractional shortening (>27%) documented by echocardiogram. For subjects with paraganglioma/ pheochromocytoma: No clinically significant cardiac dysfunction. Pulmonary Function: Patients must have clinically normal lung function as manifested by no dyspnea at rest and no oxygen requirement Reproductive Function: 1. Females of childbearing potential must have a negative pregnancy test within 1 week prior to treatment with 131I-MIBG. 2. Patients of childbearing potential must agree to use an effective birth control method. 3. Female patients who are lactating must agree to stop breast feeding Exclusion Criteria: - Pregnancy or breast feeding - Have undergone a prior allogeneic BMT. - Patients with disease of any major organ system that would compromise their ability to withstand therapy. Any significant organ impairment should be discussed with the Study Chair prior to patient entry. - Patients who are on hemodialysis. - Hepatitis B surface antigen (+) or Hepatitis C positive in preceding six months. - Patients with an active infection requiring intravenous antivirals, antibiotics or antifungals. Patients on prolonged antifungal therapy are still eligible if they are culture negative and biopsy negative in suspected residual radiographic lesions have stabilized or regressed and they meet other organ function criteria. - Prior total body irradiation, prior total abdominal or whole liver radiation - Any medical or psychological condition or situation deemed by the PI to put the patient at increased risk of complications or noncompliance. - Patients with curative treatment options. - Patients for whom busulfan/ melphalan consolidation therapy following treatment with 131I-MIBG is planned. - Patients for who CEM (carboplatin, etoposide, melphalan) therapy is administered within 30 days prior to 131I-MIBG therapy or for whom this therapy is planned within 30 days following administration of 131I-MIBG.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals. ; ; Inclusion Criteria: - 1.Patients voluntarily entered the study and signed informed consent form (ICF) 2. Age: 18 - 80 years old and life expectancy of at least 12 weeks.; 3. Clinically or histologically diagnosed as HCC; 4. There are measurable lesions that meet the RECIST1.1 standard on the baseline imaging examination; 5. Child-pugh classification A or B (score < 7); 6. The BCLC stage is stage B or C, and it is unable or unwilling to undergo surgical treatment; 7. ECOG : 0 ~ 1 ; 8. No previous immune checkpoint inhibitor treatment (including PD-1 / PD-L1 antibody and CTLA-4 inhibitor); 9. HBV-deoxyribonucleic acid (DNA) must be <500IU / mL, and receive at least 14 days of anti-HBV treatment before the start of study treatment Treatment; Exclusion Criteria: - 1. History of treatment with any local treatment (exception of liver transplantation), systemic .anti-cancer therapy, or immunotherapy; 2. Those whose tumor thrombus reaches or exceeds the main portal vein; 3. Existing or concurrently suffering from other malignant tumors, except for fully treated non-melanoma skin cancer, cervical carcinoma in situ, and papillary thyroid carcinoma; 4. There is any active autoimmune disease or has a history of autoimmune disease and may relapse; 5. Use strong CYP3A4 / CYP2C19 inducers including rifampicin and Hypericum perforatum or strong CYP3A4 / CYP2C19 inhibitors within 14 days before starting the study treatment; 6. Known history of severe allergy to any monoclonal antibody; 7. Patients who are going to undergo or have undergone organ or allogeneic bone marrow transplantation; 8. Non-compliance with TACE or Camrelizumab; 9. Moderate and severe ascites with clinical symptoms require therapeutic puncture, drainage, or Childa-Pugh score> 2 (except imaging only shows a small amount of ascites but not accompanied by clinical symptoms); uncontrolled or moderate and Above pleural effusion and pericardial effusion; 10. Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before the start of the study treatment; 11. Thrombosis or embolism occurred within 6 months before the start of study treatment, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction, pulmonary embolism, etc.) 12. Known inherited or acquired bleeding or thrombophilia ; currently or recently (10 days prior to the start of study treatment) have used full dose oral or Injection of anticoagulant drugs or thrombolytic drugs (prophylactic use of low-dose aspirin and low molecular weight heparin); 13. Major vascular disease within 6 months before the study treatment; 22. Past or present central nervous system metastasis; 14. Metastatic diseases involving major airways or blood vessels or a large mediastinal tumor mass in the center (<30 mm from the crest) 15. Those with a history of hepatic encephalopathy; 16. Palliative radiotherapy for non-target lesions allowed for symptom control must be completed at least 2 weeks before the start of study treatment. Adverse events caused by radiotherapy have not recovered to ≤CTCAE level 1; 17. There were severe infections within 4 weeks before starting the study treatment; 18. Patients with congenital or acquired immune deficiency (such as those infected with HIV); 19. Co-infection with hepatitis B and C; 20. For patients with bone metastases, the palliative radiotherapy area> 5% bone marrow area received within 4 weeks before participating in the study;	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
Numerous evidences verified that erlotinib could dramatically improve the PFS and OS of non-small cell lung cancers who harbor EGFR sensitive mutations, however, primary or secondary resistance will be developed after TKI treatment, doctors do plenty of researches to overcome TKI resistance. FAST ACT-2 study present that, first line erlotinib combined with chemotherapy could improved mOS to more than 30 months in NSCLCs who harbor EGFR sensitive mutations, several study shows that sensitive mutations still exist after TKI resistance, because of the next generation TKIs(such as BIBW2992) are not avaliable at present, agents for met amplification(such as Crizotinib) are so expensive that many Chinese patients could not support. Thus, the investigators hypothesis that, after first line TKI treatment, the patients who developed TKI resistance could still benefit from second line TKI combined with chemotherapy. ; ; Inclusion Criteria: - advanced non-small cell lung cancer, stage IIIB/IV - non-squamous - EGFR sensitive mutations, such as exon 19 del, or exon 21 L858R - received first line TKIs treatment and developed TKI resistance - ECOG 0-2 Exclusion Criteria: - squamous non-small cell lung cancer - patients have unstable brain metastasis, predict survival less than 8 weeks - spinal-cord compression without evidence of stabilisation or treatment - women who were pregnant or lactating; women with a positive or no available pregnancy test result at baseline - patients have any unstable illness that could not receive further treatment	{ "inclusion_biomarker": [ [ "EGFR exon 19 del" ], [ "EGFR exon 21 L858R" ] ], "exclusion_biomarker": [] }
This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ; ; Inclusion Criteria: - Signed, informed consent must be obtained prior to any study specific procedures - Subjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts in transformation (RAEB-T) (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO), and chronic myelomonocytic leukemia (CMML) are eligible - Subjects must have an IDH2 gene mutation (IDH2-R140 or R172) as determined by local laboratory result - (Arm A only): Subject must be hypomethylating agent naive (i.e. prior azacitidine, decitabine, SGI-110 is exclusionary). Receipt of other MDS-directed therapy such as lenalidomide is allowed - (Arm A only): Subjects with high-risk MDS (i.e. International Prostate Symptom Score [IPSS] intermediate-2 or high-risk; or revised [R]-IPSS high or very-high risk). Patients with intermediate-1 risk by IPSS or intermediate risk by R-IPSS with high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations are also eligible - (Arm B only): Subject must be relapsed or refractory to prior hypomethylating agent therapy, defined as prior receipt of 6 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Serum bilirubin =< 2 x the upper limit of normal (ULN) (except for patients with Gilbert's disease) - Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x the laboratory ULN - Serum creatinine =< 2 x the ULN - Able to understand and voluntarily sign a written informed consent, and willing and able to comply with protocol requirements - Resolution of all clinically significant treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to =< grade 1 prior to the first dose of study treatment - Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potential Exclusion Criteria: - Any prior or coexisting medical condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in the study - Subject has received a prior targeted IDH2 inhibitor - Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures - Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection - Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy - Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement - Impaired cardiac function, uncontrolled cardiac arrhythmia, or clinically significant cardiac disease including the following: a) New York Heart Association grade III or IV congestive heart failure, b) myocardial infarction within the last 6 months - Subjects with a corrected QT (QTc) > 480 ms (QTc > 510 msec for subjects with a bundle branch block at baseline - Nursing or pregnant women - Subjects with known hypersensitivity to study drugs or their excipients	{ "inclusion_biomarker": [ [ "IDH2 R140" ], [ "IDH2 R172" ], [ "IDH2 R140", "TP53 mutation" ], [ "IDH2 R172", "TP53 mutation" ], [ "IDH2 R140", "ASXL1 mutation" ], [ "IDH2 R172", "ASXL1 mutation" ], [ "IDH2 R140", "EZH2 mutation" ], [ "IDH2 R172", "EZH2 mutation" ], [ "IDH2 R140", "RUNX1 mutation" ], [ "IDH2 R172", "RUNX1 mutation" ] ], "exclusion_biomarker": [] }
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG161, and recommended dose of VG161 for Phase II trials. ; ; Inclusion Criteria: 1. Males or females aged within 18 to 80 years. 2. Subject with late stage carcinoma which is refractory/relapsed after and/or intolerant of standard therapies or for which no standard therapy exists. 3. There is at lease one injectable tumor lesion that meet the requirements of the assigned dose level. The superficial lesions are preferred, and the deep lesions that can be injected under the guidance of B ultrasound or computed tomography (CT) scan can also be selected. 4. Eastern Cooperative Oncology Group (ECOG) scores 0 or 1. 5. Life expectancy is at least 3 months. 6. Required organ function: 1) Hematology blood (no blood transfusion or colony stimulating factor treatment within 14 days): Absolute neutrophil count (ANC)≥1.5×10^9L, Platelets ( PLT)≥75×10^9L, hemoglobin (Hb)≥85g/L; 2) Liver function: Total Serum bilirubin (TBIL)≤1.5×ULN (the upper limit of the reference range), Alanine aminotransferase (ALT)≤3×ULN, aspartate aminotransferase (AST)≤3×ULN (acceptable for patients with liver metastasis or liver cancer: TBIL≤5×ULN, AST≤5×ULN, ALT≤5×ULN); 3) Renal function: Serum creatinine≤1.5×ULN, and creatinine clearance≥50 ml/min (calculated per Cockcroft-Gault formula); 4) Coagulation function: activated partial thromboplastin time (APTT)≤1.5×ULN, international standardized ratio (INR)≤1.5×ULN. 7. Subjects of childbearing potential (male and female) must agree to use a reliable contraceptive method (hormone or barrier method or abstinence) during the study and for at least 90 days following the last dose; females of childbearing potential must have a negative blood or urine pregnancy test within 7 days of study enrollment. 8. Signed written informed consent. Exclusion Criteria: 1. Subject in prior anti-tumor therapies such as chemotherapy, radiotherapy, biotherapy, endocrinotherapy, targeted therapy, immunotherapy within 4 weeks of study treatment initiation. 2. Participation in clinical trials of any other investigational agents within 4 weeks of study treatment initiation. 3. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks of study treatment initiation. 4. Patients who received systemic treatment with either corticosteroids ( >10 mg/ daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study treatment initiation. 5. Subjects with any ≥Grade 1 toxicity (as per NCI CTC AE Version 5.0) related to prior anti-cancer therapy (except for toxicity that the investigator assessed to be no safety risk, such as alopecia.). 6. Subjects with any uncontrolled active Central Nervous System (CNS) metastasis or meningeal metastasis with clinical symptoms. 7. Seronegative for Herpes Simplex Virus (HSV) (HSV-1IgG and HSV-1IgM). 8. Subjects with the relapse of HSV infection and relevant clinical manifestations, such as lip herpes, herpes keratitis, herpes dermatitis, and genital herpes. 9. Subjects with other uncontrolled active infections. 10. Known history of immunodeficiency and test positive of human immunodeficiency virus (HIV). 11. Active infection of hepatitis B (HBV) (hepatitis b virus titer higher than the detection limit or those requiring antiviral therapy), or hepatitis C virus (HCV). 12. History of severe cardiovascular disease: 1)Ventricular arrhythmias requiring clinical intervention; 2)QTc interval >480 ms; 3)Acute coronary syndrome, congestive heart failure, stroke or other cardiovascular events of III grade or above within 6 months; 4)The cardiac function grade≥II or left ventricular ejection fraction (LVEF) <50% per the New York Heart Association (NYA); 5)Uncontrolled hypertension. 13. Subjects with active or past autoimmune diseases that are likely to recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.); acceptable for patients with clinically stable autoimmune thyroiditis. 14. Subjects with any prior ≥Grade 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent. 15. known to have alcohol or drug dependence. 16. Persons with mental disorders or poor compliance. 17. Pregnant or lactating women. 18. Subjects with any significant unrelated systemic illness that to the investigator's opinion would compromise the subject's eligibility to participate the study.	{ "inclusion_biomarker": [], "exclusion_biomarker": [] }
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours. To characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or advanced epithelial tumours ; ; Inclusion Criteria: - Provide written informed consent to participate - Patients must have one of eleven histologically or cytologically confirmed metastatic/advanced carcinoma or adenocarcinoma that has progressed after at least one line of systemic therapy and are incurable by local therapy (contact Sponsor for more details regarding the tumour types) a. Tumour types included are: urothelial carcinoma, squamous cell carcinoma of the head and neck (SCCHN), microsatellite instability (MSI)-high/deficient mismatch repair (dMMR) cancer, non-small cell lung cancer (NSCLC), uterine/endometrial cancer, cervical cancer, oesophageal cancer, gastric cancer, triple-negative breast cancer (TNBC), cutaneous squamous cell carcinoma and hepatocellular carcinoma - At least one measurable site of disease according to RECIST Version 1.1 criteria; this lesion must be either (i) outside a previously irradiated area or (ii) progressive if it is in a previously irradiated area - Prior treatment with a PD-1/PD-L1 inhibitor (prior PD-1/PD-L1 may have been given as monotherapy or combination therapy) - Tumour accessible for biopsy - Aged 18 years or over - ECOG performance status 0 or 1 - Predicted life expectancy of ≥6 months - Adequate lung reserve (Oxygen saturation on ambient air at sea level ≥95% or the equivalent based on altitude (i.e. ≥90% at 5000 feet)) - Adequate renal function: 1. Creatinine ≤1.5 × upper limit of normal (ULN) and estimated glomerular filtration rate (eGFR) ≥60 mL/minute/1.73m2 (or measured creatinine clearance ≥60 mL/minute) 2. Spot albumin-to-creatinine ratio (ACR) for proteinuria at screening and baseline ≤30 mg/g. Patients with a spot ACR >30 mg/g who undergo a subsequent 24-hour urinary protein test with a result of <1 g/24 h may be included - Adequate hepatic function: 1. Serum total bilirubin ≤1.5 × ULN OR direct bilirubin ≤1 × ULN 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN range 3. Albumin ≥3 g/dL - Adequate bone marrow function: 1. Absolute neutrophil count ≥1.5 × 109/L 2. Platelets ≥100 × 109/L 3. Haemoglobin ≥90 g/L (9 g/dL) - Coagulation profile within the normal range - Meeting reproductive status requirements: 1. Must not be pregnant or breastfeeding 2. Female patients of childbearing potential, must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotrophin) within 24 hours before the first dose of study treatment 3. Female patients of childbearing potential who are heterosexually active must agree to use a highly effective method of contraception to prevent pregnancy, for the duration of study treatment and 6 months following the last dose of study treatment. Female patients who are continuously not heterosexually active are exempt from contraceptive requirements, but must still undergo pregnancy testing 4. Female patients who are heterosexually active, irrespective of childbearing status, must ensure their male partner agrees to use a condom with spermicide during sexual intercourse for the duration of study treatment and 6 months following the last dose of study treatment 5. Patients must be willing to refrain from egg donation during treatment and for at least 6 months following the last dose of study treatment 6. Male patients who are sexually active with men or women must agree to use a condom with spermicide during intercourse for the duration of study treatment and 6 months following the last dose of study treatment. In addition, patients must be willing to refrain from sperm donation during this time. - Exclusion Criteria: - Prior or planned allogeneic or autologous bone marrow or organ transplantation - Splenectomy - Active infections requiring antibiotics, physician monitoring or systemic therapy within 1 week of the anticipated first dose of study drug, or recurrent fevers (>38.0˚C) associated with a clinical diagnosis of active infection - Treatment with the antiviral agents: ribavirin, adefovir, lamivudine or cidofovir within 10 days prior to the first dose of study treatment; or pegylated interferon in the 4 weeks before the first dose of study treatment - Active viral disease or positive test for hepatitis B virus using hepatitis B surface antigen test or positive test for HCV using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection. Positive test for HIV or AIDS - Patients who have active, known or suspected autoimmune disease that has required systemic therapy in the past 2 years, are immunocompromised in the opinion of the Investigator, or are receiving systemic immunosuppressive treatment a. Patients with vitiligo, type I diabetes mellitus, asthma/atopy, residual hypothyroidism due to autoimmune disease (which only requires hormone replacement therapy), or conditions not expected to recur in the absence of an external trigger are permitted to enrol providing they comply with the other eligibility criteria relating to renal function. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed - Treatment with any live, live-attenuated or COVID-19 vaccine in the 30 days before the first dose of NG-641 or nivolumab (COVID-19 vaccines known not to be live/live-attenuated or based on an adenoviral vector (e.g. mRNA vaccines) are not subject to the 30-day exclusion) - Treatment with any other vaccine (including known non-live/live-attenuated and non-adenoviral COVID-19 vaccines) in the 7 days before the first dose of NG-641 - History of prior Grade 3-4 acute kidney injury or other clinically significant renal impairment - History of clinically significant interstitial lung disease or non-infectious pneumonitis - Lymphangitic carcinomatosis (clinically suspected or radiographic evidence) - Infectious or inflammatory bowel disease in the 3 months before the first dose of study treatment - Myocardial infarction, stroke or other significant cardiovascular or cerebrovascular event in the 12 months before the first dose of study treatment - Pulmonary embolism, deep vein thrombosis, or other uncontrolled thromboembolic event in the 12 months before the first dose of study treatment, or current treatment with therapeutic or prophylactic anticoagulation therapy - Grade 3 or 4 gastrointestinal bleeding (or risk factors for gastrointestinal bleeding) or haemoptysis in the 3 months before first dose of study treatment, or any history of bleeding requiring an investigative procedure (e.g. endoscopy), transfusion or hospitalisation in the 12 months before the first dose of study treatment - Tumour location/extent considered by the Investigator to present a significant risk if tumour flare or necrosis were to occur (e.g. an initial increase in tumour size that may lead to intestinal, airway or ureter obstruction, or penetrating tumour infiltration of major blood vessels, or other hollow organs potentially at risk of perforation) - Use of the following prior therapies/treatments: 1. Treatment with any other enadenotucirev-based virus (parent virus or transgene-modified variants), or fibroblast activation protein (FAP) targeting agent at any time 2. Treatment with an investigational or licensed anti-cancer monoclonal antibody (mAb), immune checkpoint inhibitor, immune stimulatory treatment or other biological therapy in the 28 days prior to the first dose of study treatment. - Prior anti-PD-1/PD-L1 therapy is permitted without a 'washout' phase c. Treatment with an investigational or licensed chemotherapy, targeted small molecule or other investigational drug in the 14 days or five half-lives (whichever is shorter) before the first dose of study treatment d. Major surgery in the 28 days before the first dose of study treatment e. Radiation therapy in the 14 days before the first dose of study treatment f. Treatment with complementary medications (e.g. herbal supplements or traditional Chinese medicines) to treat the disease under study within the 14 days prior to first study treatment. Such medications are permitted if they are used as supportive care g. Bisphosphonate therapy or treatment with Receptor Activator of Nuclear factor Kappa-Β (RANK)-ligand inhibitors for metastatic bone disease is permitted - All toxicities attributed to prior anti-cancer therapy (including radiation therapy) other than alopecia must have resolved to Grade 1 or baseline before the first dose of study treatment - Known allergy or hypersensitivity (Grade ≥3) to NG-641 transgene, immune checkpoint inhibitor products or formulation, or other monoclonal antibodies - Discontinuation from prior treatment with an immune therapy due to a Grade ≥3 immune-related AE, or any history of life-threatening toxicity related to prior immune therapy - Other prior malignancy active within the previous 3 years, except for local or organ confined early stage cancer that has been definitively treated with curative intent, does not require ongoing treatment, has no evidence of residual disease and has a negligible risk of recurrence and is therefore unlikely to interfere with the primary and secondary endpoints of the study, including response rate and safety - Symptomatic brain metastases or any leptomeningeal metastases that are symptomatic and/or requires treatment - Any serious or uncontrolled medical disorder that, in the opinion of the Investigator or the Medical Monitor, may increase the risk associated with study participation or study treatment administration, impair the ability of the patient to receive protocol therapy or interfere with the interpretation of study results	{ "inclusion_biomarker": [ [ "MSI-high" ], [ "dMMR" ] ], "exclusion_biomarker": [] }
This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program. ;NA; Inclusion Criteria: 1a. Pathologically documented and definitively diagnosed non-resectable or metastatic NSCLC with a RET fusion for patients who are either treatment naïve, or who have been previously treated with systemic therapy. In the presence of a primary driver mutation, such as EGFR, ALK, ROS1, NTRK, or BRAF, the patient must be treated with the appropriate targeted therapy first. Patient is eligible if RET fusion is confirmed AND patient has undergone initial therapy for his/her driver mutation, or 1b. Pathologically documented and definitively diagnosed RET mutation in advanced MTC patients who are treatment naïve or who have been previously treated with MKI therapy, or 1c. Pathologically documented and definitively diagnosed advanced solid tumor with an oncogenic RET fusion previously treated with standard of care appropriate for the tumor type. 2. If previously treated with a selective RET inhibitor (e.g., RETEVMO), confirm patient has not progressed but has discontinued due to adverse event(s). 3. Patient is not eligible for an ongoing study of pralsetinib or cannot access an ongoing study of pralsetinib. 4. Patient is ≥ 12 years of age. 5. Patient has adequate vital organ function, including heart, lungs, liver, kidneys, bone marrow and endocrine, and is expected to tolerate therapy with a tyrosine kinase inhibitor. 6. No presence of clinically symptomatic interstitial lung disease or interstitial pneumonitis, including radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention). 7. Patient or patient's legal guardian, if permitted by local regulatory authorities, intends to provide informed consent prior to the start of treatment with pralsetinib. 8. Patient does not require therapy with a concomitant medication that is a strong inhibitor or strong inducer of cytochrome P450 (CYP) 3A4. 9. Patient has not received treatment with any systemic anticancer therapy (except for immunotherapy or other antibody therapies) and all forms of radiotherapy within 14 days or 5 half-lives prior to the first dose of pralsetinib. Pralsetinib may be started within these washout periods if considered by the healthcare provider to be safe and within the best interest of the patient, with prior Sponsor approval. 10. Patient has not received treatment with any immunotherapy or other antibody therapy within 28 days prior to the first dose of pralsetinib (immune related toxicities must have resolved to < Grade 2 prior to starting pralsetinib). 11. Patient has not had a major surgical procedure (minor surgical procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures) within 14 days prior to the first dose of pralsetinib. 12. Women must be willing, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception during pralsetinib administration period and for at least 30 days after the last dose of pralsetinib. Men, if not surgically sterile, must be willing to abstain from sexual intercourse or employ highly effective contraception during pralsetinib administration period and for at least 90 days after the last dose of pralsetinib. 13. Women must not be pregnant or breastfeeding.	{ "inclusion_biomarker": [ [ "RET fusion" ], [ "RET fusion", "EGFR mutation" ], [ "RET fusion", "ALK mutation" ], [ "RET fusion", "ROS1 mutation" ], [ "RET fusion", "NTRK mutation" ], [ "RET fusion", "BRAF mutation" ], [ "RET mutation" ] ], "exclusion_biomarker": [] }
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies. ; ; Key Criteria: Parts 1a and 1b (Dose Escalation + Fulvestrant): - Patient has histological or cytological confirmation of breast cancer. - Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit. - Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: - Minimum of one prior line of therapy for advanced/metastatic disease. - Maximum of five prior lines of therapy for advanced/metastatic disease. - Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. - Prior treatment has included a CDK4/6 inhibitor. - Tumor is ER+ (defined as ER IHC staining > 0%). Cohort EMNK: - Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate. - Tumor has a known KRAS-activating mutation; Patients with KRAS G12C mutations are excluded. Cohort EMBF: - Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: - Minimum of one prior line of therapy for advanced/metastatic disease. - Maximum of five prior lines of therapy for advanced/metastatic disease. - Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting, which may include combination therapy (eg, with a CDK4/6 inhibitor). - Tumor is ER+ (defined as ER IHC staining > 0%) and has FGFR amplification. Cohort EMBH: - Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: - Minimum of one prior line of therapy for advanced/metastatic disease. - Minimum of one line of HER2-directed therapy Note: Prior treatment with CDK4/6 inhibitors is permitted. - Tumor is ER+ (defined as ER IHC staining > 0%) and HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+). Cohort ECNS: - Patient has histologically or cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC. - Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate. Note: Patients who have declined approved therapy(ies) or who per treating physician are not eligible for approved therapy(ies) (eg, due to intolerance) may be eligible following discussion with the Medical Monitor. - Tumor has a known G12C KRAS-activating mutation. Note: Patients who have been previously treated with KRAS-specific therapy are excluded. Cohort ECBF: - Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: - Minimum of one prior line of therapy for advanced/metastatic disease. - Maximum of five prior lines of therapy for advanced/metastatic disease. - Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. - Prior treatment has included a CDK4/6 inhibitor. - Tumor is ER+ (defined as ER IHC staining > 0%). Cohort ECBF+A: - Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: - Minimum of one prior line of therapy for advanced/metastatic disease. - Maximum of five prior lines of therapy for advanced/metastatic disease. - Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. - Tumor is ER+ (defined as ER IHC staining > 0%) and HER2- (defined as absence of HER2 3+ IHC staining and/or absence of FISH+). Cohort ECBT: - Patient has progressed after treatment with at least one approved anti-HER2 agent and has been administered at least one line of chemotherapy. - Tumor is HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+). Cohorts EMBF, EMBH, ECBF, ECBF+A: There is no limit on the number of lines of prior endocrine therapies. Cohort ECBF-D1: - Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit. - Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: - Minimum of one prior line of therapy for advanced/metastatic disease. - Maximum of five prior lines of therapy for advanced/metastatic disease. - Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. - Prior treatment has included a CDK4/6 inhibitor. - Tumor is ER+ (defined as ER IHC staining > 0%). - Tumor has amplification of Cyclin D1 as determined by next generation sequencing or in situ hybridization.	{ "inclusion_biomarker": [ [ "ER positive" ], [ "KRAS activating mutation" ], [ "ER positive", "FGFR amplification" ], [ "ER positive", "HER2 positive" ], [ "KRAS G12C" ], [ "ER positive", "HER2 negative" ], [ "HER2 positive" ] ], "exclusion_biomarker": [ [ "KRAS G12C" ] ] }

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.